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Abstract  
Oncolytic viruses are multifunctional cancer agents with huge clinical 
potential, and recently the first Herpes Simplex Virus (HSV) oncolytic virus has 
been approved as a licensed cancer treatment. Increasingly, it is becoming 
apparent that no one cancer treatment is likely to be a ‘golden bullet’ – a 
treatment that, on its own is enough to cure all cancers. The answer seems to 
lie in combination therapies; by combining more than one type of treatment 
the chances of success, in terms of patient survival, increase.  
The aim of the project was to investigate the potential of HSV1716 in 
combination with other anti-cancer agents. As there is a vast array of current 
and potential cancer therapies, a high throughput screen using a range of 
cancer cell lines spanning a number of indications currently of clinical interest 
to Virttu Biologics was set up. This exploratory screen revealed a number of 
interesting results – synergies between HSV1716 and other drugs were seen 
across a number of different classes of drugs. This thesis first describes this 
‘fishing’ exercise, then investigates the mechanism of action by which a 
subset of those drugs, highlighted as acting either synergistically or enhancing 
the amount of cell death in combination with HSV1716, are acting.  
MTOR inhibitors (targeted agent), Doxorubicin (a chemotherapeutic) and two 
receptor tyrosine kinases, Sorafenib and Sunitinib, were identified in the 
screen. Subsequent analysis of these combination revealed that, despite the 
differences between the classes of drugs, all worked to greatly reduce viral 
replication, indicating that mechanisms other than viral oncolysis are killing 
cancer cells.  
The mechanism by which these cells were dying was investigated, HSV1716 in 
combination with mTOR inhibitors increased levels of intrinsic, mitochondrial 
driven apoptosis.  
Much of the observed enhanced cell killing was seen at low level of HSV1716 
infection – where only 1 in 10 cells was infected with virus. It was postulated 
that there is also some form of secreted signal that sensitises non infected 
cells to apoptosis. If this is the case these cells may be sensitised to the effect 
of drugs – and hence the levels of cell killing would be increased relative to 
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the non viral sensitised cells. The experiments detailed in this thesis indicate 
that this is indeed the case: HSV1716 infected cells secrete a ‘death signal’ 
that can be exported to non-infected cells. This signal itself increases cell 
death in non-infected cells but may also sensitise cells to the effect of drugs.   
Within the clinic, oncolytic viruses are effective agents at reducing tumour 
bulk by viral oncolysis and promote an anti-tumour immune response. The 
work presented in this thesis suggests that the virus may also induce infected 
cells to secret a factor that sensitises the surrounding cancer cells, generally 
resistant to apoptosis, to become more sensitive to apoptosis. These 
sensitised cells are then more susceptible to the effects of other anti-cancer 
agents. 
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Chapter I- Introduction 
1.1 Oncolytic virotherapy 
Advances in surgery, radiotherapy and chemotherapy have improved the 
outlook for many cancer patients, and targeted therapies, such as kinase 
inhibitors and angiogenesis inhibitors, offer the potential to arrest tumour 
growth and extend survival. More recently, immunotherapeutics, in particular 
immune checkpoint inhibitors, a new class of cancer treatment that harnesses 
the innate powers of the immune system to fight have been approved for use 
in patients with a  wide range of cancer indications (Teng et al., 2016, Khanna 
et al., 2016). These therapies may hold greater potential than current 
treatment approaches, and even the hope of a cure. This represent a huge 
step change in cancer treatment – some patients are achieving complete 
remission from diseases that would have previously have had an extremely 
poor prognosis. Unfortunately, not all patients respond to these new 
treatments and there still remains an urgent need for more effective 
therapies for primary and metastatic disease.  
Many alternative cancer treatments are being investigated and one of the 
most promising is the use of Oncolytic Viruses (OVs).  Many virus families are 
currently being developed as OVs, both naturally occurring and engineered 
viruses. To date, adenoviruses, poxviruses, HSV, Coxsackie virus, poliovirus, 
measles virus, Newcastle disease virus, reovirus, and others have all 
undergone early clinical phase clinical trials (Patel and Kratzke, 2013).Table 1 
describes the primary advantages and disadvantages of the most common 
oncolytic viruses in development both preclinically and in clinical trials.  
Using viruses to treat cancer is not a new idea. For more than 100 years there 
have been clinical observations that cancer patients who contracted viral 
infections would enter periods of remission. During the 1950s and 60s there 
was considerable activity using wild-type viruses as anti cancer treatments 
but many of these trials were limited by the toxicity of the wild-type virus, 
for a historical perspective see (Kelly and Russell, 2007). Progress has only 
recently been possible as advances in virology and molecular biology have 
19 
 
allowed either the identification of naturally occurring viruses with intrinsic 
tumour selectivity or by genetically engineering oncolytic viruses. 
An oncolytic virus is a virus that preferentially infects and kills cancer cells.  
As the infected cancer cells are destroyed by oncolysis, they release new 
infectious virus particles or virions to help destroy the remaining tumour. 
Oncolytic viruses not only to cause direct destruction of the tumour cells, but 
also to stimulate host anti-tumour immune responses. 
 Of all the oncolytic viruses currently being studied, oncolytic herpes simplex 
viruses (oHSV) are the only ones that have successfully completed clinical 
trials and become an approved, licensed treatment for cancer in the US and 
Europe. Herpes viruses have a number of features that lend themselves to 
success, both now and in the future as improved oncolytic agents. These 
features are summarised in Table 2. 
OHSV replicates and kills cancer cells by lysis, releasing multiples of the input 
doses into surrounding cancer cells. Lytic cell death is  immunogenic (Takasu 
et al., 2016), with the tumour specific infection promoting an anti tumour 
immune response. Furthermore oHSV can be armed with additional 
transgenes, either protein that enhance cell killing or enhance an anti tumour 
immune response.  
Table 3 lists the principal oHSV in current clinical development. Oncolytic HSV 
have demonstrated excellent safety profiles and, in numerous studies, signals 
of efficacy. In 2015 Talimogene Laherparepvec (T-VEC), also known as 
IMMYLGIC became the first oncolytic virus to be licensed by the FDA as a 
cancer therapeutic (Andtbacka et al., 2015). 
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Table 1: Viruses that are being studied as potential anti cancer agents 
(oncolytic viruses). 
Oncolytic 
Virus 
Primary advantages Primary disadvantages 
Adenovirus  Possible to be produced at 
high titre 
Possibility of adding DNA 
transgenes 
Dependent on receptor chimeric antigen 
receptor (CAR) expression 
dependent of loss of tumour protein 53 
(TP53) 
Potential for significant local tissue 
inflammation /immune Rx 
Coxsackie  Naturally preference for 
tumour cells  
Infection depends on the presence of 
specific receptor molecules 
HSV-1  M=Multimodal mechanism 
of action 
High yields and low viral 
antigen load 
Possibility of adding DNA 
transgenes 
Broad biodistribution of 
receptors 
Foes not integrate into the 
host genome 
Antiviral agents - 
acyclovir/gancyclovir 
Potential for virus to return to a latent 
state in the peripheral nervous system 
(PNS) and therefore not enter lytic 
replication cycle 
Maraba High potency 
Strong anti tumour  
Not well studied 
Measles virus  Oncolytic Pathogenic 
Narrow tropism 
Myxoma  Non pathogenic to humans Replicates only in cells with activated 
STAT1 
Newcastle disease 
virus  
Non-pathogenic in humans 
Moderate efficiency 
No permanent infection in 
host 
Oncolytic 
High potency 
Unclear mechanism 
Not well studied 
Non-recombinant viruses used 
Transgene reduces viral replication 
Parvovirus Strongly oncolytic Small – unable to insert transgenes 
Polio virus  Oncolytic Narrow tropism, 
Pathogenic, Difficult manipulation 
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Oncolytic 
Virus 
Primary advantages Primary disadvantages 
Respiratory enteric 
orphan virus 
(Reovirus)  
Mild pathogen 
Unable to infect normal 
cells 
Specific oncolytic activity 
Previous antigens exist 
Infects only cells with activated Ras 
Vesicular 
Stomatitis Virus  
Relatively non-pathogenic 
Oncolytic 
Difficult to manipulate 
Requires  interferon-resistant cells 
Vaccinia virus  High transduction 
efficiency 
Systemic dissemination - 
Resistant to clearance 
Possibility of adding DNA 
transgenes 
Long history of human use 
Antiviral agents - vaccinia 
Ig or cidofovir 
Activated Ras dependent 
Different forms of the virus may affect 
production 
Immune response /adverse reactions to 
vaccination  (1:50000) 
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Table 2: Features of Herpes Simplex Virus that lend it to being a potent 
oncolytic virus. 
Feature  Advantage  
Replicates only 
within tumour cells 
to generate 
multiples of the 
input dose  
Infection results in cytolysis of tumour cells and propagation beyond 
the cancer cells infected initially. 
Self-limiting –the virus only replicates within cancer cells leaving 
normal cells unaffected. 
Unique lytic 
mechanism of 
action  
Decreases risk of resistance developing to oHSV therapy and of cross-
resistance to other cancer therapies  
Immunogenic cell 
death and tumour-
specific infection 
promotes anti-
tumour immune 
response  
Lysis is an immunogenic form of cell death (ICD). This ICD stimulates 
an immune response to both virus and tumour. OVs are therefore 
important cancer immunotherapeutics  
Emerging evidence 
of safety and 
synergy with other 
anti-cancer 
treatment 
modalities  
OV may work synergistically with other forms of anti cancer 
treatments 
Can be armed to 
enhance tumour-
specific 
immunological 
reactions  
OVs can be engineered to carry therapeutic or immuno-stimulatory 
genes. For example,, by arming viruses with immunomodulatory genes 
such as IL12(Toda et al., 1998, Varghese et al., 2006, Parker et al., 
2005), IL2(Carew et al., 2001) , soluble B7.1- Ig (Todo et al., 2001) or 
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) (Hu et 
al., 2006, Malhotra et al., 2007, Kaufman and Bines, 2010, Kaufman et 
al., 2010) to help promote the antitumor immune response the 
modified viruses are more efficacious.  
Replication/lysis of 
cancer stem cells  
Oncolytic viruses have been shown to replicate within and destroy 
cancer stem cells (Li et al., 2012) 
Can be engineered 
to express 
additional 
transgenes that 
enhance tumour 
cell killing  
Virus directed enzyme prodrug therapy (VDEPT) systems have also been 
utilised with oncolytic HSV. For example, HSV1yCD – a modified HSV 
coding for the yeast cytosine deaminase (CD) enzyme, which converts 
the non toxic 5-flurocytosine (5-FC) into 5-FU, a highly toxic 
chemotherapeutic agent, (Nakamura et al., 2001). 
rRp450 ,carrying rat cytochrome P450 (CYP2B1) which converts 
cyclophosphamide (CPA) into the alkylating toxin phosphoramide 
mustard(PM)(Chase et al., 1998) 
 Nitroreducatase (NTR) which converts the prodrug CB1954 to an active 
alkylating agent (Braidwood et al., 2009). 
 oHSV have also been armed to increase a cells sensitivity to radiation 
therapy (Sorensen et al., 2012)  
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Table 3: Oncolytic HSV’s in clinical trials.  
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OncoVex 
GM-CSF 
(T-Vec) 
IMMLYGIC 
Deletion in 
both copies 
of ICP34.5 + 
ICP47 
disruption 
US11 
expressed as 
an 
immediate 
early gene 
Encodes GM-
CSF 
I 
I/II 
II 
III 
Solid Tumours 
SCCHN 
Melanoma 
Melanoma 
Now 
approved 
and 
licences for 
the 
treatment 
of 
melanoma. 
Current 
trials 
ongoing in 
melanoma 
in 
combinatio
n with 
Keytruda 
 
Evidence of virus 
replication in 
injected and 
adjacent 
uninjected tumours 
(head and neck). 
Regression of 
injected and 
uninjected tumors 
in late stage 
melanoma 
NCT02658812 
NCT02819843 
(Liu et al., 
2003), (Hu et 
al., 2006) 
(Harrington et 
al., 2010) 
(Sheridan, 
2013, 
Andtbacka et 
al., 2015) 
 
R7020 
(NV1020) 
Deletion of 
1 copy of 
ICP34.5 + tk 
under ICP4 
promoter 
control + 
deletion in 
UL24, 55 
and 56. 
I 
II 
Colorectal 
cancer liver 
metastases 
Completed In phase II 
disease,  
stabilisation in 
40-45% cases 
(Kemeny et 
al., 2006) 
(Kelly et al., 
2008) 
(Geevarghese 
et al., 2010) 
(Sze et al., 
2012) 
G207 Deletion in 
both copies 
of ICP34.5 + 
disruption 
of UL39 
I/II Recurrent 
brain cancer 
glioma, 
astrocytoma 
glioblastomas 
Recurrent 
brain 
tumours 
Completed 
 
 
 
Ongoing 
Well tolerated. 
Evidence of viral 
replication, 
radiographic and 
neuropathologica
l signs of anti 
tumor activity 
(Yazaki et al., 
1995) 
(Mineta et al., 
1995) 
(Hunter et al., 
1999) 
(Todo et al., 
2000), 
(Markert et 
al., 2000) 
(Markert et 
al., 2009) 
(Aghi and 
Chiocca, 2009) 
NCT02457845 
G47Δ Third 
generation 
HSV, ICP47 
null 
I/II Glioma ongoing  (Todo, 2012) 
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M032 Deletion in 
both copies 
of ICP34.5, 
expresses 
IL-12 
I Glioma Ongoing Safe in 
preclinical 
models 
NCT02062827 
(Roth et al., 
2014) 
HSV1716 Deletion in 
both copies 
of ICP34.5 
I 
I/II
a 
Glioma 
Melanoma 
HNSCC Non-
CNS solid 
tumours 
Malignant 
pleural 
mesotheliom
a 
Ongoing 
 
 
Ongoing 
No toxicity. In 
phase I/II 
(recurrent 
glioblastomas) 3 
of 12 patients 
showed disease 
stabilization. No 
toxicity in 
melanoma or 
HNSCC 
 
NCT01721018 
NCT00931931 
(Harrow et 
al., 2004, 
Papanastassio
u et al., 2002, 
Rampling et 
al., 2000, 
McKie et al., 
1996), 
(Mace et al., 
2007) 
 
HF10 Spontaneou
s 
generation 
of HSV-1 
variant 
I Pancreatic 
cancer 
Recurrent 
breast cancer  
Bladder 
cancer 
HNSCC 
 
Ongoing in 
solid 
tumours. 
Active in 
melanoma
. 
Complete 
HNSCC 
No adverse 
events and 
possible 
therapeutic 
potential 
NCT02428036 
NCT02272855 
NCT01017185 
(Nakao et al., 
2011) 
rQNestin
-34.5 
Expresses 
ICP34.5 
under a 
synthetic 
Nestin 
promoter 
I Malignant 
Glioma 
Ongoing  (Ning and 
Wakimoto., 
2014) 
References are given but in many cases open trials will not have published 
data. In these cases the clinical trial identifier (from cliniicaltrials.gov) is 
given. 
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1.2 Oncolytic Herpes Simplex viruses  
 Oncolytic herpes viruses (oHSVs) are attenuated, replication competent 
herpes simplex type 1 viruses that selectively infect, replicate within and lyse 
cancer cells. Among the promising oncolytic HSV-1 mutants is HSV1716.  
HSV1716, like most oncolytic viruses, directly kills host tumour cells. This 
oncolytic activity is influenced by a number of factors including efficiency of 
cell receptor targeting, viral replication and host cell antiviral response 
elements, as well as the susceptibility of the cancer cells to the different 
forms of cell death (apoptosis, necrosis, pyrotosis and autophagy).  
 HSV1716 (SEPREHVIR®) is a herpes simplex oncolytic virus and lead product 
from Virttu Biologics, a University of Glasgow spin out company. HSV1716 is a 
deletion mutant of herpes simplex virus type 1 (HSV-1), strain 17+. The 
deletion removes the RL1 gene encoding infected cell protein 34.5 (ICP34.5), 
a specific neurovirulence determinant (MacLean et al., 1991, Valyi-Nagy et 
al., 1994). The deletion is shown figuratively in Figure1B. HSV1716 has been 
studied extensively over the last 25 years and is the subject of numerous 
scientific publications. HSV1716 forms the body of the work described in this 
thesis and as such OV’s from other virus families will not be generally 
discussed. 
To date (August 2016), 100 cancer patients have been treated with HSV1716 
in clinical studies. The first of these clinical studies of HSV1716 involved a 
single intratumoural (i.t) injection of virus at doses of 103 to 105 infectious 
units (i. u) 9 patients with primary or recurrent glioblastome multiforme 
(GBM) were treated: 3 at 103 i.u., 3 at 104 i.u, and 3 at 105 i.u. No adverse 
clinical symptoms attributable to HSV1716 were identified (Rampling et al., 
2000). No induction of encephalitis or any re-activation of latent wild type 
HSV was observed. Although patients in this study were immuno-compromised 
as a result of previous anti-tumour therapy and corticosteroid treatment, 
there was no evidence of replication of HSV1716 within normal brain. Buccal 
swabs showed no evidence of HSV shedding. Biopsy material was obtained 
from 3 of the patients (at 3.5 weeks, 2 months and 3 months). No HSV antigen 
was detected in the samples and no HSV DNA was detected by PCR. Post 
mortem material obtained from two patients who died 2 and 6 months after 
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HSV1716 injection showed no evidence of encephalitis but in each case the 
site of the injected virus could be identified as a cyst. One patient was still 
alive at 182 months following HSV1716 injection (as of Aug 2013 unpublished, 
Virttu Biologics). This study was extended with the recruitment of an 
additional 12 patients; 3 received a single dose of 105 i.u and 9 received a 
single dose of 106 i.u. No toxicity was observed in any patient. One patient 
from this subgroup was still alive at 45 months after HSV1716 injection (as of 
Dec-2006, unpublished, Virttu Biologics). 
A second clinical study of HSV1716 assessed the potential for efficacy in GBM 
patients. 12 patients with biopsy-verified primary or recurrent malignant 
glioma received a single i.t injection of 105 i.u. HSV1716. 4-9 days following 
virus injection, tumours were resected and analysed for evidence of viral 
replication. Of the 12 subjects, 2 were HSV seronegative before treatment 
and sero-converted. In both cases, HSV1716 in excess of the input dose was 
recovered from tumour at the injection site (Papanastassiou et al., 2002). 
Given the low chance that the bulk of the input virus could be retrieved 
during sampling, this offers strong evidence that HSV1716 replicates in 
malignant glioma.  
In the third glioma study, a further 12 patients (4 recurrent GBM, 6 de novo 
GBM, 1 anaplastic astrocytoma and 1 anaplastic oligodendroglioma) were 
treated. HSV1716 was injected into the brain surrounding tumour immediately 
following tumour resection (Harrow et al., 2004). No toxicity due to HSV1716 
was observed.1 patient showed remarkable clinical improvement and there 
was imaging evidence of reduction in residual tumor over a 22 month period 
despite no further medical intervention. His clinical response was of 
particular note given his very poor pre-operative condition, the size of his 
tumour and that he declined all other adjuvant treatments. Another patient 
(newly diagnosed GBM) from this group was still alive 141 months following 
HSV1716 injection (as of Aug 2013, Virttu Biologics, unpublished).  
Two further clinical studies of HSV1716 have been completed: a study in 
melanoma patients involved 5 patients with metastatic melanoma and 
accessible soft tissue tumour nodules. Patients received i.t injections of 
HSV1716 at a dose of 103 i.u. per injection: 2 patients received 1 injection, 2 
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received 2 injections, and 1 received 4. No local or systemic toxicity 
associated with HSV1716 was observed (MacKie et al., 2001). In 1 patient, 
flattening of previously palpable tumour nodules was observed 14 days after 2 
direct injections of HSV1716. In virus-injected nodules in the 3 patients who 
received two or more injections, there was evidence of tumour necrosis with 
no morphological evidence of damage to surrounding tissues. 
Immunohistochemical staining of injected nodules demonstrated evidence of 
virus replication confined to tumour cells.  
The second of these additional studies involved 20 patients with resectable 
squamous cell carcinoma of the head and neck (HNSCC). Patients received a 
single preoperative i.t injection (either at 1, 3 or 14 days prior to surgery) 
with HSV1716 at a dose of 1x105 i.u. (5 patients) or 5x105 i.u. (15 patients). 
No toxicity was experienced by any of the patients and evidence of virus in 
tumour tissue was observed (Mace et al., 2008). 
There are 2 ongoing clinical studies of HSV1716: a phase I/IIa study sponsored 
and funded by Virttu Biologics (in UK) to assesses the safety, tolerability and 
biological effect of single and repeat intrapleural administration of HSV1716 
in patients with inoperable malignant pleural mesothelioma. To date 12 
patients have been treated, 3 with a single dose of 1x107 i.u. HSV1716 as a 
loco-regional injection into the pleural cavity via an indwelling pleural 
catheter, 3 have received 2 doses and 6 patients have received 4 doses. 
Results for this study are as yet unpublished. 
The second ongoing study is phase I dose escalation study in paediatric/young 
adult patients with refractory and actively progressing non-CNS solid tumors 
(in USA). To date 3 patients have received a i.t dose of 1x105 i.u. of HSV1716; 
2 patients have received a single i.t dose of 2x106 i.u; 1 patient has received 2 
dose via i.t administration of 2x106 i.u. and 2 patients have received a single 
i.t administration of 1x107 i.u. There have been no dose limiting toxicities 
with HSV1716 being well tolerated with minimal side effects. The protocol has 
been expanded to include an intravenous (IV) administration with 4 IV 
patients have received a single systemic administration of 2x106 i.u. HSV1716. 
Again, as this study is ongoing, results are as yet unpublished. 
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1.3 HSV infection and host cell defence mechanism against infection 
HSV-1 virion and genome. 
HSV1716 is a deletion mutant of HSV-1 (strain 17+), a human neurotropic 
virus. The morphological structure of the infectious virus particle, the virion, 
is characterised by a central icosahedral capsid, containing the core dsDNA 
genome. The capsid is surrounded by the tegument, which is in turn 
surrounded by a protein-containing lipid bilayer, the envelope. The tegument 
is an electron dense material composed of at least 20 distinct viral proteins 
(Kelly et al., 2009) while the envelope is composed primarily of lipids derived 
from the host cell membrane, into which are inserted HSV glycoproteins. 
Membrane glycoproteins mediate HSV-1 entry into the cell, cell to cell spread, 
cell fusion and immune evasion.  
The HSV-1 genome is a linear double stranded DNA duplex, 152 kb in length as 
shown illustratively in Figure 1A. There are two unique regions, long and short 
(termed UL & US) which are linked in either orientation by internal repeat 
sequences (IRL & IRS). At the non linker end of the unique regions are terminal 
repeats (TRL & TRS). Most of the known genes are located in the long or short 
regions, and they are named according to their location within L or S. Three 
main classes of HSV-1 genes have been identified, namely the immediate – 
early (IE), early (E) genes or late (L) genes as described in Figure 1.  
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Figure1: (A) Wild type HSV 1genome and (B) illustrating the deletion in 
HSV1716 
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HSV viral entry into host cells 
HSV1716 uses the same cellular receptors as wild type HSV-1 to initiate 
infection of cells. Entry of HSV-1 into the host cell involves interactions of 
several viral glycoproteins, namely gB, gD and the heterodimer comprising gH 
and gL (Campadelli-Fiume and Menotti, 2007). These glycoproteins, on the 
surface of the enveloped virus interact with receptors on the surface of the 
host cell.  
Initial contact is between viral gB and cellular heparan sulphate. gD then 
interacts specifically with the cellular receptors for HSV-1 entry which include 
herpes virus entry mediator (HVEM), nectin-1, and 3-O-sulphated heparan 
sulphate. Membrane fusion requires the concerted activities of gB and gH/gL 
so that the nucleocapsid gains access to the cell and infection is initiated. 
Nectin-1 is the main entry receptor for infection of central and peripheral 
nerve cells, whereas HVEM expression is more restricted and limited to cells 
of lymphoid origin (Simpson et al., 2005). HSV-1 entry mediators have a wide 
bioavailability and many different human tumour cell types are permissive for 
HSV1716 infection.  
The virus penetrates the cell by fusion of the virus envelope with the plasma 
membrane and the viral nucleocapsid is released into the cytoplasm of the 
cell.  Following binding of the capsid to the nuclear pore the genome is then 
released into the nucleus where transcription, replication of viral DNA and 
assembly of progeny nuclear capsid takes place.  
HSV replication  
The expression of HSV-1 genes occurs through a highly regulated cascade 
beginning with the production of the or immediate-early (IE) proteins. The α 
regulatory proteins, ICP 0, 4, 22, and 27, cooperatively act to regulate the 
expression of all classes of viral genes. The β or early (E) gene products, such 
as the viral thymidine kinase (TK), are synthesized next and are the proteins 
principally involved in viral DNA synthesis (reviewed in Roizman & Sears, 
1996). The last set of viral proteins produced are the γ or late (L) proteins 
and are mainly associated with virion structure and assembly, such as the 
VP16, gD, and gC proteins (Batterson and Roizman, 1983,Fenwick and Walker, 
1978) and Read et al., 1993).  
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The γ gene class is further subdivided into the γ1 and γ2 groups, where γ2 
expression is absolutely dependent on viral DNA synthesis. The completion of 
the HSV-1 replication cycle leads ultimately to the destruction of the cells.  
Cell antiviral response elements 
In normal cells, a variety of signalling pathways operate to detect and clear 
viral particles. The rapid detection of viral agents is essential for the effective 
initiation of host defence mechanisms against infection. The antiviral defence 
system starts to act through viral recognition by intracellular Toll like 
receptors (TLR) Single stranded (ss) RNA binds TLR-7 while double stranded 
(ds) RNA binds TLR-3 (Kawasaki and Kawai, 2014). TLRs induce intracellular 
signalling that leads to the activation of interferon (IFN) regulatory factors 
and activation of IFNα and IFNβ. Released IFNs, through STAT3, lead to the 
transcription of the target genes, which include PKR; the double stranded 
RNA-activated protein kinase. Activated PKR can phosphorylate eukaryotic 
Initiation Factor-α (eIF2α). Phosphorylation of eIF2α inactivates it and results 
in inhibition of mRNA translation initiation, shut down of protein synthesis of 
the host cell and therefore blocking viral replication. Wild-type HSV-1 has 
evolved multiple mechanisms to prevent such shut down. The key 
determinant responsible for preventing this translational host cell shutdown, 
hence allowing virulence of HSV-1, was mapped to the viral protein ICP34.5 
(Chou et al., 1990). ICP34.5 binds to Protein Phosphatase 1α (PP1α) resulting 
in dephosphorylation of eIF-2α allowing viral replication to proceed (Figure 
2)As ICP34.5 deleted viruses are unable to recruit factors required for viral 
replication or circumvent this PKR-mediated host defence pathway, this 
results in no viral replication and no spread in normal tissues (Figure 2B). HSV 
viruses that lack ICP34.5 protein have a 10,000-fold reduction in replication 
and neurovirulence in normal mice (Leib et al., 1999). ICP34.5 null viruses 
such as HSV1716 fail to cause disease in animals sensitive to HSV-1 infection. 
(Valyi-Nagy et al., 1994). 
Experiments in cancer cell lines and in human xenograft animal models 
demonstrated that ICP34.5 mutants are destructive to tumours(Varghese and 
Rabkin, 2002). The efficacy of tumour lysis in animal model systems, as 
measured by reduction in tumour volume or survival, directly correlates with 
the efficiency of viral replication (Smith et al., 2006). 
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STING (stimulator of IFN genes) has recently been identified as a key cytosolic 
DNA sensor for the detection of viruses. The presence of dsDNA in the cytosol 
is recognised by cyclic GMP-AMP synthase (cGAS). In the presence of ATP and 
GTP, cGAS catalyses the production of cyclic dinucleotide (CDN). A single CDN 
generated by cGAS binds to molecules of STING in the endoplasmic 
reticulum(ER). This binding changes STING conformation and it relocates to 
the perinuclear region of the cell where it phosphorylates transcription 
factors that in turn translocate to the nucleus to initiate innate immune gene 
transcription. The pathway is shown in Figure 3 (Barber, 2015). Colon cancers 
containing mutations in the STING-cGAS pathway are highly susceptible to 
DNA virus based oncolytic virus therapies (Xia et al., 2016) suggesting STING 
has an important role in innate responses to HSV. These factors activate the 
JAK-STAT (Janus kinase signal transducer and activator of transcription) 
pathway, resulting in IFN release (Randall and Goodbourn, 2008). The 
surrounding cells (which are uninfected by the virus) are induced into an 
antiviral state to limit the replication and spread of the invading virus.  
 IFN mediate a wide range of innate immune responses towards the invading 
virus. Interferons act as secreted ligands of specific cell surface receptors, 
eliciting the transcription of hundreds of interferon-stimulated genes (ISGs), 
whose protein products have antiviral activity, as well as anti microbial, 
antiproliferative/anti tumour and immunomodulatory effects (Schneider et 
al., 2014). IFNs, and their receptors have been extensively studied, and 
several detailed reviews have been dedicated to IFNs and their receptors (de 
Weerd et al., 2007, Pestka et al., 2004, Uze et al., 2007). As a brief overview, 
IFNs fall into the following categories: 
Type I- IFN-α/β. Nearly every cell is capable of producing IFN-α/β; however, 
during the course of a viral  infection, specialized immune cells known as 
plasmacytoid dendritic cells produce the vast majority of IFN-α (reviewed inLiu, 
2005). There are several ways in which this induction occurs, most 
importantly by the recognition of double stranded RNA (Randall and 
Goodbourn, 2008). 
 Type II - IFNγ is secreted only by immune cells, specifically NK cells and T 
lymphocytes, but nearly all cell types care capable of responding to IFNγ, The 
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most well-characterized function of IFN-γ is the upregulation of the MHC class 
I molecules to aid in the priming and presentation of antigens to antigen-
presenting cells such as dendritic cells (DCs) (Seliger et al., 2008).  
Type III IFNs—IFNL1, IFNL2, and IFNL3 [also known as IFN-λ1, IFN-λ2, and IFN-
λ3, or interleukin (IL)-29, IL-28A, and IL-28B, respectively] were described 
independently by two research groups in 2003, Kotenko et al., 2003 and   
Sheppard et al., 2003). This receptor complex signals through a similar JAK-
STAT pathway as the type I IFN receptor complex and induces many of the 
same ISGs (Marcello et al., 2006, Bolen et al., 2014). 
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Figure 2: Wild type HSV-1 replication prevents host cell protein synthesis 
shutdown in normal cells. (B) HSV1716 replication does not prevent host 
cell proteins synthesis shutdown in normal cells  
(A) In non-dividing cells wild-type HSV-1 (ICP34.5 +) virus enters the cell, 
begins replication and viral dsRNA is produced. The presence of the 
dsRNA in the cytosol induces and activates PKR. The viral ICP34.5 
protein can bind to Protein Phosphatase 1 leading to dephosphorylation 
of eIF2α resulting in protein translation and viral replication, and hence 
the virus can escape host defence. 
(B)  (B): In non-dividing cells ICP34.5 deleted viruses, such as HSV1716 are 
not capable of dephosphorylating eIF2a since ICP34.5 is absent, and so 
PKR-mediated inhibition of translation initiation blocks virus replication 
in non-dividing cells. 
 Figure used with permission of Virttu Biologics.  
 
 
A B 
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Figure 3: Initiation of innate immune system by virus infection 
 Stimulator of interferon genes (STING) is activated by cyclic dinucleotides 
(CDNs). Viral DNA in the cytosol of the host cells is recognised by cyclic GMP–
AMP synthase (cGAS), which in the presence of ATP and GTP catalyses the 
production of the CDN  cGAMP (cyclic GMP–AMP) .When cGAMP binds to STING, 
STING forms a complex with TANK-binding kinase 1 (TBK1). This complex 
traffics to the perinuclear Golgi to deliver TBK1 to endolysosomal 
compartments where it phosphorylates the transcription factors interferon 
regulatory factor 3 (IRF3) and nuclear factor-κB (NF-κB). Stimulation of the 
IRF3 and NF-κB signalling pathways leads to the induction of cytokines and 
proteins, such as the type I interferons (IFNs) that exert anti-pathogen 
activity. c-di-AMP, cyclic di-AMP; dsDNA, double-stranded DNA; ISGF3, 
interferon-stimulated gene factor 3; JAK, Janus kinase; STAT, signal 
transducer and activator of transcription; TYK, tyrosine kinase.  
Image downloaded with permission from Nature review: Immunology  
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MEK pathway 
 ICP34.5 mutants can infect cells from diverse tumour tissue types equally 
well, as demonstrated by the equivalent expression of early viral proteins 
expressed after viral entry (Smith et al., 2006). This suggests that the 
observed variability in viral yields across different tumour cell types might be 
a function of differences in overall viral protein synthesis, rather than 
differential infectivity. The presence of mechanisms in tumour cells that 
circumvent the PKR-mediated antiviral response may be essential for 
replication of ICP34.5 mutants. In permissive tumour cells, PKR is quiescent 
and viral protein synthesis proceeds uninhibited with efficient viral 
replication. In several studies, the differential susceptibility of various human 
tumour cell lines to ICP34.5 mutant infection was dependent on the activation 
status of the endogenous MAPK kinase (MEK) which can block the activation of 
PKR (Smith et al., 2006)(Figure 4).  
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Figure 4: Constitutive MEK activation in cancer cells prevents the host 
protein synthesis shutdown in the presence of virus infection. 
In ICP34.5 (-) mutants, the MEK activated pathway in tumour cells will block 
PKR activation, and in the absence of ICP34.5 protein, will result in 
translation initiation and viral replication. 
 Image is from Virttu Biologics and used with permission.  
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PCNA  
Proliferating cell nuclear antigen (PCNA) has been identified as another 
molecular mechanism that contributes to the selectivity of HSV1716. PCNA 
plays a critical role in cellular proliferation and its tight association with 
cancer transformation has resulted in the frequent use of PCNA as a 
diagnostic and prognostic cell-cycle marker. PCNA levels are normally very 
low in non-cycling cells, but levels can be much higher in cycling cells, for 
example active tumour cells.  
The HSV neurovirulence factor ICP34.5 was shown to form a complex with 
PCNA in-vitro and in-vivo through its 63-amino-acid carboxyl domain that is 
conserved in mouse MyD116, and hamster GADD34 (Brown et al., 1997, 
Harland et al., 2003). 
Tumour expression of PCNA may be a component of oncolytic specificity and 
may determine its efficacy. The in-situ PCNA profiles, in histological sections 
of tumour biopsies obtained from patients undergoing craniotomy, were 
examined (Detta et al., 2003). Biopsies of 10 metastatic tumours were 
positive for PCNA expression by IHC and supported the replication of HSV1716. 
In tumour cells, where PCNA is already engaged in DNA replication, ICP34.5 is 
not required to activate the cellular replication machinery to allow viral DNA 
replication to commence, and so HSV1716, even though it lacks ICP34.5, can 
still replicate effectively. Although encouraging, correlation between the 
levels of PCNA and sensitivity to HSV1716 in a large cohort remains to be 
demonstrated.  
Autophagy  
Autophagy is a basic cellular maintenance mechanism involving the lysosomal 
degradation of dysfunctional or unnecessary proteins and organelles.  The 
autophagy process can ensure cellular survival during starvation by providing 
essential cellular energy.  Autophagy has an antiviral role with autophagy 
proteins targeting viral components or virions for lysosomal degradation as 
well as playing a role in initiating innate and adaptive immune responses to 
viral infection (Alexander et al., 2007). During wild-type HSV-1 infection, 
ICP34.5 interferes with autophagy by binding Beclin-1. Beclin-1 is a critical 
component of several highly regulated complexes that control the formation 
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and maturation of autophagosomes (Alexander and Leib, 2008). Tumour cells 
often display defects in autophagy and this is associated with increased 
tumourgenesis.  As oncolytic HSV1716 is ICP34.5 deleted and thus cannot bind 
Beclin-1 to block autophagy, HSV1716 is more susceptible to autophagy-
mediated inactivation in cells that have ‘normal’ functioning autophagy such 
as neurons and fibroblasts. US11, a late gene product of HSV-1 is another viral 
protein known to inhibit autophagy through its interaction with PKR, although 
it does not bind to Beclin-1 itself (Lussignol et al., 2013). 
The fact that HSV-1 encodes two anti-autophagic proteins suggests that 
autophagy has a strong anti viral effect: however in vitro HSV-1 replicates as 
well in autophagy deficient cells as it does in wild type cells (Alexander et al., 
2007). Orvedahl produced an HSV-1 mutant that had a mutation in ICP34.5 
that abrogates binding to Beclin-1 and found that it was neuro-attenuated in 
mice, suggesting that the inhibition of autophagy by HSV-1 contributes to the 
neurovirulence of wild type HSV as a result of the ICP34.5 protein interacting 
with Beclin-1(Orvedahl et al., 2007).  
Anna Claudia Lima, in a University of Strathclyde MSC project in collaboration 
with Virttu Biologics, investigated autophagy in a number of  human cancer 
cell lines from the Virttu cell line panel (see M&M)  during both wild-type 
HSV-1 and oncolytic HSV1716 infection. The autophagy response to HSV 
infection in the in vitro human cancer cell lines studied was variable and 
independent of ICP34.5 status (Results were presented as a poster at The 8th 
International Oncolytic Viruses meeting-see Appendix). 
Apoptosis 
Apoptosis is a form of programmed cell death that is triggered in normal 
development and as a response to stress stimuli. In normal cells, the initiation 
of apoptosis is tightly regulated by activation mechanisms, because once 
apoptosis has begun, it inevitably leads to the death of the cell. There are 
two well defined pathways for the induction of apoptosis – the intrinsic (also 
called the mitochondrial pathway) and the extrinsic pathway (Figure 5) shows 
both pathways, with the important key caspases highlighted in yellow.  
In the extrinsic pathway, as the name suggests, the signal is initiated at the 
cell surface. Death ligands, such as TNFα or Fas ligand, bind to their death 
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receptors, type 1 TNF receptor (TNFR1) and a related protein called Fas 
(CD95), respectively. These death receptors have an intracellular death 
domain that recruits adapter proteins such as TNF receptor-associated death 
domain (TRADD) and Fas-associated death domain (FADD). The binding of the 
death ligand to the death receptor results in the formation of death-inducing 
signalling complex (DISC) comprising the death receptor and its adaptor 
protein. The DISC formation activates a specific set of cysteinyl aspartate 
proteases, called caspases, but specifically caspase 8. Active caspase 8 
cleaves and initiates downstream caspases 3 and 7. These caspases cleave 
cellular proteins which maintain the integrity of the cell, an irreversible 
process. 
The intrinsic pathway is activated by intracellular signals. Internal stimuli 
such as irreparable DNA damage, hypoxia, extremely high concentrations of 
cytosolic Ca2+ and severe oxidative stress increase mitochondrial permeability 
and consequent release of pro-apoptotic molecules, such as cytochrome-c, 
into the cytoplasm. The intrinsic pathway is heavily regulated by proteins of 
the Bcl-2 family, named after the BCL2 gene originally identified at the 
chromosomal breakpoint of the translocation of chromosome 18 to 14 in 
follicular non-Hodgkin lymphoma. There are two main groups of Bcl-2 
proteins, the pro-apoptotic proteins such as Bax, Bak, Bad, Bcl-Xs, Bid, Bik, 
Bim and Hrk and the anti-apoptotic proteins such Bcl-2, Bcl-XL, Bcl-W, Bfl-1 
and Mcl-1. The anti-apoptotic proteins regulate apoptosis by blocking the 
mitochondrial release of cytochrome-c whereas the pro-apoptotic proteins act 
by promoting its release. The balance between the pro- and anti-apoptotic 
proteins governs whether apoptosis will be initiated (Nguyen and Blaho, 
2007). Other apoptotic factors can be released from the mitochondrial 
intermembrane space into the cytoplasm including apoptosis inducing factor 
(AIF), second mitochondria-derived activator of caspase (Smac), direct IAP 
Binding protein with Low pI (DIABLO) and Omi/high temperature requirement 
protein A (HtrA2) (Wong, 2011). Cytoplasmic cytochrome c combines with 
Apaf-1 and caspase 9 to form the apoptosome whereas Smac/DIABLO or 
Omi/HtrA2 promotes caspase activation by releasing sequestered caspase 3 or 
9 from inhibitor of apoptosis proteins (IAPs). Once caspase 3 or 9 is released 
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from sequestration, it becomes activated and apoptosis proceeds (Wong, 
2011).   
Both extrinsic and intrinsic pathways converge on the execution phase of 
apoptosis which involves a series of caspases. Activated caspase 9 initiates the 
executioner phase for the intrinsic pathway whereas caspase 8 is the central 
node for the extrinsic pathway. Both activate caspase 3 which then cleaves 
the inhibitor of the caspase-activated deoxyribonuclease, which is responsible 
for nuclear apoptosis. Other downstream cleavage targets are protein kinases, 
cytoskeletal proteins and DNA repair proteins. 
The intrinsic endoplasmic reticulum (ER) pathway is less well understood and 
involves caspase 12 and is independent of the mitochondria. Briefly, ER injury 
via hypoxia, free radicals or glucose starvation, causes unfolding of proteins 
and reduced protein synthesis. Consequently, the adaptor protein TNF 
receptor associated factor 2 (TRAF2) dissociates from procaspase-12, resulting 
in its activation (Nakagawa et al., 2000). This apoptotic pathway may be 
important in OV therapy, with evidence of increased levels of ER stress, 
induced apoptosis when B-raf inhibitors were given in combination with a 
oncolytic reovirus type 3RT3D (Roulstone et al., 2015)  
Apoptosis and HSV 
HSV-1 infection triggers the host cell apoptotic pathway as a defence 
mechanism – the aim being to contain the spread and replication of the 
pathogen. Induction of host cell apoptosis by HSV-1 requires expression of the 
first class of viral genes (IE genes) (Sanfilippo and Blaho, 2006). 
While productive HSV-1 replication induces major biochemical changes in 
infected cells, collectively referred to as cytopathic effect (CPE), the virus 
also triggers apoptosis in transformed or tumor cells, but not primary cells. 
Synthesis of virus ICPs during an apoptotic-prevention window (Aubert et al., 
1999) delays the apoptotic process from killing the virally infected cells, 
presumably to allow productive viral replication to take place. A number of 
viral proteins which act to modulate apoptosis during infection have been 
identified. They include the immediate early proteins ICP27, ICP24 and ICP4. 
Deletion of any of these viral proteins results in virus that triggers apoptosis. 
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In addition, loss of either ICP4 or ICP27 also attenuates expression of early 
and late viral gene products, suggesting it also has regulatory functions (Su et 
al., 2016).  
Other early HSV gene products including Glycoprotein D(Zhou and Roizman, 
2001), US3 (Leopardi et al., 1997), R1 (Langelier et al., 2002) and latency 
associated transcripts (LAT) (Nguyen and Blaho, 2009) are involved in 
preventing apoptosis. Single deletions of either of these late viral genes do 
not cause apoptosis to the same extend as the ICP27 or ICP4 deleted viruses 
suggesting that the late viral genes may have redundant functions or act in 
concert to prevent apoptosis during a wild type HSV infection.  
Cells infected with recombinant viruses with mutations in the anti apoptotic 
viral gene products die through a process called Herpes Simplex Virus-
Dependent Apoptosis (HDAP). Early studies of HDAP were done in vitro using 
transformed cell lines but when studies were expanded to include non 
transformed lines fundamental differences were revealed (Aubert and Blaho, 
2001). Primary, non transformed cells are resistant to HDAP whereas 
transformed, tumourigenic cells were sensitive to HDAP. Two cellular 
proteins, P53 and telomerase, two key oncogenes, have so far been identified 
as regulators of HDAP sensitivity (Nguyen et al., 2007a). As this HDAP only 
occurs in transformed, or cancerous cells, HSV viruses, could cause increased 
cell death in cancerous, but not normal cells through HDAP. HDAP is caspase 
dependent. Using specific caspases inhibitors, Aubert et al, 2007 showed that 
inhibitors of caspase 9 suppressed HDAP while caspase 8 inhibitors did not, 
indicating that HDAP occurs through the intrinsic pathway of apoptosis 
(Aubert et al., 2007).  
Potentially, this difference in the ability of HSV virus to cause apoptosis in 
cancerous but not in normal cells could be exploited as a cancer therapy. 
Generally cancer cells are resistant to apoptosis, so a mechanism that 
specifically targets cells that are transformed is rare. HSV1716, like wild type 
HSV-1 retains a full complement of viral proteins that inhibit apoptosis of the 
host cell. In terms of production of progeny virions prevention of apoptosis by 
HSV1716 is positive, as it allows complete viral replication before the host cell 
is killed. However, HSV1716 infection could still result in cancer cell death, by 
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HDAP, if the production of the HSV1716 viral proteins that inhibit apoptosis 
was prevented. Therefore, anticancer drugs that inhibit viral replication, 
combined with HSV1716 could enhance cancer cell death by HDAP. 
As HDAP is caspase dependent and occurs via the intrinsic pathway, one way 
of measuring this enhanced HDAP would be to look for increased levels of 
specific caspases. Caspase 3/7 levels could be measured to look for increased 
apoptosis, and caspase 8 or 9 could be used to differentiate between intrinsic 
and extrinsic pathways.  
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Figure 5: The extrinsic and intrinsic routes to apoptosis.  
The extrinsic pathway is initiated by factors outside the cell, like death 
signals such as TNFα. These bind to the death receptors on the surface of the 
cell and form a death-induced signalling complex (DISC) which initiates the 
activation of pro-caspase 8 into caspase 8. This in turn cleaves the 
executioner caspase 3 downstream. The intrinsic mitochondrial pathway is 
initiated within the cell by internal stimuli.  
Diagram adapted from Wong, 2011. 
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1.4 Induction of anti-tumour immune response 
When oncolytic viruses were first described it was assumed that their primary 
mechanism of action was through direct oncolysis of tumour cells. Certainly 
within the in vitro setting, and within immune compromised xenograft 
models, the primary mode of action in terms of cell death is direct oncolysis 
of the cancer cell usually by a mixture of apoptosis, necrosis, pyrotosis and 
autophagic cell death (Bartlett et al., 2013). Evidence is accumulating, 
however, that although direct oncolytic effects are important, the induction 
of a systemic innate and tumour-specific adaptive immune response is critical 
for tumour eradication. The initial oncolysis causes an immunogenic cell 
death (ICD) that can activate innate and tumour-specific immune cells 
(Melcher et al., 2011),(Prestwich et al., 2008) generating an anti-tumour 
immunity vaccination effect to eliminate the uninfected cancer cells in 
primary and metastatic nodules (Bartlett et al., 2013).  
ICD is defined as a type of cell death that engages the adaptive arm of the 
immune system. The ICD induced by OVs provide danger signals and a natural 
repertoire of tumour associated antigens (TAA) to DCs that triggers an 
adaptive immunity  (Matzinger, 2002). These danger signals include Damage 
associated molecular pattern (DAMPs) and pathogen associated molecular 
pattern (PAMP) molecules derived from the OVs. PAMPs were first described in 
the late 1980s by Charles Janeway as a way that the immune system protects 
itself from infectious agents such as viruses(Janeway, 1989). They consist of 
essential components of the invading pathogen, for example nucleic acids 
(DNA, dsRNA, ssRNA), proteins and components of the cell surface and 
membrane that can be recognised by the host as ‘non self’(Tang et al., 2012, 
Kono and Rock, 2008). DAMPs are molecules derived from normal host cells. 
They can be proteins, DNA, RNA or metabolic products. Among the protein 
DAMPS are high mobility group box 1 proteins (HMGB1), heat shock proteins 
(HSPs) and proteins in the inter-cellular matrix such as hyaluronan fragments 
that are generated following cellular injury (Krysko et al., 2012). Both PAMPs 
and DAMPs stimulate the innate immune system through pattern recognition 
receptors including the Toll like receptors (TLRs) and retinoic acid inducible 
gene 1 (RIG-1) like receptors. DCs express a wide repertoire of these PRRs –it 
is the binding of PAMPs and DAMPs to these PRRs on the antigen presenting 
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cells (APC) that promote the maturation of antigen presenting cells such as 
DCs. They, in turn, activate CD4+ and CD8 + T cell responses. Once activated 
CD8+ T cells expand into cytotoxic effector T cells. The T cells mediate anti-
tumour immunity upon antigen recognition (Figure 6). 
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Figure 6: ICD of cancer cells induced by OVs leads to anti-tumour 
immunity.  
An OV, delivered either intra-tumourally or systemically, reaches tumour 
tissue and selectively replicates in tumour and/or stromal cells. This leads to 
induction of death of these cells, presenting “eat me” DAMP and PAMP signals 
on the cell surface and later release of danger signals from necrotic cells. 
Apoptotic bodies are engulfed by APC, and TAAs are processed and presented 
along with MHC complex and co-stimulatory molecules. The released DAMPs 
(and PAMPs) activate and mature DCs and TAAs are cross-presented to naive 
T-cells. The resulting cytotoxic immune response against tumour, involving 
CD4+ and CD8+ T cells, may help in complete eradication of tumour mass. 
Additional immunotherapies targeting DCs, T cells, and the 
immunosuppressive TME can further enhance this antitumor immune response. 
Figure fromBartlett et al., 2013.  
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Evidence that HSV1716 induces an anti-tumour immune response 
The role of the immune response during HSV1716-mediated tumour 
destruction has been studied in a syngeneic murine intracranial melanoma 
model (Miller and Fraser, 2000). The authors reported a significant 
prolongation in survival in the HSV1716 group compared with mock-treated 
mice. Additionally, 60% of the animals treated with HSV1716 had complete 
regression of their tumours. When SCID mice were tested rather than 
immunocompetent animals, no difference was observed in the mean survival 
rates between HSV1716 and mock treated groups. Similarly, when 
cyclophosphamide was used to deplete leukocytes in the syngeneic model 
before and during HSV1716 administration there was no significant difference 
observed in the survival times of the mock vs. HSV1716 treated mice (Miller 
and Fraser, 2000). The immune cell infiltration into the tumour after viral 
administration (when little or no immune cells were present) was also 
examined –CD4+ T cells and macrophages were the main early infiltrating 
cells, but polymorphonuclear leukocytes (PMN), CD8+ T cells, B cells, NK cells, 
and microglia cells were also present (Miller and Fraser, 2000). Significant 
Natural Killer cell (NK) infiltration was seen on day 7, with significant CD4+ T 
cells again present on day 12. HSV-1 antigen staining was found throughout 
the tumour mass. MHC class I expression was down-regulated 3 days after viral 
therapy in treated mice when compared with mock-treated mice, in 
accordance with previous reports on the ability of HSV-1 to down-regulate 
MHC class I expression through ICP47 (Jugovic et al., 1998). 
The down-regulation of MHC class I expression also corresponds with the 
concurrent shift from CD4+ and CD8+ T cells to NK cell and PMN infiltration. 
This correlates with the proposed escape from CTL recognition of tumours and 
the importance of NK cells in tumour clearance (Ockert et al., 1999). 
As the natural hosts for HSV-1 are humans many rodent tumour cell lines are 
resistant to HSV-1 infection. Miller and Fraser, 2003 stably transfected murine 
cell lines and used these HSV1716 replication-competent cell lines to form 
tumours in syngeneic C57/BL6 mice, and 4 strains of knockout mice (RAG2 -/-, 
CD4 -/-, CD8 -/-, and NK-/-). Only immunocompetent C57/BL6 mice showed 
an increase in survival when treated with HSV1716, suggesting that all 
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components of the immune system are necessary to mediate the prolongation 
in survival seen following HSV1716 therapy (Miller and Fraser, 2003).  
HSV1716 therapy has also been shown to reduce the growth of primary 
tumours and increase survival time in the highly malignant 4T1 mouse 
mammary carcinoma model. Coincident with this increase in survival was a 
reduction in metastases in the lungs. HSV1716 therapy of the primary tumour 
was also able to reduce the establishment of a second challenge of 4T1 
tumours. Immunohistochemical analyses showed that as early as day 12 post-
injection of tumour cells, inflammatory cells, such as neutrophils, could be 
detected throughout the mass of HSV1716-treated tumours. CD4+ and CD8+ T 
cells could also be detected throughout the HSV1716-treated tumours at 
higher levels than in mock-treated tumours. HSV1716 therapy did not reduce 
the growth of 4T1 tumours in SCID mice, suggesting a role for the T cell 
infiltrates (Thomas and Fraser, 2003).  
A vaccination effect has also been demonstrated by intra-tumoural 
administration of HSV1716 in a murine model of ovarian cancer, where 
previously HSV1716 showed a significant reduction of tumour growth and a 
survival advantage. Upon HSV1716 infection, mouse ovarian tumour cells 
showed high levels of expression of gB and gD and were readily phagocytosed 
by dendritic cells (DCs). The increased phagocytosis of tumour-infected cells 
by DCs was impaired by heparin, and anti-HSV g B and gD, suggesting that 
viral infection enhances adhesive interactions between DCs and tumour 
apoptotic bodies (Benencia et al., 2008). 
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1.5 Hallmarks of Cancer  
In parallel with an increased understanding that oncolytic virotherapy is much 
more complex than the simple idea of a lytic virus infecting and killing a 
tumour cell, understanding of the complexity of tumour biology has taken 
great strides. Tumours, once thought of as a mass of homogenous replicating 
cells, are becoming recognised as complex ecosystems with a range of 
cancerous and non cancerous cells, all with roles in allowing the tumour to 
grow and evade the immune system.  In addition, no two tumours are likely to 
be the same, even tumours within the same patient. Even different areas 
within the same tumour are likely to have different microenvironments.   
There are, however a number of commonalities that all tumours share. These 
are often referred to as the ‘hallmarks of cancer’ that distinguish a tumour 
cell from its non malignant counterpart (Hanahan and Weinberg, 2011) and 
are detailed below. All cancers must:  
· Resist cell death 
· Increase genome instability and mutation 
· Evade growth suppressor signals / sustain growth signals 
· Evade immune detection 
· Enable replicative immortality  
· Reprogramme energy metabolism  
· Induce angiogenesis 
It is increasingly important to understand that cancer progression is not so 
much a signalling pathway as it is a signalling web. The normal cellular 
processes involve signalling pathways that cross-talk with each other: the 
components of one pathway can regulate another. The ‘hallmarks of cancer’ 
described here are not isolated processes; each mutation or driver feeds the 
others, amplifying their effects and driving cells towards the uncontrolled 
growth that results in cancer.  
Resisting cell death- One of the hallmarks of cancer is the ability of 
malignant cells to evade apoptosis. Consequently, cancer cells tend to 
survive.  
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The process of apoptosis is complex and described in relation to HSV-1 
infection above. There are a number of ways in which a cell can become 
resistant to apoptosis but they can be broadly divided into the following 
categories which are shown figuratively in Figure 7. 
Defects/mutations in p53: P53 induces apoptosis by up regulating pro 
apoptotic proteins in response to substantial levels of DNA breaks and other 
chromosomal abnormalities reviewed in (Speidel, 2015). Loss of the p53 
protein is the most common way of limiting or circumventing apoptosis, and 
the p53 pathway is defective in >50% of human cancers (Kunisaki et al., 2006)  
Disrupting the balance of pro and anti – apoptotic proteins: Many proteins 
exert anti and pro apoptotic activities within the cell. It is not the absolute 
quantity that is important but rather the balance of the pro and anti 
apoptotic members of the BCL-2 family. BCl-2 along with Bcl-xl, Bcl-w, MCL-1 
and A1 are inhibitors of apoptosis, while BAX and BAK and pro apoptotic 
proteins (Letai, 2008). 
 
Reduced caspase function: Caspases are central to all routes of apoptotic 
death; they can function as both initiators and executioners. Low levels of 
caspase function lead to a decrease in apoptosis and carcinogenesis. Shen et 
al., 2010 found that dowregulation of caspase 9 was a frequent event in 
patients with late stage colorectal cancer and correlated with poor clinical 
outcome.  Caspase 3 has also been shown to be down regulated or lost in a 
significant proportion of breast cancers (Devarajan et al., 2002). 
 
Impairs death signalling: Down-regulation of death receptors or impairment 
of their function will contribute to reduced level of signalling, hence reduced 
apoptosis (Fulda, 2010).  
 
Increased expression of inhibitors of apoptosis proteins (IAPs): IAPs, as 
their name suggests, inhibit apoptosis. There are, to date, 8 IAPs identified all 
of which inhibit caspase activity by binding their conserved domains to the 
active sites of caspases, either promoting the degradation of caspases or  
keeping them from their substrates (Wei et al., 2008), and their dysregulation 
has been reported in many cancers (Krepela et al., 2009) 
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Figure 7: Deregulation of apoptosis in cancer cells 
Cancer cells acquired resistance to apoptosis in a number of ways. (used with 
permission (Wong, 2011). 
 
 
 
 
 
 
 
 
 
 
53 
 
Evading growth suppressor signals / sustaining growth signals: Cell signalling 
is a complex system that governs basic activities such as cellular growth and 
division. When the ability of cells to perceive and correctly respond to their 
microenvironment is altered, then cells can continue to grow and divide in an 
uncontrolled manner, leading to malignancy. Cell proliferation in normal cells 
is a tightly controlled process wherein the pro- and antiproliferation signals 
coordinate their activities at the cell-cycle level. Growth in normal cells is 
blocked generally by inducing the cell to enter G0 phase, blockage at the G1/S 
phase boundary, or terminal differentiation of a cell. Cancer cells circumvent 
these normal growth suppressors in order to keep proliferating (Lehrmann et 
al., 2002). 
Just as it is important for cancer cells to avoid growth suppressors, it is 
equally important for them to sustain proliferative signalling. These enabling 
signals are conveyed by growth factors that bind cell surface receptors, 
typically intracellular tyrosine kinase domains. These tyrosine kinases emit 
signals via a branched network of pathways affecting growth, proliferation, 
migration and angiogenesis. These include PI3K-Akt-mTOR and MAPK pathways 
which are often mutated in cancer cells to support unchecked cellular 
replication. 40% of human melanomas contain activating mutations affecting 
the structure of the B-raf protein, resulting in constitutive signalling of the 
mitogen activated protein (MAP) kinase pathway (Davies and Samuels, 2010), 
similarly 80% of glioblastomas have alterations in the PI3K (phosphoinositide 3 
– kinase) signal pathways, including its key Akt-mTOR signal transducers 
(Engelman, 2009).  
Immune detection: Immune surveillance is a proactive process that prevents 
tumour formation by recognising and eliminating most potentially cancerous 
cells before they can establish tumours (Prendergast, 2008).  However, some 
tumour cells are not detected and escape immune surveillance and continue 
to divide and grow. For example, cancer cells may secrete IL-10 (Marques et 
al., 2004), which down-regulates T cell immune recognition and reduces 
cytokine production and impairs infiltrating effector T cells. Tumours may 
also express molecules that directly inhibit cytotoxic T cells, such as CTLA-4 
(Contardi et al., 2005) or PD-L1 (Weber, 2010).  
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Induce angiogenesis: The formation of new blood vessels is critical for 
sustained tumour growth and metastasis. Tumor angiogenesis is a multistep 
process and involves signalling input from several pro-angiogenic growth 
factors (Bergers and Benjamin, 2003). The moment at which a tumor begins to 
over express pro-angiogenic factors, such as vascular endothelial growth 
factor (VEGF), is generally referred to as the ‘angiogenic switch’. By 
delivering oxygen and nutrients and producing growth factors angiogenesis 
enables tumor expansion and local invasion. Furthermore, the exit of tumour 
cells through the new tumour vasculature into the systemic circulation results 
in distant metastases being formed (Hicklin and Ellis, 2005). 
Energy metabolism: In order to sustain their uncontrolled proliferation 
cancer cells require more energy than ‘normal’ cells. Normal respiration, 
under aerobic conditions, in normal cells processes glucose as the primary 
energy source. Cells break down glucose to pyruvate, to eventually form ATP 
(adenosine triphosphate) while releasing carbon dioxide as a waste product. If 
there is not enough oxygen cells can switch to anaerobic respiration, where 
glucose is incompletely broken down and lactic acid is produced rather than 
carbon dioxide. Aerobic respiration is far more efficient at producing ATP: 32 
ATP molecules are produced per glucose molecule compared to anaerobic 
respiration which only yields 2. Otto Warburg (1956) first observed over 50 
years ago a characteristic of cell energy metabolism of cancer cells (termed 
the Warburg effect(Warburg, 1956)). Even when oxygen is not limited, cancer 
cells preferentially get their energy requirements by aerobic glycolysis (see 
Figure 8). Despite the fact this process is 16 times less efficient than normal 
respiration, energy can be produced much faster – cancer cells can produce 
ATP almost a hundred times faster than normal cells. Furthermore glycolysis 
produces many biosynthetic intermediate precursors that can be used as 
building blocks for the production of the necessary proteins, lipids and DNA 
required by the rapidly dividing cancerous cells (Vander Heiden et al., 2009).  
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Figure 8: Cancer cells preferentially undergoing aerobic glycolysis  
Cancer cells preferentially used aerobic glycolysis, despite in being far less 
efficient than normal aerobic respiration. Glucose gets broken down to 
pyruvate and the lactic acid, producing only 2 ATP molecules. In cells 
undergoing normal respiration (orange) glucose gets completely broken down 
into pyruvate, which is further processed into carbon dioxide producing 32 
ATP molecules (image credit : Buddhini Samarasinghe).  
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Genome instability and mutation rate: Situations of genome instability are 
common in cancer cells, and they are considered a ‘hallmark’ for these cells. 
The unpredictable nature of these events also contributes to 
the heterogeneity observed among tumour cells.  
Sporadic tumours (non-familial cancers) are thought to originate due to the 
accumulation of genetic errors (Storchova and Pellman, 2004). Within breast 
and colon cancers, Vogelstein et al., 2013 showed cancerous cells have 60- 70 
protein altering mutations. Of these 3 or 4 are considered “driver” mutations, 
with the remaining mutations being acquired thereafter. These ‘driver’ 
mutations increase the mutation rate and, as a consequence, increase the 
acquisition of new mutations, further increasing the probability of 
tumourgenesis. Common mutations include those  in genes responsible for 
maintaining genome integrity (caretaker genes), as well as in genes that are 
directly controlling cellular proliferation (gatekeeper genes)(Kinzler and 
Vogelstein, 1997). 
Replicative immortality: Cancer cells require unlimited replicative potential 
in order to become large tumour masses. Most normal cells can only undergo a 
limited number of successive cell growth-and-division cycles. Cells can 
become terminally differentiated, an irreversible process that results in viable 
but non-proliferative cells. Otherwise, cells die. When primary cells are 
propagated in vitro, most cells in the population die. Rarely, a few cells will 
not die and continue growing. The surviving cells are termed immortalised 
cells, a trait that most established cell lines possess by virtue of their ability 
to proliferate in culture without evidence of either senescence or crisis. 
Telomeres, protecting the ends of chromosomes, are centrally involved in the 
capability for unlimited proliferation (Kipling et al., 1999, Martinez-Delgado 
et al., 2012). In normal, non-immortalised cells, telomeres, composed of 
multiple tandem hexanucleotide repeats, shorten progressively with every 
round of cell division and eventually the ability of these telomeres to protect 
the ends of chromosomal DNA from end-to-end fusions is lost resulting in loss 
of cell viability. Cancer cells over express telomerase, an enzyme that 
maintains telomere length, which protects the ends of the chromosomes, 
allowing cancer cells to escape replicative mortality (Artandi and DePinho, 
2010).  
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1.6 Oncolytic viruses in combination with other anticancer drugs 
Oncolytic viruses are emerging as a potential new way of treating cancers. 
They are selectively replication-competent viruses that propagate only in 
actively dividing tumour cells but not in normal cells and, as a result, destroy 
the tumour cells by consequence of lytic infection. Oncolytic cell killing is 
independent of many genomic alterations that lead to drug-resistant tumours 
so may be effective in drug-resistant cancers.  
Intuitively, therapeutically beneficial interactions between oHSV and 
chemotherapeutic and targeted therapeutic drugs would be limited as the 
virus requires actively dividing cells for maximum replication efficiency and 
most anticancer agents are cytotoxic or cytostatic. However, since the initial 
studies by Toyoizumi et al,1999 with HSV1716 and four standard 
chemotherapeutic drugs, methotrexate, cisplatin, mitomycinC and 
doxorubicin(Toyoizumi et al., 1999), there have been many reports of the 
combinations of such agents displaying a range of responses, with 
antagonistic, additive, or synergistic enhancement of anti-tumour activity.  
When synergistic interactions in cancer cell killing are observed, the clinical 
implications of this combination therapy are not limited to enhanced efficacy. 
The dose reduction index, the most relevant clinical parameter derived by 
Chou and Talalay analysis (Chou and Talalay, 1984), reveals the potential for 
significant dose reduction without compromising cell kill. Reducing the dose 
of drugs such as chemotherapeutics by giving them in combination with an 
oHSV would minimize the toxicity and may allow patients to remain on an 
otherwise intolerable regime, or increase their quality of life whilst still 
receiving treatment for their disease. Therefore, the combination of an oHSV 
with “standard-of-care” anti-cancer agents makes a logical and reasonable 
approach to improved current therapy, and merits further investigation, both 
preclinically and in the clinic.  
Numerous publications have reported positive interactions between o HSV and 
anti-cancer agents, with many of these combinations shown in Table 4. 
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Table 4: HSV1716 in combination with wide range of chemotherapeutic 
agents that are currently approved and used in many cancer patients 
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HSV1716 Cisplatin UM_SCC 
14CUM-SCC 
22A 
UM-SCC 
22B 
HNSCC 
HNSCC 
HNSCC 
Additive 
Additive 
additive 
ND 
ND 
ND 
(Mace et 
al., 2007)  
HSV1716 Cisplatin, 
Doxorubicin, 
MitomycinC, 
Methotrexate 
NCI-H460 NSCLC Additive ND (Toyoizumi 
et al., 
1999) 
NV1066  Cisplatin  H-2452,  
H-Meso, 
H-2373,  
H-28 
JMN, 
 Meso-9 
MSTO-211H 
VAMT, 
 H-2052 
 Meso-10 
Malignant pleural 
mesothelioma 
(MPM) 
Synergistic 
Synergistic 
Synergistic 
Synergistic 
Additive 
Additive 
Additive 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
(Adusumilli 
et al., 
2006) 
G207 Cisplatin SCC-25/CP 
Sq20B 
UMscc-38 
HNSCC No effect 
ND 
ND 
ND 
No effect 
Additive to 
synergistic 
(Chahlavi 
et al., 
1999) 
G47Δ Cisplatin LNCaP Prostate cancer Antagonistic ND (Passer et 
al., 2009) 
OncoVex
-
GALV/C
D 
Cisplatin EJ 
T24 
 TCCSUP-G 
 KU19-9 
Bladder 
transitional 
carcinoma 
Antagonistic  
Antagonistic 
Antagonistic 
ND 
ND 
ND 
(Simpson 
et al., 
2012) 
rRp450 
(CYP2B1
) 
Cyclophosphamid
e 
Rh30 Alveolar 
rhabdomyosarcom
a 
ND Enhanced (Currier et 
al., 2008) 
G47Δ Doxorubicin LNCaP Prostate cancer Antagonistic ND (Passer et 
al., 2009) 
G207 Doxorubicin KAT4 
DRO90-1 
Anaplastic thyroid 
cancer 
Additive 
Additive 
Enhanced 
ND 
(Lin et al., 
2008) 
G47Δ Docetaxol LNCaP 
DU145 
Prostate cancer Synergistic 
Synergistic 
Enhanced 
ND 
(Passer et 
al., 2009) 
G47Δ Etoposide LNCaP Prostate cancer Antagonistic ND (Passer et 
al., 2009) 
G207 Fluorodeoxyuridi
n 
HCT8 Colon cancer Synergistic ND (Petrowsky 
et al., 
2001) 
G207 5-fluorouracil KIGB-5 
(murine) 
MKN45 
(human) 
Gallbladder  
 
Gastric cancer 
Enhanced  
 
Enhanced 
(viral 
replication) 
Enhanced (Syrian 
hamster)Enhance
d (SCID mouse) 
(Nakano et 
al., 2005) 
NV1020 5-fluorouracil HT29 
WiDr 
HCT116 
CT-26 
Colon cancer 
Colon 
Colon 
Colon 
Enhanced 
Enhanced 
Enhanced 
ND 
ND 
ND 
ND 
enhanced 
(Guterman
n et al., 
2006) 
OncoVex
-
GALV/C
D 
5-fluorouracil A549, 
 H460 
CAPAN-1 
MIA PACA-2, 
 BXPC-3 
HCT-116, 
HT-29, 
SW620 
9L LacZ 
(rat) 
Lung cancer 
Pancreatic cancer 
 
Colon cancer 
 
Gliosarcoma 
Enhanced 
Enhanced 
 
Enhanced 
 
ND 
ND 
ND 
 
ND 
 
Enhanced 
(Simpson 
et al., 
2006) 
NV1066 Gemcitabine Hs 700T 
PANC-1 
aPaCa-2 
Pancreatic cancer 
Pancreatic cancer 
Synergistic 
Synergistic 
ND 
ND 
(Eisenberg 
et al., 
2005) 
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R3616 
 
hrR3 
Gemcitabine CAPAN1 
PaCa-2 
SW1990 
Pancreatic cancer 
 
Pancreatic cancer 
ND 
 
ND 
Enhanced both 
cell lines) 
Not enhanced 
(Watanabe 
et al., 
2008) 
OncoVex
-
GALV/C
D 
Gemcitabine EJ 
 T24 
 TCCSUP-G 
 KU19-9 
Bladder 
transitional 
carcinoma 
Antagonistic 
Antagonistic  
Antagonistic 
Antagonistic 
ND (Simpson 
et al., 
2012) 
HF10 Gemcitabine CT26 Murine colorectal 
model 
Antagonistic 
if given 
together. 
Synergistic if 
GEM is pre-
treatment 
Enhanced effect 
in both injected 
tumour and 
distal tumour 
(Esaki et 
al., 2013) 
NV1020 
 
Irinotecan (SN38) HT29 and 
WiDr 
HCT-116 
Colon cancer 
 
Enhanced 
Enhanced 
ND 
ND 
(Guterman
n et al., 
2006) 
MGH2 Irinotecan (SN38) Gli36 EGFR
, U87 EGFR 
 U251 
 T98G 
Glioma Enhanced 
Enhanced 
Enhanced 
Enhanced 
Enhanced  
ND 
ND 
ND 
(Tyminski 
et al., 
2005) 
G207 MitomycinC  OCUM-
2MD3 
MKN-45-P 
Gastric cancer Synergistic 
Synergistic 
Enhanced 
ND 
(Bennett 
et al., 
2004) 
NV1066 MitomycinC  KU19-19 
SKUB 
Bladder 
transitional 
carcinoma 
Synergistic 
Synergistic 
ND 
ND 
(Mullerad 
et al., 
2005) 
OncoVex
-
GALV/C
D 
MitomycinC  EJ 
 T24 
TCCSUP-G 
KU19-9 
Bladder 
transitional 
carcinoma 
Synergistic  
Synergistic 
 
Synergistic 
ND 
ND 
ND 
ND 
(Simpson 
et al., 
2012) 
NV1020 Oxaliplatin HT29 and 
WiDr 
HCT-116 
Colon cancer 
Colon cancer 
Enhanced 
Enhanced 
ND 
ND 
(Guterman
n et al., 
2006) 
G207 Paclitaxel KAT4 
DRO90-1 
Anaplastic thyroid 
cancer 
Synergistic 
Synergistic 
Enhanced 
ND 
(Lin et al., 
2008) 
NV1023 Paclitaxel KAT4 
DRO90-1 
Anaplastic thyroid 
cancer 
Synergistic 
Additive 
ND 
ND 
(Lin et al., 
2008) 
G47Δ Paclitaxel LNCaP 
DU145 
Prostate cancer Synergistic 
Synergistic 
ND 
ND 
(Passer et 
al., 2009) 
MGH2 Paclitaxel MDA-MB-
435S 
Mammary 
carcinoma 
ND Enhanced (Nagano et 
al., 2008) 
G207 Temozolomide 
 
U87 
U87-dnp53  
U373 
T98  
 
U87MG 
Malignant glioma Synergistic 
(with O6-
benzylguanine
) 
Synergistic 
(with O6-
benzylguanine
) 
Enhanced 
ND 
ND 
ND 
 
ND 
(Aghi et 
al., 2006) 
G47Δ Temozolomide 
 
GBM13, 
BT74, 
U87MG, 
 T98, 
GBM4, 
 GBM6, 
 GBM8 
Glioma Stem cells 
(TMZ 
resistant/MGMT+v
e 
Glioma 
Glioma 
Glioma Stem cells 
(TMZ sensitive/ 
MGMT-ve) 
No synergy 
No synergy 
No synergy 
Synergistic 
Synergistic 
Synergistic 
Not enhanced in 
the presence of + 
O6-
benzylguanine) 
ND 
ND 
Enhanced  
(Kanai et 
al., 2012) 
G207 Vincristine KFR, 
KF-RMS-1 
Rhabdomyosarcom
a 
ND Enhanced 
Enhanced 
(Cinatl et 
al., 2003) 
NV1042 Vinblastine CWR22 
PC3 
Prostate Synergistic 
Synergistic 
Enhanced 
ND 
(Passer et 
al., 2013) 
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1.7 Mechanisms underlying synergistic interactions between oncolytic 
viruses and other agents. 
There are a number of different ways in which an oHSV in combination with 
an anti-cancer drug can be synergistic. The simplest way of increasing the 
efficacy of viral therapy would be to combine it with a drug that increases 
viral replication.  
O HSVs have selective replication competence in cancer cells and by 
increasing the replicative capacity of the virus within those cells, the number 
of progeny viruses produced during a cycle of infection is increased. 
Theoretically, replication of an oHSV within a tumour should result in much 
higher levels of virus than the input dose but studies have shown the gradual 
loss of virus over time in animal tumours (Lou et al., 2002). One reason for 
the loss of oHSV from the tumours is that not all cells within the tumour are 
cancer cells, many are stromal or cancer associated cells that do not support 
oncolytic virus replication. Furthermore, not all cancer cells (see table in 
materials and methods) support viral replication to the same extent. This 
could be partially, but not exclusively due to differential MEK expression 
(Smith et al., 2006). Another reason for the loss of oHSV from tumours is the 
anti-viral host response to an invading pathogen. One of the results is the 
induction of apoptosis in both infected cells and in surrounding non infected 
cells. By eliminating the non infected cells surrounding the infected cell, the 
host limits the spread of virus. Stanziale et al., 2004 reported that the 
increase in apoptosis in cells that neighboured oHSV NV1066 [derived from 
wild type HSV-1 F strain backbone, with single copy deletions of ICP4, ICP0 
and ICP34.5 (Wong et al., 2002) infected cells could be prevented by 
treatment with an inhibitor of apoptosis, N-acetylcysteine (NAC), and this 
block improved the propagation of viral progeny, maximising the lateral 
spread of virus and potentially improving tumour destruction.  
 Wood and Shillitoe, 2011 reported on viral replication in the presence of 
zVADfmk, a pan-caspase inhibitor that has previously been shown to prevent 
apoptosis (Aubert et al., 2007). The authors showed that blocking apoptosis 
had no effect on wild type HSV replication in a number of cell lines but 
restored an ICP34.5 null mutant replication back to the levels of wild type 
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HSV-1. In terms of clinical relevance, it is unlikely that a drug that prevents 
apoptosis (hence makes cells, including tumour cells, less likely to die) could 
be used in cancer patients. Drugs that prevent apoptosis increase viral 
replication in ICP34.5 null mutants suggest an anti-apoptotic role for viral 
protein ICP34.5 in wild type HSV. 
The differentiating reagent hexamethylene bisacetamide (HMBA) has also 
been shown to improve viral yield. Naito et al, (2006) reported up to 10000-
fold increase in vitro for an ICP34.5 null virus, R849 (Andreansky et al., 1997), 
at low MOI. Mice treated with both HMBA and R849 virus had significantly 
smaller tumour burden and survived longer than either virus or HMBA 
treatment alone (Naito et al., 2006). HSV-1 immediate early, early and late 
gene expression was all increased in the presence of HMBA, suggesting that an 
increase in viral replication resulted in increased numbers of infected cells. 
HMBA was initially described as a drug that has some potential as a stand-
alone anti-cancer agent, however the level of drug require for such activity 
could not be achieved in cancer patients (Egorin et al., 1987). There has 
recently been success in synthesising less toxic analogues of HMBA.  In the 
study with oHSV, a much lower dose of drug was used; one which could easily 
be achieved in patients and potentially would act as a promoting agent for 
oncolytic therapy.  
Eisenberg reported that hyperthermia potentiates oncolytic viral killing. After 
hyperthermic insult the heat shock protein Hsp72 (which inhibits cellular 
apoptosis) is upregulated, thereby allowing increased viral replication and, in 
turn, enhanced tumor kill. This finding has great potential, as in a clinical 
setting the application of heat is likely to be non- invasive and relatively 
toxicity free (Eisenberg et al., 2010). 
Histone Deacetylase inhibitors (HDACis) are a class of compounds that may act 
to increase oHSV efficacy. HDACs are a class of proteins that have pleiotropic 
effects on cells through deacetylation of proteins, including histones, that 
then alter epigenome and transcription profiles (Lehrmann et al., 2002, Mai et 
al., 2005). There are numerous HDACs which have been targeted for drug 
discovery for cancer therapies, either for use as a single agent or in 
combination with chemotherapeutic agents (Xu et al., 2007). Pre-treatment 
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with the HDACi Valproic acid (VPA) was shown to enhance the o HSVs MGH2 
(oHSV expressing 2 prodrug-activating transgenes, Kasai et al., 2013) and 
rQNestin34.5 (HSV engineered by expressing ICP34.5 under control of a 
synthetic Nestin promoter,Kambara et al., 2005a) replication and spread in 
tumours through inhibition of the IFN anti-viral response. VPA used in 
combination with rQNestin34.5 (with the VPA as a pre-treatment to oHSV) 
extended the survival of mice bearing intracerebral tumours (Terada et al., 
2006). Alvarez-Breckenridge et al., 2012 showed that VPA also inhibits NK 
cells. NK cells are involved in viral clearance hence by inhibiting NK cells virus 
avoids clearance thus enhancing its therapeutic effect.  
The effects of HDACis on other OVs are also of interest in this respect. Nguyen 
et al., 2008 reported on a VSV that replicates efficiently only in cells lacking 
an intact IFN response. The IFN responsive prostate cell line PC3 is refractory 
to VSV. However when the cells were pre-treated with HDACis the cells 
become permissive to VSV infection and the combination showed strong 
synergy as measured by the Chou & Talalay method both in vitro and in vivo. 
HDACi-induced sensitisation of tumour cells to non-HSV OVs has been shown in 
adenoviruses (Kitazono et al., 2002), Semliki Forest virus (Nguyen et al., 2008) 
and vaccinia virus (MacTavish et al., 2010). Similarly compounds that abrogate 
innate and adaptive responses to a virus such as cobra venom factor (Ikeda et 
al., 2000) and cyclophosphamide (Currier et al., 2008, Fulci et al., 2006, 
Kambara et al., 2005b) show synergy with OVs both in vitro and in vivo. Other 
compounds, such as Rapamycin, an immunosuppressant drug used to 
prevent rejection in organ transplantation, have been shown to significantly 
prolong survival of malignant glioma-bearing rats when given in combination 
with VSV (Tyminski et al., 2005, Alain et al., 2010). 
It has been reported that rapamycin, an mTOR inhibitor can increase both the 
yield and spread of the oHSV in tumour cells in which oHSV only replicates 
poorly (Fu et al., 2011).  
In addition, work carried out at Virttu Biologics as a undergraduate project by 
Leigh McGibbon, suggested that levels of Lactate dehydrogenase (LDH) in the 
medium of human cancer cells treated with HSV1716 + AZD8055 (a dual mTOR 
inhibitor) were higher compared to the levels of LDH when either HSV1716 or 
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AZD8055 treatment was given alone. LDH is only released from cells into the 
surrounding medium upon cell death, indicating levels of cell death are higher 
than expected when HSV1716 is given in combination with AZD8055, 
suggesting the two modalities may be working synergistically to increase 
cancer cell death. MTOR inhibitors are not generally cytotoxic to cancer cells, 
but are cytostatic and prevent further growth and division of the cancer cell. 
Oncolytic viruses on the other hand replicate in actively dividing cells. There 
are multiple redundancies within these signalling pathways, for example 
rapamycin only reduces mTOR activity for 12 hours before another kinase 
substitutes and re-engages the mTOR network (Kudchodkar et al., 2004). 
Potentially, there is enough redundancy in the system to subvert the action of 
one particular drug but, if combined with oncolytic virus assault, the cell may 
not have the option to recruit the alternative pathway thus potentiating the 
action of the drug. 
Upregulation of DNA damage pathways benefits oncolytic viral therapy 
Many chemotherapeutic drugs are DNA damaging agents and following 
exposure to such agents’ cells up-regulate their DNA damage repair pathways. 
Up-regulation of DNA repair genes appears to be beneficial for OV replication; 
mitomycin C (Bennett et al., 2004), temozolomide (Kanai et al., 2012, 
Hadjipanayis et al., 2008) and 5FU (Eisenberg et al., 2005) have all been 
shown to increase o HSV replication. 
Growth Arrest and DNA Damage inducible protein (GADD34) is induced by 
stressful growth arrest conditions and treatment with DNA damaging agents. 
The carboxyl terminal of GADD34 bears significant homology with the 
virulence factor ICP34.5, which is deleted in some oHSV, e.g. HSV1716, 
NV1066 (Stiles et al., 2003), and T-Vec (Kohlhapp and Kaufman, 2016).  
Previous studies (Roizman, 1996) have shown that the carboxyl terminus of 
GADD34 can substitute for ICP34.5 in preventing premature shutoff of protein 
synthesis and  ICP34.5 null mutants can use the host cell GADD34 protein for 
viral replication. Thus the presence of GADD34 in tumour cells following 
treatment with a DNA damaging agent would increase the number of cells 
that oHSV can replicate in, and increase the viral spread through the tumour. 
Indeed when GADD34 siRNAs were added to block GADD34 expression after 
treatment with a DNA damaging agent (cisplatin), the previously observed 
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synergy with the oHSV NV1066 and cisplatin was abolished (Adusumilli et al., 
2006).  
HSV DNA replication occurs in discrete compartments in the nucleus that 
assemble as pre-replicative sites with viral DNA and the HSV DNA binding 
protein ICP8. HSV DNA polymerase and cellular factors are then recruited to 
these compartments for use in viral replication. The DNA Damage and Repair 
(DDR) pathways repair the damage to the cancer cell DNA caused by 
treatment with DNA damaging drugs such as temozolomide (TMZ). However in 
the presence of oHSV infection, key components of these pathways have been 
sequestered into discrete compartments for use in viral replication and the 
cell is unable to repair the damage. Thus the damage, in terms of number of 
cancer cells killed by a specific amount of drug, is greater in the presence of 
oHSV (Kanai et al., 2012). 
Another potential mechanism for synergy with some oHSVs is up-regulation of 
cellular ribonucleotide reductase (RR) by DNA damaging chemotherapeutic 
agents (Petrowsky et al., 2001). High throughput screening has been reported 
to identify small-molecule compounds that augment the replication of HSV 
G47Δ (Passer et al., 2010) and of the 2460 compounds screened, 6 compounds 
were identified and subsequently validated for enhanced G47Δ replication. 
Two of these compounds, dipyridamole and dilazep, interfered with 
nucleotide metabolism by potently and directly inhibiting the equilibrative 
nucleoside transporter-1 (ENT-1) and were dependent on HSV mutations in 
ICP6, the large subunit of RR. ENT-1 antagonists are thought to augment oHSV 
replication in tumour cells by increasing cellular RR activity (Passer et al., 
2010). Oncolytic HSV such as G207, hrR3 and rRp450 has mutations in the 
UL39 gene which encodes ICP6, the large subunit of viral RR. As oHSV’s with 
UL39 deletions can only replicate in cells with active cellular RR, increasing 
cellular RR will improve viral replication. Nakano et al, 2005 reported an up-
regulation in RR in tumours mediated by 5FU which augmented the 
therapeutic effect of G207 (Nakano et al., 2005). Gutermann et al, (2006) also 
found synergy both in vitro and in vivo with oHSV NV1020 and 5FU, despite 
the fact that 5FU actually reduced viral yields (Gutermann et al., 2006). The 
authors speculated that the synergy was in part due to the cells being 
sensitised to 5FU as the virus caused the cells to arrest in S phase. They 
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further speculated that the reduction in viral progeny could be due to the 
immune IFNγ response as well as the 5FU-induced up-regulation of cell death-
molecules such as TRAIL and Fas ligand.  
Compounds that modulate the immune system  
The immune response to oncolytic viral therapy is an essential factor 
determining the success of oHSV as an anti tumour agent; it could be a 
hindrance if it causes premature viral clearance, but it is becoming 
increasingly recognised that the TAAs liberated by oncolysis, and the 
recognition of DAMPs and PAMPs by the innate immune system drive an anti-
tumour immune response. In order to magnify such a response 
immunomodulatory genes have been inserted into a number of OV’s. IMLYGIC, 
for example has the immunomodulatory gene granulocyte-macrophage colony 
stimulating factor (GM-CSF) inserted into its genome (Andtbacka et al., 2015). 
In parallel with clinical development of OVs, the field of cancer 
immunotherapy has, and likely will continue, to revolutionise treatment 
options for cancer patients. Recently, monoclonal antibodies (mAb) targeting 
immune checkpoint molecules CTLA-4 (e.g. Yervoy, Bristol Myers Squibb 
(BMS)) and PD1 (Keytruda (Merck) and Opdivo (BMS)) have been approved in a 
number of cancer indications. These immune checkpoint inhibitors (ICIs) 
effectively ‘take the brakes off’ pre-existing anti tumour immunity by 
interrupting the negative feedback loops within a tumour (Pardoll, 2012). 
Results to date with these ICIs are extremely impressive, with as many as 20-
30% of patients (depending on the indication) receiving this treatment as a 
monotherapy showing a durable long term response (Topalian et al., 2012). 
For the remaining patients these ICIs have limited efficacy, due to either a 
lack of anti-tumour immune response or other immune suppressive aspects of 
the tumour microenvironment that still needs to be corrected before ICIs can 
provide benefit. Tumour cell infection by OV’s leads to an inflammatory 
response with localised production of cytokines, all of which that favours an 
immune response (Breitbach et al., 2007). OVs would appear to be a perfect 
complement to ICIs. Indeed, an early trial with IMLYGIC and Keytruda suggest 
this is the case, with 44% of patients who received the combination reported 
to have a durable response lasting longer that 6 months, compared to either 
IMLYGIC or Keytruda alone(Puzanov et al., 2016). The oncolytic virus 
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CAVATAK, a Coxsackie Type A21 is also in clinical trials with Keytruda and 
Yervoy. The trial is ongoing but initial data showed an impressive 67% 
response rate in the first six patients treated with CAVATAK and Yervoy 
(http://www.viralytics.com). 
Compounds that alter the tumour microenvironment  
Tumours need blood vessels to grow and spread thus inhibitors of angiogenesis 
which prevent the formation of new blood vessels, are being investigated as 
agents that prevent or slow the growth and spread of tumours. Unlike 
chemotherapeutic agent, angiogenesis inhibitors do not kill cancer cells 
directly but instead prevent tumours from growing, therefore in order to 
completely eradicate a tumour an anti-angiogenic drug would have to be 
given in combination with a modality that kills cancer cells, such as an OV.  
VEGF is a key component in tumour angiogenesis and is over expressed in 
many human tumours. Inhibitors of VEGF, such as Avastin, Sorafenib and 
Sunitinib appear to ‘normalise’ tumour vasculature, potentially enhancing 
localisation of systemically delivered OV.  
Tumours receiving the dual therapy of both oHSV and Avastin were 
significantly smaller than either treatment alone in several studies using 
different xenograft models (Eshun et al., 2010 suggesting Avastin does indeed 
improve replication and spread of the oHSV within a tumour. 
Vinblastine, a microtubule disrupting agent that has been shown to inhibit 
angiogenesis in humans (Albertsson et al., 2008)  in combination with oHSV 
NV1042 (as 2nd generation mutant of NV1020 expressing the cytokine IL-
12Varghese et al., 2006) showed increased anti-tumour and anti-angiogenic 
effects in vivo in prostate cancer models (Passer et al., 2013), providing 
further evidence that the combination of an antiangiogenic agent and an 
oncolytic virus may have clinical benefit. Although Sunitinib has been 
investigated in combination with other oncolytic viruses (in VSV (Jha et al., 
2013,Breitbach et al., 2012)and reovirus (Kottke et al., 2010), there are no 
published studies of preclinical oHSV in combination with small molecule 
VEGF receptor inhibitors such as Sorafenib or Sunitinib. Heo et al., (2011) 
reported on a clinical trial with JX-594 (an oncolytic vaccinia virus) in which a 
number of patients treated with JX-594, and then Sorafenib up to 8 weeks 
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later had objective tumour responses (i.e. tumour shrinkage) compared to 0 
of/15 untreated patients matched for age, stage and gender. Furthermore, 
they also reported a complete cure in one patient treated with Sunitinib, 8 
weeks after JX594 treatment. As the virus is likely to be cleared from the 
patient by 8 weeks the mechanism by which the oncolytic virus can sensitise 
tumours to these inhibitors is unclear. Interestingly the patients who have the 
best responses to Sorafenib are those patients who have Hepatitis C related 
HCC (Cabrera et al., 2013) suggesting that there may be a therapeutic class 
effect, where viruses sensitise tumours to VEGFR inhibitors.  
Conclusions – oHSV in combination 
Numerous preclinical studies have shown that oHSV can synergise with a 
variety of chemotherapeutic, monoclonal antibodies and small molecule 
targeted agents. The outcome of a specific drug oHSV effect on cells varies 
depending on the virus, the drug, the dosing schedule and the cell itself. Even 
within cell lines of the same cancer type there is variation, with synergy in 
some lines but not in others (Kulu et al., 2013). It is conceivable that the 
drugs can inhibit virus replication but the combined effects of virus and drug 
act in concert to enhance cell death and seemingly conflicting results serve to 
illustrate our poor understanding of such interactions. 
Each oHSV, even those with similar deletions, are subtly different and may 
impact differently on different pathways. Many oHSVs have a deletion in 
ICP34.5 (including HSV1716). Likewise different cell lines have different 
mutations and have different expression of multiple gene sets. The majority 
of virus: drug combinations listed on Table 11 show synergistic, enhanced or 
additive effects, but this may in part reflect the fact that antagonistic 
combinations might be unlikely to be submitted for publication. Potentially 
gene expression profiling of the synergistic and non synergistic combinations 
could reveal patterns that correlate with and predict treatment efficacy.  
Furthermore, the sequence in which the drug and oHSV are given may impact 
on cell killing. For example gemcitabine and HDACis such as VPA are 
synergistic when given as a pre-treatment to the virus, thus sensitising the 
tumour to virus, whereas Sorafenib appeared to work better given after 
oncolytic virus, thus the virus is acting as the sensitizer. Similarly when oHSV 
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rRp450 (Currier et al., 2008) was given before Avastin (bevacizumab) there 
was a significantly prolonged survival compared to the same combination in 
reverse order (Eshun et al., 2010). 
Many of the combination studies examined the effects of combinations in 
vitro. These identify combinations that enhance cancer cell cytotoxicity. 
However, many of the interactions between oHSV and drugs either affect the 
tumour or host biology, and these interactions will only be seen in vivo. The 
immune system is a key player in the efficacy of any combination treatment – 
it appears that the initial suppression of the innate immune response in order 
to allow the virus to undergo initial replication, followed by up-regulation of 
the immune system to clear the virus and tumour would be a rational strategy 
in terms of reducing tumour burden. 
Anti-angiogenic drugs are gaining support for cancer treatment, and 
combining these with oHSV appears to be beneficial. Tyrosine kinase 
inhibitors as anti-cancer therapies are currently of great interest, but, to the 
best of our knowledge, there are limited published studies of their 
interactions with oHSV. However, the picture here will probably be 
complicated as not all viruses appear to have the same effect in one 
particular cell line and different cells with different mutation profiles will 
probably behave differently.  
It’s worth noting that synergy may not be necessary for clinical translation, 
even an additive effect would be of benefit, particularly if the effective 
chemotherapy dose could be reduced to decrease the toxic side effects. 
However careful consideration must be paid to the scheduling regime as the 
mechanism by which the synergy occurs will determine whether pre or post-
treatment will be more efficacious.  
As preclinical studies progress into the clinical setting major progress in the 
understanding of oHSV in combination with other treatments is likely to occur. 
Early clinical trials usually involve patients who have already exhausted all 
the available standard treatment options, and even later phase III trials will 
often compare standard of care versus standard of care + oHSV. Such studies 
should help confirm pre-clinical findings on useful virus/drug combinations 
and hopefully bring benefit to cancer sufferers.  
69 
 
As the mechanisms for synergy with oHSV are different for different drugs it is 
likely that combining more than one drug with oHSV may result in even more 
synergistic effects. For example, pre-treating tumours with gemcitabine, 
which down-regulates innate immune responses, then treating with oHSV, and 
then treating with an anti-angiogenic agent may result in an even greater 
anti-tumour effect.  
Project limitations 
All in vitro systems, not just the assay developed in this thesis, have a number 
of limitations. The first and most obvious limitation is that in vitro assays are 
carried out using tumour cell lines grown on a monolayer in dishes, in 
laboratories – a system far removed from an actual, naturally occurring 
tumour. The benefits however of using such an in vitro system are the cost, 
both in terms of finances and time. The initial assay set up in this thesis 
allowed 2 different drugs to be tested in ~10 cell lines every week, meaning 
that screening a large number of drugs could be carried out in a few months. 
In vitro assay systems and tumour cell lines have been established and used in 
scientific research for over 40 years and despite their inherent limitations, 
have been used in most of the seminal work in the cancer field since that 
time. Rarely are they used in isolation – more often they are used in early 
experiments that lead to larger, most sophisticated studies. By carrying out 
initial in vitro screens in a rapid in vitro screening programme, combinations 
of interest that show the most promise can be selected for further in vivo 
screening.  
There are concerns about the authenticity of the tissue origin and tumour 
type of many cell lines. Also, cell lines at high passage numbers experience 
alterations in morphology, response to stimuli, growth rates, protein 
expression and transfection efficiency compared to low passage cells (Wenger 
et al., 2004).  
To this end, the Virttu cell bank panel was created in-house to attempt to 
harmonise and validate all work carried out within Virttu laboratories. The 
first step was obtaining cells from well known biological resource centres 
(mainly ECACC and ATCC), which were grown up in bulk to create a bank of 
low passage cells. Cells used throughout this thesis were never used after 
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passage 10 (based on passage 1 being designated when cells were received 
from an appropriate repository). Consistency in the environment is a key 
factor in maintaining the integrity of a cell line – cell passage time, media and 
sera, control buffers, gases & temperature were all maintained to minimise 
any selection pressure to cells in culture.  
The second limitation of in vitro assays is they do not fully reflect what is 
happening within a tumour. Cells within a cell culture environment are evenly 
spread out over a dish and all have an equal chance of being infected by the 
substance being tested – whereas a tumour is a 3D structure. To this end, a 
project to make better in vitro models, such as using raft type 3D modelling 
systems is underway.  
Thirdly, tumours are made up of not only cancer cells but also non malignant 
cells, each with roles in enabling tumour growth and persistence. The tumour 
microenvironment, which varies by tumour type and location, even within an 
individual patient, is often composed of stromal cells such as vascular 
endothelial cells, pericytes, tumour associated fibroblasts, hematopoietic 
cells & innate immune cells such as macrophages, neutrophils and 
myelocytes. Even within a single tumour the environment is heterogeneous; 
there are often necrotic regions within a tumour & regions of hypoxia. These 
regions are hard to reach - they have a poor blood supply and often high 
interstitial pressure meaning delivery of any agent to these areas is 
challenging. None of these factors can be modelled in vitro, and even a 3D 
modelling system will not account for these factors.  
Lastly, it is becoming increasing apparent that the immune system has a vital 
role to play in cancer therapy. Again, none of these factors can be assayed 
using an in vitro assay but have huge impact on the efficacy of any therapy, 
not just oncolytic virotherapy. In order to look at the effects of HSV1716 as an 
immunotherapy, whole animal systems are still necessary. It is interesting also 
to consider the rapidly evolving therapeutic landscape in cancer treatments, 
when this project was initiated; kinase inhibitors were at the forefront of 
treatment paradigms whereas now they have largely been supplanted by 
immunotherapies 
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Despite such limitations, in vitro assays have a key role to play - relatively 
quickly, cheaply and reproducibly, they can reveal key aspects of the 
mechanisms of action that OVs and drug combinations use to kill cells, and 
allow selection of the most likely synergistic candidates to take forward for 
translational in vivo work. 
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Background to this thesis 
I have been employed by Virttu Biologics since 2004, in this time I have been 
involved in many projects involving HSV1716 and new variant viruses. I am the 
head of in vivo research and previous to this thesis have published a number 
of papers of HSV1716, including two first author papers. The first paper 
concerns the HSV1716 variant HSV1790, a variant that expressed the E.Coli 
enzyme nitroreducatase. The presence of this enzyme converts the relatively 
inert pro drug CB1954 into an active chemotherapeutic (Appendix 1).  
My second first author paper, in the Journal of Hepatocellular Carcinoma 
(Appendix 1), assesses HSV1716 in preclinical studies with two human 
hepatocellular carcinoma cell lines. This work was carried out as Virttu has 
approval to move ahead with a clinical trial in Hepatocellular Carcinoma. The 
plan for this trial was to administer HSV1716 via a transcatherter infusion in 
combination with the chemotherapeutic agent doxorubicin and a chemo 
embolisation agent which essentially blocks the veins in the liver allowing the 
doxorubicin (and HSV1716) to remain in the liver for longer periods to 
enhance the efficacy of the therapy. As HSV1716 had not previously been used 
in combination with doxorubicin either in the clinic, or in the lab, a project to 
look at the combination was undertaken. This in turn, lead to the wider 
question of what effects would other agents has on HSV1716, or what effect 
would other agents have on HSV1716, and after setting up a collaboration 
with Professor S Graham at the University of Glasgow, the basic aims of this 
thesis were set up. 
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Aims of this thesis:  
To investigate HSV1716 in combination with anti-cancer agents 
1. Develop a high throughput screen to look at HSV1716 in 
combination with a number of anti cancer drugs across a number 
of different classes. (i.e. chemotherapeutics, targeted agents, 
and receptor tyrosine kinases).  
2. Identify a number of drugs or classes of drugs that are synergistic 
with HSV1716 and determine the mechanism of action behind 
this synergy 
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Chapter II -Materials & Methods 
2.1 Virttu cell line panel  
Cell lines shown in Table 5 were used for all experiments. Cells had been 
bought from the source shown in Table 5.  
2.2 Cell line media composition: 
The medium used in all experiments, both routine cell passaging, plate set up 
and titrations are summarised in Table 6. All plastic ware was sourced from 
Greiner.  
2.3 Viruses  
HSV1716 GFP for combination studies - An HSV1716 variant expressing green 
fluorescent protein (GFP) is used for combination analysis and subsequent 
caspase and apoptosis assays. HSV1716GFP was produced from the parental 
HSV1716 by insertion of a CMV-GFP expression cassette in the UL-43 gene. The 
virus stock used was originally created on 23.07.99 (Conner, Virttu Biologics) 
and was titrated by plaque forming assay to reconfirm titre in December 2012 
(1x10e9 pfu/ml).  
Virus was diluted to generate 200 aliquots of 1x10e6 pfu/ml working stock 
aliquots to ensure consistency across combination experiments and stored at -
70oC. Virus was stored in the same conditions as Virttu Biologics clinical grade 
virus which is subject to stability testing yearly to determine if the virus loses 
titre over time. To date, the clinical grade stocks, stored under the exact 
same conditions as the virus described here, and used throughout this thesis, 
is stable for at least 120 months (10 years) (unpublished data, Conner & 
Braidwood) . For each combination experiment a fresh aliquot was used and 
prepared using the dilution serial dilutions of 1e. MOI are based on cell counts 
between 8000-10000 cells per well. 
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Table 5: Virttu Cell line panel 
Name  Source Details 
Hep3B ECCAC 
86062703 
Hepatocellular carcinoma derived from an 8 year old male and 
cells contain integrated Hepatitis B virus genome. However 
there is currently no evidence that this cell line produces 
infectious Hepatitis B virus. Doubling time 29 hrs ((Sagawa et 
al., 2008) 
HuH7 ECACC 
JCRB0403 
HuH-7 is a well-differentiated, hepatocyte-derived cellular 
carcinoma cell line that was originally taken from a liver 
tumour in a 57-year-old Japanese male. HuH-7 is epithelial-like 
tumourigenic cells which are able to form subcutaneous 
xenografts in nude mice. COSMIC: HuH7 cells have mutated 
FAM123B andTP53genes. Doubling time 51 hrs 
HepG2 ECACC 
85011430 
Hep G2 cell line itself was isolated from a liver biopsy of a 
male Caucasian aged 15 years, with a well differentiated 
hepatocellular carcinoma. The cells secrete a variety of major 
plasma proteins e.g. albumin, alpha2-macroglobulin, alpha 1-
antitrypsin, transferrin and plasminogen but Hepatitis B virus 
surface antigens have not been detected. Doubling time 29hrs 
HepG2-
luc2 
Bio 
ware  
Calliper 
HT1080-
luc2 
HepG2-luc2 is a luciferase expressing cell line which was stably 
transfected with firefly luciferase gene (luc1). The cell line 
was established by transducing lentivirus containing luciferase 
2 genes under the control of human ubiqution C promoter.  
A2780 ECACC -
93112519 
Human, ovarian cancer derived cell line established from 
tumor tissue of an untreated ovarian cancer patient.  
According to the COSMIC entry there is a mutation in the 
Kinase insert domain receptor (KDR) which is also known as 
vascular endothelial growth factor receptor 2 and has been 
linked to various cancers. 
CP70 ECACC 
93112517 
Human, ovarian cancer derived cell line. The CP70 cell line is a 
cisplatin-resistant derivative of A2780 cells and the cells have 
approximately 13-fold more resistance to cisplatin than the 
parental A2780 line. The A2780 human ovarian cancer cell line 
was established from tumour tissue from an untreated patient. 
According to their entry in COSMIC (Catalogue of Somatic 
Mutations in Cancer) they have a mutated PTEN gene 
Ovcar3 ATCC – 
HTB-161 
Adherent, epithelial cells derived from the ascitic fluid from a 
60 year old Caucasian female with an ovarian tumour. 
Reported by ATCC to be tumourigenic but cells established in 
Virttu cell bank did not form xenografts in 10/10 nude mice 
injected subcutaneously with approximately 5e6 cells 
(unpublished data, Braidwood). The cell line is aneuploid 
human female, with chromosome counts in the sub to near-
triploid range. COSMIC entry indicates somatic mutation in 
TP53. 
Skov3 ECCAC -
91091004 
Adherent, epithelial cells derived from the ascitic fluid from a 
64 year old Caucasian female with an ovarian tumour that form 
moderately well-differentiated adenocarcinoma consistent 
with ovarian primary cells. Cells have a hypodiploid to 
hypotetraploid karyotype. COSMIC entry indicates somatic 
mutations in CDKN2A, CDKN2a (p14), MLH1, PIK3CA and TP53. 
Doubling time 35hrs 
(http://physics.cancer.gov/docs/bioresource/ovary/NCI-PBCF-
HTB77_SK-OV-3_SOP-508.pdf) 
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U87MG ECCAC - 
89081402 
Epithelial like cells derived from a malignant glioma from a 
female patient by explant technique and reported to produce a 
malignant tumour consistent with glioblastoma in nude mice. 
Karyotype is 2n (=46). COSMIC entry indicates somatic 
mutations in CDKN2A, CDKN2C, CDKN2a (p14) and PTEN 
UVW ECCAC - 
86022703 
Cell line established from an anaplastic astrocytoma of normal 
adult brain and forms xenografts in nude mice. No entry in 
COSMIC 
One58 ECCAC 
10092313 
This cell line was derived from the pleural fluid of a patient 
with malignant mesothelioma. The patient had known 
exposure to crocidolite asbestos. Cells express cytokeratin and 
epithelial membrane antigen (EMA) but not mucin. Cells are 
epithelial-like and spindle-shaped with few vacuoles. No entry 
in COSMIC. Doubling time 24 hrs (Manning et al., 1991) 
SPC-
111 
ECCAC 
11120716 
SPC111 was derived from the pleural effusion of a 55-year old 
male patient, prior to treatment, with a known history of 
exposure to asbestos. The cells are Epitheloid/mesenchymal. 
No entry in COSMIC. 
Vero ECACC 
84113001 
Established from the kidney of a normal adult African Green 
monkey. Susceptible to a wide range of viruses hence used for 
titration were obtained from the VIRTTU Biologics Ltd cell 
bank. No entry in COSMIC 
BHK ECACC 
85011433 
Sub clone of parent line derived from 5 1-day-old unsexed 
hamster kidneys. Used extensively for virus replication studies 
i.e. poliovirus, rabies, foot and mouth disease, VSV (Indiana 
strain), herpes simplex, Ad25 and arboviruses. 
3T6 ECACC 
86120801 
Established from disaggregated Swiss mouse embryos in 1963. 
3T6 cells are not permissive to HSV1176 replication – failure to 
express ICP34.5 results in a defect in virus maturation and 
egress from the nuclei to the extracellular space (Brown et al., 
1994). No entry in COSMIC Doubling time 16hrs (Rath et al., 
1984) 
A431 ECACC -
85090402 
Human squamous carcinoma derived from the epidermal 
carcinoma of the vulva taken from an 85 year old woman. The 
cells carry large numbers of EGF binding sites. COSMIC entry 
shows a mutation in PTCH1.Doubling time 24 hrs (Bonner et 
al., 2009) 
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Table 6: Cell medium, supplements, titration and overlay medium.  
Cell lines Medium  Supplemented 
All except 
Hep3B 
For normal passaging 
and plate set up 
Dulbecco's Modified 
Eagle Medium Nutrient 
Mixture F-12 (DMEM/F-
12 no glutamine, 
Invitrogen), 
50 ml Newborn Calf Serum NBCS, 16010159, Invitrogen) 
5.5 ml Penicillin-Streptomycin-Glutamine 10378-016, Invitrogen) 
2.5 ml Fungizone Antimycotic (15290-026, Invitrogen 
Hep3B For normal passaging 
and plate set up 
Advanced RPMI 1640 (, 
12633-012, Invitrogen) 
100 ml Newborn Calf Serum NBCS, 16010159, Invitrogen) 
5.5 ml Penicillin-Streptomycin-Glutamine 10378-016, Invitrogen) 
2.5 ml Fungizone Antimycotic (15290-026, Invitrogen 
All 
titrations 
Overlay  
100 ml 10 X GMEM 
medium 
Glasgow's MEM powder (11710-035, Invitrogen) is mixed with Baxter’s 
water (UKF7114), + 7.5% Sodium Bicarbonate solution (25080102, 
Invitrogen). The solution is mixed using a magnetic stirrer until 
dissolved. Ph the solution to pH 7.2-7.3. The medium is then filter 
sterilised using 0.45uM bottle top filter (Nalgene 296-4545) using a 
vacuum into sterile 50 ml tubes. These can be stored for up to 6 months 
at -20oC.  
300 ml Methyl cellulose  4.2 g Carboxymethyl cellulose sodium salt (9004-32-4, VWR) is added to 
300 ml Baxter’s water (UKF7114). The powder should be fully dissolved 
in the solution. The lid of the bottle is left loose and then autoclaved at 
121oC for 15mins. The lid is tightened then bottle allowed to cool 
before being stored at 4oC for up to three months 
50 ml Newborn Calf 
Serum  
Newborn Calf Serum(NBCS, 16010159, Invitrogen)  
5.5 ml Penicillin-
Streptomycin-Glutamine  
(10378-016, Invitrogen) 
2.5 ml Fungizone 
Antimycotic  
(15290-026, Invitrogen 
33 ml Tryptose 
Phosphate Broth 
11.8 g Tryptose Phosphate Broth powder (Sigma T9157) is dissolved in 
500ml Baxter’s water (UKF7114). The lid of the bottle is left loose and 
then autoclaved at 121oC for 15mins. The lid is tightened then bottle 
allowed to cool before being stored at 4oC for up to three months 
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2.4 Drugs for combination studies 
Drugs used in combination studies are shown in Table 7. 
2.5 Cell line panel for HSV permissivity 
Virttu has been working with the cell panel shown above for a number of 
years, so prior to the work described in this thesis the permissivity of the cell 
lines to HSV1716 and wild type virus have been tested. The expected yields 
are shown in Table 8.  
2.6 Culturing, passaging and setting up plates 
All tissue culture was performed in a microbial safety cabinet, adhering to 
aseptic techniques at all times. Cells were maintained, passaged and 96 & 6 
well plates set up as described in Freshney ISBN: 978-0-470-52812-9  
2.7 Plaque assay 
Determination of infectious particle titre by plaque forming assay is described 
in Harland & Brown (1999) with the basic premise shown in Figure 9. 
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Table 7: Drugs used in combination studies. 
Drug Selleck 
Chem 
cat no. 
Target Preclinical/Clinical Indications 
Temsirolimus S1044 
 
mTOR Approved for the treatment of renal cell 
carcinoma and mantle cell lymphoma 
AZD8055 
 
S1555 
 
mTORC1/mT
ORC2  
Completed phase I trials in recurrent glioma, 
liver cancer and advanced tumours. 
Ku0063794 S1226 
 
mTORC1/mT
ORC2 
Inhibits tumour growth in xenograft model of 
renal cell carcinoma  
GSK690693 
 
 S1113 
 
pan 
Akt1/2/3 
inhibitor 
Evidence of inducing apoptosis and inhibiting 
cell growth in leukemic cell lines  
LY294002 
 
 S1105 
 
PI3K Inhibits cell proliferation and induces apoptosis  
Sunitinib 
 
 S7781 
 
RTK Approved for the treatment of renal cell 
carcinoma and imatinib resistant 
gastrointestinal stromal tumour. 
Sorafenib 
 
 S7397 
 
Raf-1, B-Raf 
and VEGFR-2 
Approved for the treatment of renal cell 
carcinoma, hepatocellular carcinoma and 
iodine resistant advanced thyroid carcinoma 
Pazopanib 
 
S3012 
 
TKI Approved for the treatment of renal cell 
carcinoma and soft tissue sarcoma 
Cabozantinib 
 
S S1119 
 
VEGRR-2 Approved for the treatment of medullar 
thyroid cancer and advanced renal cell 
carcinoma 
Nintedanib 
 
 S1010 
 
VEGFR1/2/3, 
FGFR1/2/3 
PDGFRα/β 
Approved for the treatment of idiopathic 
pulmonary fibrosis and some forms of non-
small-cell lung cancer 
Crizotinib 
 
 S1068  
 
c-Met  
 ALK 
Approved for the treatment of some non-small-
cell lung carcinoma, undergoing phase I and II 
trials in advanced cancer, metastatic breast 
cancer, solid tumours and anaplastic large cell 
lymphoma 
Dovitinib 
 
 S1018  
 
 RTK  Undergoing phase II/III and phase II trials for 
solid tumours and prostate cancer 
Gefitinib 
 
S1025 
 
EGFR Approved for the treatment of breast and non-
small cell lung cancer  
Erlotinib 
 
S1023 
 
EGFR Approved for the treatment of non-small cell 
lung cancer, pancreatic cancer and other 
cancers 
GSK1120212 
(Trametinib) 
 
S2673 
 
MEK1/2 Approved for the treatment of metastatic 
melanoma, recruiting for a phase I trial in 
neuroblastoma and a phase II trial in recurrent 
non-small cell lung cancer 
LY2228820 
 
S1494 
 
P38 MAPK  Recruiting for a phase II trial in metastatic 
breast cancer and a phase I trial in advanced 
or metastatic cancer 
Doxorubicin S1208 DNA 
topoisomeras
e II 
Approved for the treatment of breast and 
ovarian cancer, multiple myeloma and Kaposi’s 
sarcoma 
All powders were prepared as per manufacturer’s instructions and stored in 
aliquots at -70oC until required. 
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Table 8: Permissivity of cell line panel to HSV1716 and wild type HSV17+ 
infection. 
Cell 
Line 
HSV17+ yield 
@ 72hrs 
HSV1716 yield 
@ 72 hrs 
Replication Competence ratio 
(HSV17+ compared to HSV1716) 
Hep3B 14430 4820 0.33 
Huh7 3250 28500 9 
HepG2 40670 60030  1.5 
Cp70 223  57  0.26 
Ovcar3 95543 179009 1.9 
Skov3 27849  913  0.03 
U87MG 43100  8806  0.2 
UVW 72234  78369 1 
One58 13650  12650 1 
3T6 400 0.5 0.00125 
Spc111 11920 2710 0.23 
In Hep3B, Cp70, U87MG, Skov3 & SPC111 HSV1716 doesn’t replicate as well as 
HSV17+. In UVW, one58 & HepG2 HSV1716 replicates approximately as well as 
17+. Huh7 is unusual in that HSV1716 replicates to a higher titre than HSV17+.  
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Figure 9: Determination of viral titre by plaque assay 
Virus is serially diluted and the dilutions added to the confluent monolayers of 
Vero cells. Overlay medium is added and the cells are incubated at 37oC for 
72 hrs. At 72hours plaques are visible on the monolayer. Plates are stained 
using Giesma stain and counted using a stereo tactic microscope. The plate 
with between 100-300 plaques is counted and the PFU/ml is worked out using 
the dilution factors 
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2.8 Dead Cell Protease (DCP) Assay  
DCP was assayed using the CytoTox-Glo Cytotoxicity kit from Promega. The kit 
provides a luminogenic peptide substrate, AAF-Glo, to measure dead cell 
protease activity in the media. DCP is released from cells which have lost 
membrane integrity (Figure 10A). The peptide substrate cannot cross the 
intact cell membrane of a live cell and will only be cleaved (Figure 10B) when 
dead cell protease has been released into the media as cells die. The assay 
then uses the Ultra-Glo recombinant luciferase, which can use the released 
aminoluciferin as substrate, to generate a readily detectable luminescence 
signal. Light emission from the DCP assay was detected using a Perkin Elmer 
1420 multilabel counter Victor 3 in luminometer mode for 0.1s/well.  
2.8.1 DCP plate assay set up  
Plates for Chou Talalay combination analysis were set up as described in Table 
9. 
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Figure 10: DCP assay  
(A): DCP is leaked when membrane integrity has been compromised.  
(B): DCP coupled reaction for measuring cell death. The AFF-Glo peptide is a 
substrate for dead cell protease and cleavage releases aminoluciferin. 
Aminoluciferin is a substrate for a modified recombinant luciferase but not for 
wild-type luciferase. Figure taken with permission from www.promega.com 
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Table 9: Plate set up for IC50 determination of drug toxicity and 
combination analysis  
 (A) Plate set up for determination of drug toxicity. (B) Combination analysis 
plate set up – grey wells round the outside the plates are filled with HBSS 
only. Each virus +/- drug combo is set up in quadruplicate and each plate has 
its own no virus/no drug controls.  
 
B 
A 
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2.9 Caspase Assay 
The Caspase-Glo 3/7 (G8090), Caspase 8 (G8200) and Caspase 9 (G8210, all 
Promega, UK) assays are methods of quantifying the amount of a specific 
caspase, either 3/7, 8 or 9 as a measure of apoptosis. Figure 5 describes the 
different actions of each of the caspases within the apoptosis pathways. 
Caspase 3/7 is referred to as an executioner caspase and is the key caspase 
where the intrinsic and extrinsic apoptosis pathways converge. Caspase 8 is 
only activated if the extrinsic pathway is activated and caspase 9 only when 
the intrinsic pathway is activated (Figure 5). 
The kits contain a substrate that lyses cells, releasing any caspase 3/7, 8 or 9 
present within the cell into the surrounding medium. This released caspase 
cleaves the luminogenic substrate producing a light signal proportional to the 
amount of caspase present. The luminosity is measured a using Perkin Elmer 
Victor3 machine. 
2.9.1 Caspase Assay- Optimisation and Validation 
Assay validation and optimisation was carried out to identify the optimal 
conditions for the analysis of apoptosis in cells treated with HSV1716 + drug.  
To identify a positive control for apoptosis, the caspase 3/7 assay was carried 
out on cells from the Virttu panel (Table 5) incubated with drugs described in 
the literature as inducers of apoptosis, namely vincristine, carboplatin, 
Etoposide & docetaxel. Caspase 3/7 activity determined after 72 hours drug 
exposure. Docetaxel was the only chemotherapeutic tested which increased 
caspase 3/7 levels in all cell types tested relative to non-drug treated cells 
and was used as a positive control for apoptosis in all subsequent experiments 
(results not shown). 
2.9.2 Assay set up  
96 well plates were seeded with cells using the format  illustrated in Table 10 
with three cell lines being used per plate. Each cell line was assayed in 
quadruplicate. Control wells had equal volumes of medium added and 
docetaxel was used as a positive control to validate each plate. After caspase 
activity, the CytoTox-Glo total lysis method was used (to estimate the total 
number of cells present) to correct the caspase 3/7, 8 &9 values for the 
number of cells in each well.  
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For analysis, the caspase 3/7 or caspase 8 light output readings were divided 
by the total DCP value for the respective well to correct for the number of 
cells in each well. GraphPad Prism was used to graph the relative caspase 3/7 
or caspase 8 activities. Student T tests were used to compare the groups of 
interest. If the caspase ratio in the HSV1716 + drug combination was 
significantly (P<0.05) greater than the caspase level in both the HSV1716 
alone AND the drug alone, then the combination was said to have significantly 
increased caspase levels relative to controls 
2.10 Virus free Conditioned Medium (VF_CM) +/- drugs 
Production of virus free conditioned medium (VF_CM)  
Figure 11 shows a schematic representation of the production of VF-CM. T175 
flasks were set up using the cell line of interest. Once confluent monolayers 
had formed they were infected with HSV1716 MOI 1 and the medium 
harvested after 24 hours. To remove any live virus the medium was passed 
through a 0.1uM filter (Millipore syringe filters, McQuilkin SLVV033RS) to 
produce the VF-CM. In order to confirm that all viruses were removed from 
the VF-CM by the 0.1μM filter plaque forming assays (section 2.7) were carried 
out on a number of test samples before and after filtration. The results of 
these are shown in Figure 11B  
2.10.1 Production of UV -VF-CM The production of UV VF-CM used exactly 
the same protocol as VF-CM except prior to infection of the T175 flasks, 
HSV1716 was placed under UV light (wavelength 260 - 270nm) at room 
temperature for 15 mins. A sample of the UV treated virus was titrated as 
described in Materials and Methods section 2.7 and no plaque forming units 
were detected.  
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Table 10: Plate set up for caspase assays 
 Control  HSV1716 Drug 
alone 
HSV1716 + 
drug 
Docetaxol  
Cell line 1 
Cell line 2 
Cell line 3 
 
Each cell line was assayed in quadruplicate.  
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(B) Titre of CM before filtration Titre of VF-CM after filtration 
6x105 pfu/ml 0 
3.2x106 pfu/ml 0 
5.5x106 pfu/ml 0 
9.1x106 pfu/ml 0 
3.5x107 pfu/ml 0 
Figure 11: Production of virus free conditioned medium (VF-CM). 
(A) Monolayers were infected with HSV1716 and the medium harvested at 
24hours. The medium was then passed through a 0.1μM filter to remove 
virus. The resultant VF-CM was used in 96 well plate DCP assays to look for 
increased cell death in recipient cells that had been exposed to VF-CM +/- 
drug.  
(B) (B) Filtration using a 0.1um filter removed all HSV1716.  *The limit of 
detection using this assay is approximately 100 pfu/ml. 
 
+ Drug 
 
No drug 
A 
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2.10.2 Plate set up- VF-CM +/- Drugs 
 96 well plates of various cell lines were seeded in the wells at volumes of 
100μl. After 24hours, when the VF-CM + drug were being added, medium was 
first removed. 100ul VF-CM (or uv VF-CM)  was added and either 100μl of fresh 
medium (no drug) or 100μl of medium with the drug before being incubated 
for 48 hours at which point the amount of dead cells was quantified using the 
DCP assay (described in M&M section 2.8). 
2.11 PCR  
PCR reagents used per reaction were: 12.5ul Quick Load taq 2X master mix 
(New England Bio labs M0271S), 10μM forward primer (in 0.5μl) 10μM reverse 
primer (in 0.5μL), 1μl template + nuclease free water (to final reaction 
volume of 25μl). PCR was performed in a Techne Genius Thermal cycler under 
the following conditions: 95oC for 2 minutes (hot start) then 30 cycles x (94oC 
for 15 s 62oC for 60s, 68oC for 60s); 2 mins at 68oC followed by a 4oC 
incubation. After PCR, 20μl of the reaction was electrophoresed on a 1% 
agarose gel containing Ethidium Bromide alongside DNA markers of known 
concentrations to confirm band size. The gel was visualised using a UV lamp 
and photographed.  
Primer sequences:  
UL42:  forward (5’-ACGACGACGTCCGACGGCGA3’) reverse: (5’-GTGCTG 
GTGCTGGACGACAC3’) 
 gH forward(5'-CGACCACCAGAAAACCCTCTTT3') reverse: (5'-
ACGCTCTCGTCTAGATCAAAGC3') 
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Chapter III - Results 
3.1 HSV1716 in combination with targeted anti cancer agents 
OVs kill cancer cells while sparing normal cells. They utilize viral gene 
products to facilitate immune evasion, and commandeer cellular biosynthetic 
machinery to replicate, while manipulating cell death programs. Many of the 
pathways that viruses manipulate are the same pathways that tumour cells 
must deregulate in order to become tumourigenic, and as a consequence, 
these same pathways are the targets for anticancer drug development. Thus is 
seems reasonable to expect that certain types of chemical, radiological or 
biological therapy could enhance or synergize with OVs in terms of improving 
tumour cell killing. HSV1716 is currently a clinical stage OV. In clinical trials 
new treatments are compared to ‘standard of care’, therefore it is important 
to determine if the standard of care, usually chemotherapy or radiotherapy, 
has a negative effect on HSV1716 efficacy.  
This premise behind this thesis was to study the effect of currently approved 
and potential new therapies on HSV1716. This was both to look for synergistic 
combinations but also to look for any antagonistic combinations that could 
then be avoided in the clinical setting.  
Due to the vast numbers of current and potential anti-cancer drugs that are 
currently either approved or in late stage clinical trials it was recognised that 
in order to test them, a high throughput screen required to be designed. As 
this screen is an in vitro screen carried out on cell lines over 72hours, no 
immunotherapeutic agents were tested. 
 It is not the intent of this thesis to detail the interaction between HSV1716 
and every drug tested; instead this chapter will summarise the results of the 
screening. Chapters IV and V then investigate a smaller number of drugs 
identified within this screen as synergistic with HSV1716 in order to try and 
elucidate the mechanism of the observed HSV1716/drug interaction.  
 96 well plates were seeded with cells and treated with HSV1716, HSV1716 
plus drug or drug alone at various concentrations. After 72hours DCP 
(Materials and Methods section 2.8), a measure of cell death, was 
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determined. Validation of the assay was carried out looking at a number of 
variables. The results are detailed below: 
3.1.1 Validation of DCP assay in measuring virally mediated cell death 
HSV1716 infection over 72 hours caused an increase in DCP leakage from the 
various cell lines used which was dependent on the HSV1716 MOI 
(Figure12A).The DCP basal level varied with the different cell lines and 
probably reflected the intrinsic DCP amounts present in each cell line. Even 
the lowest MOI of 0.001 HSV1716 increased DCP levels above base line (base 
line ~ 0.0001 Figure 12A) and DCP levels increased in a dose–dependent 
manner to reach a maximum at MOI 10. In all cell lines the increase at MOI 1 
was >50% of base line. In order to study the effect of HSV1716 in combination 
with another drug, it was necessary to pick a MOI of virus that had some 
effect, but did not kill all cells. If the virus alone killed all cells then it would 
not be possible to measure any further increase in cell death. Therefore MOI 
of 0.5 and 0.05 were chosen for future studies.  
3.1.2 Validation of DCP assay in measuring drug mediated cell death 
Drug toxicity could also be detected using the DCP assay as shown in Figure 
12B. Increasing concentrations of the c-met inhibitor XL-184 caused increased 
leakage of DCP from CP70, one58, HepG2 (Figure 12B). As with virus, UVW 
cells displayed the highest basal levels of DCP (0.01 on log scale) which 
increased by ~300% at 50μM XL-184. One58 had the lowest basal levels and 
smallest increase at 50μM (~50%). Basal levels of DCP were intermediate in 
CP70 and HepG2 cells (0.01 on log scale) and exposure to 50μM XL-184 
increased DCP leakage by ~100% in these cells lines.  This indicates the DCP 
assay is sensitive enough to be able to measure dose-dependent changes in 
cell death.  
3.1.3 Validation of DCP assay- cell density dependent. 
Another assay variable that was investigated was the effect of different cell 
densities on the DCP assay. If cells are overgrown there will be higher basal 
DCP levels. The results for the two cell lines UVW and Ovcar3 cells incubated 
for 72 hrs with HSV1716 (C and D), or XL-184 (Figure 12E and 12F) are shown.  
Ovcar3 and UVW were plated out at different cell densities ranging from 8000 
cells/well to250 cells/well and, 24 hours after plating out at these densities, 
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they were treated either with XL-184 at 50, 10 or 1μM or HSV1716 at MOI 10, 1 
or 0.1 for 72 hours. Although the basal DCP levels at higher cell densities were 
higher per se, the difference between HSV1716 or drug-treated cells and 
control cells was greatest at 5000 cells/well and this density was used in all 
subsequent studies. 
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Figure 12: Validation of DCP assay  
(A): MOI-dependent DCP leakage from various cell lines infected with 
HSV1716. (B): Dose-dependent toxicity of XL-184 in CP70, one58 and HepG2 
cells using DCP assay. (C): Effects of UVW cell density on DCP readings after 
treatment with HSV1716 at MOI 10, 1 or 0.1 for 72 hours. (D): Effects of Ovcar 
cell density on DCP readings after treatment with HSV1716 at MOI 10, 1 or 0.1 
for 72 hours. (E): Effects of UVW cell density on DCP readings after treatment 
with XL-184 at 50μM, 10μM or 1μM for 72 hours. (F): Effects of Ovcar3 cell 
density on DCP readings after treatment with XL-184 at 50μM, 10μM or 1μM for 
72 hours. 
 
C 
D 
E 
F 
A 
B 
94 
 
3.1.4 DCP assay to determine drug toxicity values and plot median effect. 
As a prerequisite to Chou Talalay analysis of treatment combinations, the 
effect of each modality (i.e. drug or virus) must first be assessed on its own. 
Drug toxicity for each individual drug was assessed. 96 well plates of all cell 
lines were set up as described in Materials and Methods 2.6 and treated with 
serial dilutions of drug. Serial dilutions were used to determine a range where 
the high doses would induce death in almost 100 % of cells, and low doses 
would have an effect close to the baseline of untreated cells. Drug doses were 
chosen based on the data available from the manufacturer 
(www.Selleckchem.com) with a starting doses at least 100 fold higher than 
any suggested dose. The dose effect curve was plotted. In order to use the 
sigmoidal dose effect curve for analysis it must first be transformed into the 
corresponding linear form, termed the median effect plot. Examples of the 
median effect plot (Figure 13B) for the dose effect curve (Figure 13A) are 
show in Figure 13.  
The dose effect curve graphs the dose on the X axis and the Fa (fraction 
affected) on the Y axis. Fraction affected means the amount of cells (as a 
ratio of the total proportion) that is killed by the drug dose. For example, if 
75% of the cells are killed by a particular dose of drug, the Fa would be 0.75. 
The Fu is the fraction unaffected. In this example the Fu would be 0.25 (25% 
or cells are not killed by this dose of drug). LD50, ID50, ED50 or CI50 are often 
used interchangeably as a measure of how toxic a drug is. Although often used 
interchangeably IC50 is the maximal concentration of drug to cause 50% 
inhibition of biological activity of cancer cells, ED50 refers to the dose of the 
drug which causes 50% response in a biological system or which treats 
effectively 50% of the  population and LD50 is the concentration causing 50% 
cell death (LD = lethal dose). Within this thesis the term IC50 will be used, in 
terms of the dose of drug required to cause a 50% increase in cell death.  
There are three features of the linear median effect plot that are important 
for subsequent combination analysis: M, which indicates the slope of the line 
(three examples are shown where m =2, 3 and 5 in Figure 13B). The second 
parameter is the point at which the line intercepts the x axis (log (Fa/fu=0); 
and R2 . R2 indicates how well the real data from the actual experiment fits 
the trend line an R2 value of 1 means the experimental data fits the line 
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perfectly. An R2 value of >0.9 is considered good. If the R2 value was less than 
0.85 then the data was considered not being accurate enough for Chou 
Talalay analysis and repeated. If an accurate median effect plot could not be 
obtained, the drug + HSV1716 combination was analysed by the enhancement 
of data analysis. 
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Figure 13: Transformation of various sigmoidal dose effect curves. 
(A) Into the corresponding linear forms. 
 (B) By the median-effect plot, where y = log (fa/fu) versus x = log (D). The 
slopes (in this case, equal to 2, 3, and 5 for curves a, b, and c) signify the 
degree of sigmoidicity, and the antilogs of the x-intercepts on the axis, where 
fa/fu = 1 [or log(fa/fu) = 0], give the Dm values, which signify the potency of 
each drugs. 
 (C) An example of the median plot produced, for Cp70 cells treated with 
AZD8055. The R2 value in (c) is 0.9458. The M value is 0.3065and the Dm is-
0.3105. Figures A and B are from (Chou, 2006). 
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3.2 Combination analysis 
Chou Talalay is the most widely used method of studying drug/drug (or 
virus/drug) interactions between two modalities in vitro (Chou and Talalay, 
1981, Chou and Talalay, 1984).This type of analysis is one of the few available 
that identifies beneficial interactions based on an extrapolated equation. The 
possibility of predicting a false positive is minimized as the analysis takes 
account of both the potency (the IC50, LD50 or DM value) and the shape of the 
dose effect curves (M values) in the precise analysis of two therapeutic 
combinations. The method defines the expected additive effect of two (or 
more) agents and quantifies synergy or antagonism by way of how different 
the measured effect is from the expected additive effect. The equations are 
detailed elsewhere (Chou and Talalay, 1981, Chou and Talalay, 1984, Chou, 
2006). Interpretation of the CI (combination Index) values are defined as: CI=1 
indicates an additive effect; a CI of <1 indicates synergy; and a CI > 1 
indicates antagonism. Synergy is the working together of two agents to 
produce a result greater than the sum of their individual effects, while 
antagonism is less than that of an additive effect. A negative Fa value occurs 
when the test DCP value is less than the control without any drug, which 
indicates a decreased cell death, and is therefore scored as antagonistic. 
Initially the commercially available Compysyn software was used to analyse 
the data, but in order to streamline the analysis an Excel spreadsheet was 
designed where the raw DCP values could be pasted in and the spreadsheet 
would then automatically calculate Fa and CI values and graph the 
corresponding results from the raw data.. 
Figure 14 shows an example of Chou Talalay analysis, where synergy 
betweenHSV1716 + the mTOR inhibitor AZD8055 were assessed in Hep3b and 
Huh7 cells. Combinations were set up at two HSV1716 MOIs (0.5 and 0.05) and 
8 AZD8055 doses. Results were divided into high dose (25, 12.5, 2.5 and 1.25 
μM) and low dose (0.25, 0.125, 0.025 and 0.0125 μM) AZD8055 and separate 
plots along with their respective Fa and CI table of values are presented. 
HSV1716 in combination with AZD8055 in Hep3B cells (Figure 14A & B) was 
highly synergistic with 14/16 drug/virus combinations generating CI values <1. 
The only two combinations not synergistic were 25μM and 12.5μM AZD8055 
with HSV1716 at MOI 0.5. HSV1716 in combination with AZD8055 in HuH7 
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(Figure 14 C& D) cells was highly synergistic with 14/16 drug/virus 
combinations generating CI values <1. The only two combinations not 
synergistic were 25μM and 12.5μM AZD8055 with HSV1716 at MOI 0.05. 
For the initial round of screening, looking at the  mTOR inhibitors AZD8055, 
Ku003 and Temsirolimus, 8 drug doses with 2 MOI of HSV1716 resulting in 16 
different combinations were tested. For the rest of the drugs tested, (listed in 
Table 7) 4 drug doses and 2 virus doses were used, resulting in 8 different 
combinations points. Synergistic points are scored as a percentage of the total 
measured, so for example if 6/16 combinations were synergistic this would be 
given a score of 37.5%.  
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Figure 14: Chou Talalay plots for HSV1716 in combination with AZD8055  
 (A& B) Hep3B, (C&D) HuH7. The relevant tables of Fa (x axis) and CI values (y 
axis) for the individual AZD8055 concentrations and HSV1716 MOI accompany 
each Chou Talalay plot. If the Fa value was negative then the corresponding 
CI value could not be determined and CI values above 4 are not presented in 
the graphs. 
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3.3 Enhancement of cell death 
Chou Talalay analysis depends on both modalities (both drug and virus) being 
cytotoxic to cells. Many of the drugs that were examined in combination with 
HSV1716 were cytostatic, preventing cell growth rather than cytotoxic. 
Despite looking for toxicity across a wide range of concentrations, median 
effect plots could not be derived within the confines of this screen.  As an 
alternative, another method of analysing the data in which the drug itself was 
not toxic to the cells, termed ‘enhancement of cell death’ was designed. 
Measuring enhancement is based on the drug alone not having any effect in 
terms of increasing DCP (or cell death) levels on its own. Enhancement as 
described in this thesis is defined as any increase in cell death seen in the 
presence of a non toxic drug when given in combination with HSV1716, above 
the cell death levels seen with HSV1716 alone.  
Comparison was made between the percentage of cell death relative to 
untreated control cells (no virus, no drug) resulting from increasing 
concentrations of drug alone or in combination with HSV1716. The results are 
presented graphically and points (referring to each combination point) were 
scored for enhancement (greater than control) or antagonism (combination 
less than control). Figure 15 shows a schematic illustration. The drug X alone 
(blue line) doesn’t increase DCP levels above the basal level of untreated 
cells. HSV1716 is shown at two different MOI, 0.5 and 0.05. Both MOI increase 
the DCP levels. At MOI 0.05 the level is increased to 2 (double the 
background) when virus is given alone (no drug). With MOI 0.5 the DCP level 
increases to 3 (x the background level in the absence of drug). When drug X is 
given in combination with HSV1716 the levels of cell death increase, in this 
example to 2.3 and 3.4 respectively, despite the drug having to effect on its 
own. The drug is therefore assumed to be enhancing the virally mediated cell 
death. 
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Figure 15: Schematic illustration of enhancement of cell death analysis. 
Drug X has no effect alone (blue line), however when given in combination 
with HSV1716 increased cell killing above the levels expected by HSV1716 
alone (dotted lines). 
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3.4 Heat map of combination analysis between HSV1716 + targeted 
agents 
It was identified early in the process that the results varied from cell line to 
cell line; hence in order to try and build up as complete a picture as possible, 
each combination was tested in a number of difference cell lines from the 
Virttu Cell line panel. A total of 17 agents were assessed for 
synergy/enhancement with HSV1716 in between 8-10 cell lines, resulting in 
approximately 170 Chou Talalay /enhancement plots. Rather than detail every 
drug and cell line separately a ‘heat map’ (Table 11) was produced. The heat 
map gives the percentage of synergistic/enhancement of cell death’ hits’ – for 
example if a drug had been studied at 4 concentrations using 2 different 
HSV1716 MOI i.e. = 8 combination points then if 6/8 points were 
synergistic/enhanced cell death then they would be given a score of 75%. The 
heat map does not take into account if the synergies were seen at low or high 
drug concentration, or at low or high MOI.  
When taken as a group, mTOR inhibitors + HSV1716 had the most ‘hits’. 
AZD8055 + HSV1716 combination generated some ‘hits’ in every cell line. In 
terms of least ‘hits’ Dovitinib, a FLT3/cKIT inhibitor, and Erlotinib and 
gefitinib (both EGFR inhibitors) had almost no ‘hits’, with only 1/8 
combination points in Hep3B being synergistic with dovitinib.  
VEGFR inhibitors, Sunitinib and Sorafenib, all had ‘hits’ in 8/10 cell lines, 
while pazopanib, another similar VEGFR inhibitor had ‘hits’ in 9/9 lines, 
although Huh7 only had 1/8 points synergistic.  
The heat map gives a percentage of the number of combination points 
measured that were ‘hits’. Generally synergies were seen at some drug dose 
with some virus doses.  
Drug sensitivity was charted (Table 12). There does not appear to be any 
correlation between sensitivity of the cell line to the drug and whether or not 
it synergises/enhances cell death when given in combination with HSV1716.  
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Temsirolimus mTOR 50 60 30 0 0 10 0 30 90 60 
AZD8055 mTOR 88 88 30 75 50 69 63 35 100 30 
Ku0063794 mTOR 50 25 13 38 0 50 13 25 45 30 
GSK690693 AKT 75 88 nd 0 100 0 0 13 0 13 
LY294002 PI3K 13 50 nd 50 100 38 38 50 0 25 
Sunitinib VEGFR 13 38 75 100 0 75 63 63 13 75 
Sorafenib VEGFR 75 63 88 100 0 0 50 63 50 50 
Pazopanib VEGFR 13 nd 50 100 88 63 38 50 75 100 
Cabozantinib cMET/VEGFR 63 50 13 63 63 0 25 38 63 13 
Nintedanib FGF/VEGFR 25 50 68 25 nd 13 25 50 25 nd 
Crizotinib ALK/ROS 38 nd 50 100 75 0 38 13 38 75 
Dovitinib FLT3/cKIT 0 13 0 0 0 0 0 0 0 0 
Gefitinib EGFR 0 63 nd 0 0 nd 0 0 0 0 
Erlotinib EGFR 0 0 nd 50 0 0 13 0 13 0 
GSK1120212 MEK 13 0 50 68 100 0 0 0 0 38 
LY2228820 p38MAPK 50 0 nd 75 63 0 13 0 63 75 
Doxorubicin  chemo 100 13 63 63 63 25 13 nd 38 63 
Table 11: Heat map of synergistic points observed by ChouTalalay or enhancement 
of cell death.  
  Analysis of 3 HCC, 2 glioma, 2 Mesothelioma and 3 ovarian cell lines when HSV1716 was 
given in combination with a targeted therapy. The therapy, alongside the target it 
inhibits is shown. Colours represent the percentages of synergistic/enhanced (shown 
underlined cell death points measures, from blue where there was no synergy to red 
where all combinations looked synergistic/enhanced cell death. 
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Temsirolimus mTOR 16 nd 0.25 25 25 15 19 25 8 11 
AZD8055 mTOR 3 12 25 25 25 25 0.3 4 3 6 
Ku0063794 mTOR 1.5 25 25 25 25 25 4 6 7 5 
GSK690693 AKT 25 3 
 
7 25 10 10 25 25 12 
LY294002 PI3K 3 8 
 
25 25 25 10 8 10 10 
Sunitinib VEGFR 7 5 7 12 15 8 20 13 13 10 
Sorafenib VEGFR 3 3 4 1.5 0.1 8 3 1 2 9 
Pazopanib VEGFR 11 6 3 6 0.3 18 40 40 40 10 
Cabozantinib cMET/VEGR 2.8 4 2.6 15 11 5 8 1.4 15 5 
Nintedanib FGF/VEGFR 40 10 40 20 15 10 15 15 15 40 
Crizotinib ALK/ROS 12 20 5 18 2 13 25 30 20 7 
Dovitinib FLT3/cKIT 0.5 5 
 
2 40 2 5 40 2 2 
Gefitinib 
 
4 15 
 
30 15 10 30 20 10 30 
Erlotinib EGFR 1 25 
 
20 1 15 40 17.5 25 10 
GSK1120212 MEK 0.6 0.1 
 
25 0.2 25 7 8 25 25 
LY2228820 p38MAPK 25 30 
 
17.5 30 15 20 10 6 30 
Doxorubicin MEK 0.2 0.2 0.02 0.7 0.2 0.08 0.15 25 0.6 0.08 
Table 12: IC50 values for each drug in μM. 
The shading refers to the sensitivity of the cell line with blue representing the 
lines most sensitive to the drug while red indicates the cell lines which are 
least sensitive. The shading for each drug is relative to the other cell lines 
with the same drug. 
 
 
 
 
 
 
105 
 
3.5 HSV1716 + anti cancer agents reduce HSV1716 replication  
Within the combination analysis described above, a HSV1716 variant that 
expresses GFP was used. GFP expression was used as a marker of viral 
replication. It was noted that despite seeing synergy when HSV1716 and 
another drug was used in combination, GFP levels (hence viral replication) 
were decreased in most combinations, suggesting that viral replication was 
inhibited (data not shown). 
In order to confirm the effects of such drugs on the replication efficiency of 
HSV1716, single step growth kinetic curves were set up at selected 
drug/HSV1716 combinations as described in the Materials and Methods section 
2.7. For virus/drug combinations, the virus yield (input virus dose/output 
progeny) was determined and compared to virus alone. 
3.5.1 MTOR inhibitors effectively inhibit HSV1716 replication 
The effect of AZD8055, Ku0063794 and temsirolimus on HSV1716 viral 
replication was tested in U87MG, Cp70 and SPC111 cells. For SPC111 cells the 
results are shown graphically in Figure 16. The viral yields are shown in Table 
13. In all cases the presence of the drug substantially and significantly 
decreases viral replication (P values comparing HSV1716 alone vs. HSV1716 + 
drug are shown in Table 13.In some instances, such as in SPC111 and CP70 
cells at 10uM and 1uM AZD8055 and Ku0063794, there was no virus replication 
(the yield was less than 1, indicating that each input virion did not produce 
any progeny virions).  
3.5.2 Doxorubicin effectively inhibits HSV1716replication 
Doxorubicin also inhibited HSV1716 replication in both UVW, which are 
sensitive to doxorubicin (IC50 of 0.2μM Table 12) and the resistant Ovcar 3 cell 
lines. At 1μM, doxorubicin reduced HSV1716 (input MOI 0.5) replication by 99% 
in UVW cells and 96% in Ovcar3 cells (Table 13B). 
The IC50 of doxorubicin in UVW cells was estimated to be approximately 
0.2uM, hence all UVW cells at 1μM Doxorubicin would be likely to be killed, 
hence viral replication is unlikely to occur (as all the cells are dead). 
However, 1μM doxorubicin in Ovcar3 cells had no effect (in terms of causing 
cell death) thus the reason for the lack of viral replication is not due to the 
lack of live cells the virus needs for replication. 
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3.5.3 Sunitinib effectively inhibits HSV1716replication 
HSV1716 replication (at MOI 0.5 only) was tested in the presence of Sunitinib 
at concentrations 1 & 10μM as described in M&M section 2.7. At these 
concentrations synergy was observed with HSV1716 (Table 11). 6 cell lines 
were chosen for analysis, UVW and Skov3 had shown very few synergistic 
points when Sunitinib was given in combination with HSV1716, while SPC111, 
one58, Cp70 and Ovcar3 cells had shown a high number of synergistic points. 
The results are shown in Table 13B. All cell lines HSV1716 replication in the 
presence of 10μM Sunitinib completely abrogated viral replication. With the 
lower dose of 1μM Sunitinib was substantially and significantly reduced 
HSV1716 replication in all lines. In SPC111, Cp70, Ovcar3 and Skov3 the 
HSV1716 yields in the presence of 1μM Sunitinib decrease by between 50-80 
fold, for example in SPC111 the yield decreased from 9300 virions per input 
virion, to 113 per input virion. The fold decrease in yield in one58 and UVW 
was lower, with only a tenfold decreased in viral replication. As HSV1716 + 
Sunitinib combination had a high number of synergistic points, while UVW did 
not , this fold difference in yields did not correlate with whether Sunitinib is 
synergistic or not in the cell lines tested. 
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Figure 16: Yields of HSV1716 +/- drugs. 
SPC111 cells infected with HSV1716 at MOI 0.5 (V1) or 0.05 (V2) alone or in 
combination with (A) AZD8055 at 10μM, 1μM, 0.1μM or 0.01μM. (B) Ku0063794 
at 10μM, 1μM, 0.1μM or 0.01μM. (C) Temsirolimus at 10μM or 1μM.  
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Table 13: Yields from SPC111, Huh7 and Cp70 cells infected with HSV1716 
+/- Drugs.   
Treatment  Average 
 Yield 
P 
value 
Average 
Yield 
P 
value 
Average 
Yield 
P 
value  
 SPC111 Huh7 Cp70 
V1 (0.5 MOI) 35238   88095   2888   
V1+ 10 μM AZD8055 1 <0.0001 292 <0.0001 0.39 0.0004 
V1+ 1 μM AZD8055 1 <0.0001 461 <0.0001 0.69 0.0004 
V1 + 0.1μM AZD8055 984 <0.0001 9698 <0.0001   
V1 + 0.01μM AZD8055 1952 <0.0001 3444 <0.0001   
V2 (0.05 MOI) 11920   75066   1493  
V2+ 10μM AZD8055 1 <0.0001 840 <0.0001 0.36 <0.0001 
V2+ 1μM AZD8055 1 <0.0001 1120 <0.0001 0.78 <0.0001 
V2 + 0.1μM AZD8055 4466 <0.0001 9600 <0.0001   
V2 + 0.01μM AZD8055 3133 <0.0001 9333 <0.0001    
V1 (0.5 MOI) 35238   88095   2888   
V1 + 10μM Ku0063794 998 <0.0001 998 <0.0001 0.87 0.0004 
V1 + 1μM Ku0063794 1317 <0.0001 1317 <0.0001 0.92 0.0004 
V1 + 0.1μM Ku0063794 193 <0.0001 9984 <0.0001   
V1 + 0.01μM Ku0063794 284 <0.0001 13174 <0.0001   
V2 (0.05 MOI) 11920   75066   1493  
V2 + 10μM Ku0063794 786 <0.0001 786 <0.0001 0.73 <0.0001 
V2 + 1μM Ku0063794 1400 <0.0001 1400 <0.0001 1.69 <0.0001 
V2 + 0.1μM Ku0063794 213 <0.0001 7866 <0.0001   
V2 + 0.01uM Ku0063794 398 <0.0001 14000 <0.0001    
V1 (0.5 MOI) 35238   88095   2888  
V1+ 10μM Temsirolimus 857 <0.0001 1285 <0.0001 71 <0.0001 
V1+ 1μM Temsirolimus 2269 <0.0001 2714 <0.0001 113 <0.0001 
V2 (0.05 MOI) 11920   75066     
V2+ 10μM Temsirolimus 186 <0.0001 1746 <0.0001 72 <0.001 
V2+ 1μMTemsirolimus 866 <0.0001 2973 <0.0001 170 <0.001 
Cells were infected with HSV1716 at MOI 0.5 (V1) or (V2)0.05 alone or in 
combination with 10μM, 1μM 0.1μM or 0.01μM AZD8055, between10- 0.01μM 
Ku0063794 and 10μM or 1μM Temsirolimus.  The average yield of three 
replicates is shown. The difference between the yield of virus alone vs. virus + 
drug was analysed by Students T test, with P values shown.  
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Table 13B: Titres from HSV1716 alone were compared to HSV1716 + drug 
Cell 
line 
Treatment Yield P 
value 
 Yield P 
value 
Cp70 no drug 553    
Sunitinib(1μM) 11 <0.002 
Sunitinib(10μM) 0 <0.002 
one58 no drug 3196  
Sunitinib(1μM) 282 <0.004 
Sunitinib(10μM) 0 <0.002 
Ovcar3 no drug 86830  No drug 83333 
Sunitinib(1μM) 1070 <0.005 Doxorubicin(0.1uM) 60 <0.002 
Sunitinib(10μM) 13 <0.002 Doxorubicin(1uM) 27 <0.002 
Skov3 no drug 3370    
Sunitinib(1μM) 42 <0.003 
Sunitinib(10μM) 0 <0.002 
Spc111 no drug 9300  
Sunitinib(1μM) 115 <0.002 
sunitinib(10μM) 14 <0.002 
UVW no drug 11016  No Drug  7476 
sunitinib(1μM) 660 <0.002 Doxorubicin(0.1uM) 6 <0.002 
sunitinib(10μM) 0. <0.002 Doxorubicin(1uM) 3010 <0.002 
These were analysed using Students T test. P values are shown. Values of 
<0.05 are considered statistically significantly different. 
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Conclusions chapter III – combination analysis 
The first aim of this thesis was to set up a screen that could be used to look at 
the effect of HSV1716 in combination with a wide variety of drugs in a number 
of cell lines in cancer types that were of clinical interest to Virttu Biologics. 
Table 11 summarises the results of HSV1716 in combination with 17 drugs in 9- 
10 cell lines. 
The agents tested were mostly targeted therapeutics that act upon kinase 
signalling networks frequently upregulated as part of tumourgenesis and 
therefore block drivers of growth within the cancer cell. Doxorubicin, a 
chemotherapeutic, is included in the analysis. At the time of this project 
Virttu was planning a phase I clinical trial in hepatocellular carcinoma. 
HSV1716 was going to be injected by intra-arterial injection in combination 
with TACE. TACE or trans-catheter arterial chemo-embolisation combines 
chemotherapy and small embolic particles that blocks tumour blood supply, 
acting by both keeping the chemotherapeutic agent at the tumour site, but 
also stalling tumour growth due to blood supply restriction. As HSV1716 was 
going to be given in combination with TACE doxorubicin, it was important to 
study the effects of this agent on viral efficacy.  
As most of the agents investigated block drivers of growth within the cancer 
cell it is perhaps not surprisingly that, in the presence of all drugs examined 
and detailed in this chapter, these agents almost always completely 
abrogated production of progeny virions. Despite this, synergy or enhanced 
cell death was observed with many of the drugs and the reason for such 
increased cell death is not increased virus mediated lysis of the cells. Other 
mechanisms of cell death were therefore investigated and are described in 
subsequent chapters.  
At the inception of this project, it was envisioned, perhaps somewhat naively, 
that the screen may reveal particular cell types where HSV1716 synergised 
with a specific class of drug. However the results reveal a much more complex 
picture. Even between similar drugs (for example between mTOR inhibitors 
temsirolimus, AZD8055 and Ku0063794) the results varied. There are two 
classes of mTOR inhibitor (Figure 17); rapamycin and its closely related 
rapalogues including Temsirolimus inhibit the mTOR complex (mTORC) 1 only 
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via binding to FKBP12 whereas dual mTOR inhibitors (AZD8055 and Ku0063794) 
bind directly to mTOR in both mTORC 1 and 2. In this thesis there was no 
synergy between HSV1716 and Temsirolimus in U87MG, UVW, one58 or SPC111 
cells, but with HSV1716 + AZD8055, synergy was observed at more than 50% of 
the points measured in these 4 cell lines. However another dual mTOR 
inhibitor, Ku0063794 was analysed and the results were different from both 
AZD8055 and Temsirolimus. 
Rapamycin and mTORC1 inhibitors have been reported to induce autophagy, 
(Sudarsanam and Johnson, 2010), and there are several reports of non HSV 
oncolytic viruses in combination with mTORC1 inhibitors enhancing 
autophagy,(Yokoyama et al., 2008, Zhuang et al., 2011). In parallel with this 
thesis, Anna Claudia Lima, and Leigh McGibbon (both University of Strathclyde 
MSc/BSC students respectively) carried out projects in collaboration with 
Virttu Biologics to investigate autophagy both in terms of HSV1716 as a single 
agent and in combination with other agents such as mTOR inhibitors, in a 
number of cell lines from the Virttu cell line panel. No potent induction of 
autophagy by the mTOR/HSV1716 combination was observed and results were 
presented as posters and shown in Appendix 1. We therefore discounted 
increased autophagic cell death induced by HSV1716 in combination with 
mTOR inhibitors as a source of synergy. It also seems more likely that the 
differences between the three mTOR inhibitors are due to variable off-target 
effects associated with the kinase inhibitors themselves. The various cell lines 
will have different dependencies on different signalling networks and 
therefore be more or less susceptible to inhibition by off target kinases. 
Similarly, Sunitinib, Sorafenib and Pazopanib are three kinase inhibitors that 
principally target VEGFR2, (Table 7). In combination with HSV1716 all three 
drugs were synergistic at all combinations in glioma U87MG cells. However in 
the other glioma line in the panel, UVW, only Pazopanib was synergistic while 
both Sunitinib and Sorafenib displayed no synergy in any HSV1716 + drug 
combination. Dovitinib is another multi targeted kinase inhibitor that was 
tested in combination with HSV1716. Dovitinib targets FGFR/cKIT but also has 
activity against VEGFR/PDGFR and therefore surprisingly, was antagonistic 
with HSV1716 in all cell lines. The variations between cell lines and the 
variations between similar drugs suggest that the synergistic action between 
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oncolytic virus and drugs is not universal, and depends on the cell type and 
targeted agent The finding that multi targeted tyrosine kinase inhibitors are 
not all equivalent is not novel. Canter et al., 2011 examined the in vitro 
cellular effects of Sunitinib and Pazopanib (which are used interchangeably in 
the clinical setting) in a panel of renal cell carcinomas (RCCs) and found that 
Sunitinib, but not Pazopanib, induced apoptosis and was cytotoxic across the 
panel tested, while Pazopanib was cytostatic. This indicates that the two 
agents may have a profoundly different activity, dependent upon the context 
in which they are used. 
As many of these small molecule kinase inhibitors target evolutionary 
conserved ATP binding sites within the target kinase, many inhibitors are 
promiscuous and also inhibit off target kinases. Reaction Biology Corp 
(http://reactionbiology.com/webapps/largedata/) (Anastassiadis et al., 2011) 
assayed 178 commercially available kinase inhibitors against a panel of 300 
protein kinases and found many off target interactions occurred with 
seemingly unrelated kinases. The resulting Kinase Inhibitor Resource (KIR) 
data set is available in the public domain and allows users to retrieve the 
activity of a single inhibitor against the entire kinase panel to look for off 
target inhibition. Unfortunately, AZD8055 and Ku0063794 are not profiled by 
Anastassiadis et al., 2011; however Sunitinib, Sorafenib, Pazopanib and 
Dovitinib all feature. Table 14 shows the kinases that are inhibited by more 
than 80% by each of the four inhibitors. It is therefore conceivable that the 
combinations of different kinase inhibitors with HSV1716 generate synergies 
across the various cell lines via action on an off-target kinase rather than 
inhibiting the primary target. This would explain the variation amongst closely 
related targeted agents in cell lines from the same cancer indication. For 
example, the only kinase that is inhibited by the synergistic inhibitors 
Sunitinib, Sorafenib and Pazopanib, but not by Dovitinib (which is antagonist 
with HSV1716) is FMS. FMS, first discovered as the proto-oncogene responsible 
for Feline McDonough Sarcoma, encodes the tyrosine kinase transmembrane 
receptor for colony stimulating factor 1 receptor (CSF1R). FMS is 
homodimeric, contains a kinase insert domain and is a member of the 
CSF1R/PDGF receptor family of tyrosine-protein kinases. FMS mediates most if 
not all of the biological effects of CSF1, which control the production, 
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differentiation and cell function of the monocyte/macrophage lineage (Sherr, 
1990). Mutations in FMS have been associated with sustained signals for cell 
growth and a predisposition to myeloid malignancy (Follows et al., 2005). 
There are a number of commercially available FMS inhibitors; these have not 
been tested in combination with HSV1716 yet, but such combinations warrant 
further investigation.  
Thus, further data mining of the KIR resource would hopefully identify off-
target kinases consistently inhibited by synergistic targeted agents and these 
could be screened in the cell line panel. Such analysis would hopefully 
identify key nodes to target in order to generate synergy with HSV1716. Since 
these kinase inhibitors also block virus replication, identification of such an 
important node(s), capable of regulating successful oncolysis will be 
advantageous in the design of novel next generation variants. For example 
proteins or microRNAs that augment the key activity could be expressed by an 
HSV1716 variant, leading to better oncolysis. 
The cell lines used in this study could also be useful in identifying the key 
synergy axes. The mutations within a number of cell lines used in this study 
are listed in COSMIC (catalogue of somatic mutations in cancer; 
http://cancer.sanger.ac.uk/cosmic) and this may give information on 
pathways/signalling networks upregulated in specific cell lines.  
Therefore, although a number of additional studies will identify key 
interactions that generate synergies, further insights will be gained from 
identifying the underlying mechanisms whereby inhibition of replication in a 
cancer cell leads to enhanced cell death.  
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Table 14: Off target kinases that are inhibited by 80% or more by Sunitinib, 
Sorafenib, Pazopanib or Dovitinib 
Sunitinib Sorafenib Pazopanib Dovitinib 
ALK    
 ARAF   
ARK5/NUAK1   ARK5/NUAK1 
 BRAF   
   BLK 
CAMK2a    
CAMK2d    
CHK2    
CK1g2    
c-Kit  c-Kit c-Kit 
   c-SRC 
CLK2    
 DDR2   
DAPK2    
FGR   FGR 
   FGFR1 
   FGFR3 
FLT3 FLT3  FLT3 
FLT4/VEGFR3  FLT4/VEGFR3 FLT4/VEGFR3 
FMS FMS FMS  
 HIPK4   
HGK MAP4K4   HGK MAP4K4 
KHS MAP4K5   KHS MAP4K5 
LCK   LCK 
LRRK2    
  KDR/VEGFR2  
   LYN 
   LYN B 
MELK   MELK 
MINK/MINK1   MINK/MINK1 
MLCK2/MYLK2   MLCK2/MYLK2 
  MLK1/MAP3K9  
  MLK3/MAP3K11 
MST1/STK4   MST1/STK4 
PDGFRa PDGFRa PDGFRa PDGFRa 
PDGFRb PDGFRb  PDGFRb 
PHKg1    
   PKN1/PRK1 
PKCnu/PRKD3    
 RAF1 RAF1  
RET RET  RET 
  ROS/ROS1  
RSK3   RSK3 
RSK4   RSK4 
TAK1   TAK1 
TBK1    
TRKA   TRKA 
TRKB   TRKB 
TRKC   TRKC 
ULK1    
YES/YES1   YES/YES1 
 ZAK/MLTK   
Results from queries on (http://reactionbiology.com/webapps/largedata/) 
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Figure 17: mTOR inhibitors and their targets.  
There are two classes of mTOR inhibitors, those which act only on mTOR1 and 
those that act on both mTORC1 and mTORC2. The mammalian target of 
rapamycin is a protein kinase of the PI3K/AKT signalling pathway with a 
central role in controlling cancer cellular growth. 
 
 
 
 
 
 
 
 
 
Temsirolimus 
AZD8055  
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Chapter IV - Modulation of apoptosis 
Introduction 
Results from the previous chapter show that there is greater than expected 
amount of cell death when HSV1716 is given in combination with a number of 
drugs. AZD8055, Doxorubicin and Sunitinib were initially chosen for further 
study to elucidate the mechanism behind such synergy, based on the fact that 
all three had shown synergy in a significant proportion of the cell lines. 
Furthermore, these synergies were not due to increased oncolysis, indeed the 
opposite, viral replication was substantially reduced in the presence of these 
drugs. MTOR inhibitors, like AZD8055 are largely cytostatic and exert their 
anti tumour effect by preventing cells from proliferating. On their own they 
do not increase cell death.  
If late stage viral replication is blocked, the viral proteins that usually would 
be produced to prevent cell apoptosis are not produced. Therefore the 
presence of the virus entering the cell may stimulate the cell to die by HSV 
dependent apoptosis (HDAP) (Nguyen and Blaho, 2009). This HDAP had 
previously been shown to occur only in transformed cells, and occurs by 
upregulation of the intrinsic apoptotic pathway (Nguyen et al., 2007a). Using 
specific caspases inhibitors, Aubert et al, 2007  showed that inhibitors of 
caspase 9 suppressed HDAP while caspase 8 inhibitors did not, indicating that 
HDAP occurs through the intrinsic pathway of apoptosis (Aubert et al., 2007).  
HSV1716, like wild type HSV-1, retains the ability to express a full 
complement of viral proteins that are able to inhibit apoptosis of the host 
cell. In terms of production of progeny virions this prevention of apoptosis by 
HSV1716 is positive, as it allows complete viral replication before the host cell 
is killed. However, HSV1716 infection could still result in cancer cell death, by 
HDAP, if the production of the HSV1716 viral proteins that inhibit apoptosis 
was prevented. Therefore, anticancer drugs that inhibit viral replication, 
combined with HSV1716, could enhance cancer cell death by HDAP. 
As HDAP is caspase-dependent and occurs via the intrinsic pathway, one way 
of measuring this enhanced HDAP would be to look for increased levels of 
specific caspases. Caspase 3/7 levels could be measured to look at increases 
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in apoptosis, and caspase 8 or 9 could be used to differentiate between 
intrinsic and extrinsic pathways.  
4.1: HSV1716 + AZD8055 – synergistic combinations of HSV1716 and 
AZD8055 correlates with enhanced caspase 3/7 activity  
In order to test if the combination of mTOR inhibitors and HSV1716 are 
increasing apoptosis, caspase assays (as described in the Materials and 
Methods section 2.9) were set up. Briefly 96 well plates were set up with 2 
rows of each cell type at ~5000 cells/well. After 24 hours in culture, cells 
were treated with HSV1716 (MOI 1), AZD8055 (5μM) or both and left for 48 
hours (in quadruplicate). Replicate plates were set up to measure caspase 3/7 
and caspase 8 activities.  
Both caspase 3/7 and 8 assays were performed in order to confirm apoptosis 
and to separate out the intrinsic and extrinsic pathways of apoptosis in 8 cell 
lines of the Virttu cell line panel. Caspase 3/7 activity was analysed in Huh7 
(Figure 18A), Hep3B (Figure 18B) One58 (Figure 18C), UVW (Figure 18D), Skov3 
(Figure 19A), U87MG (Figure 19B), Ovcar3 (Figure 19C) and Cp70 (figure 19D).  
The difference in the combination treatment was considered significant if it 
was different to both treatments alone. In all 8 cell lines the caspase 3/7 
levels were significantly higher than either treatment alone indicating that 
the HSV1716 + AZD8055 combination enhances cell death by increasing 
apoptosis.  
The combination of HSV1716 + AZD8055 failed to significantly augment 
caspase 8 activities relative to virus alone in any of the cell lines. Graphs of 
the data obtained for each of the cell lines are shown in Figure 20 and Figure 
21. In all 8 cell lines HSV1716 + AZD8055 did not increase caspase 8 activity 
relative to AZD8055 alone. The results are summarized in Table 15. Neither 
AZD8055 nor HSV1716 alone were strong apoptotic stimulants in tumour cell 
lines that were tested, based on caspase 3/7 and caspase 8 activity assays.  
When used in combination, however, HSV1716 + AZD8055 caused a significant 
increase in apoptosis. This increased apoptosis could explain why the 
combination of HSV1716 + AZD8055 is synergistic in killing tumour cell lines.  
As the combination HSV1716+ AZD8055 failed to augment caspase 8 activity it 
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can be concluded that the increased levels of apoptosis seen in the 
combination treatment does not act through the extrinsic apoptotic pathway 
and is likely to be through the intrinsic apoptotic pathway.  
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Figure 18: Caspase 3/7 assay in (A): Huh7, (B):one58, (C): UVW or (D): 
Hep3B cells treated with HSV1716, AZD8055 or both. 
 
Each bar represents the average of at least four separate wells with the error 
bar representing the standard deviation within the data points.  In all 
experiments docetaxel is used as a positive control. Results were analysed by 
ANOVA with post test Tukey’s analysis which analyses the differences between 
each group. For each graph the p values are shown, p values < 0.05 are 
considered to be statistically significant.  
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Figure 19: Caspase 3/7 assay in (A): Skov3, (B): U87MG (C):Ovcar3 & 
(D):CP70 cells treated HSV1716, AZD8055 or both in combination. 
Docetaxel is used as a positive control. Results were analysed by ANOVA with 
post test Tukey’s analysis which analyses the differences between each group. 
For each graph the p values are shown p values < 0.05 are considered to be 
significant.  
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Figure 20: Caspase 8 assay in (A): Huh7, (B): Hep3B (C): one58 & (D): UVW 
cells treated with HSV1716, AZD8055 or both. 
Docetaxel is used as a positive control. Each bar represents the average of at 
least four separate wells with the error bar representing the standard 
deviation within the data points. Results were analysed by ANOVA with post 
test Tukey’s analysis which analyses the differences between each group. In 
each comparison P<0.05 indicating that none of the measured differences in 
caspase 8 activity was statistically significant. 
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Figure 21: Caspase 8 assay in (A): Skov3, (B): U87MG (C):Ovcar3 & (D): 
CP70 cells–treated with HSV1716, AZD8055 or both.  
Docetaxel is used as a positive control. Each bar represents the average of at 
least four separate wells with the error bar representing the standard 
deviation within the data points. Results were analysed by ANOVA with post 
test Tukey’s analysis which analyses the differences between each group. In 
each case P>0.05 indicating that the measured differences in caspase 8 
activity in all cell lines was not statistically significant.  
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Table 15: Summary of caspase 3/7 and caspase 8 activities in Hep3B, 
HuH7, CP70, Ovcar3, Skov3, U87MG, UVW and one58 cells following 
treatment with HSV1716 and AZD8055 in combination. 
 
Cell line Caspase 3/7 Caspase 8 
Hep3B +++ - 
HuH7 +++ - 
CP70 +++ - 
Ovcar3 +++ - 
SKOV3 +++ - 
U87MG + - 
UVW +++ - 
One58 +++ - 
 
+++ = significantly increased relative to either or both HSV1716 and AZD8055 
alone, + = increased relative to both HSV1716 and AZD8055 alone, - no effect. 
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4.2: Results – HSV1716 + Sunitinib: synergistic combinations of HSV1716 
and Sunitinib correlates with enhanced caspases 3/7 activity 
Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase 
inhibitor. Results in Table 12 show that the combination of HSV1716 + 
Sunitinib is highly synergistic in Ovcar3, Hep3B, one58, & U87MG cells but not 
in Huh7, Skov3 or UVW cells. In all cell lines tested (Table 13Error! Reference 
source not found.) HSV1716 replication was significantly decreased in the 
presence of Sunitinib indicating the mechanism by which the HSV1716 + 
Sunitinib combination is synergistically increasing cell death is not due to 
increased viral replication in the presence of Sunitinib.  
 Caspase assays were carried out to investigate if the synergistic effect is due 
to increased apoptosis (Described in Materials and Methods section 2.9). The 
caspase 3/7 assay measures changes in apoptosis levels and the caspase 9 
assays allow differentiation between the intrinsic and extrinsic pathways.  
The cell lines Hep3B and Ovcar3, where HSV1716 + Sunitinib were shown to be 
synergistic by combination analysis, also had significantly enhanced caspase 
3/7 activity. Figure 22A and C respectively shows the levels of caspase 3/7 in 
Hep3B and Ovcar3 while Figure 22B and D shows the caspase 9 activity. 
Caspase 3/7 is significantly increased in the combination treatment compared 
to either treatment alone. Caspase 9 activity was significantly increased in 
both lines tested with HSV1716 + Sunitinib suggesting that the stimulated pro 
apoptotic response acts primarily through the intrinsic, mitochondria – 
dependent pathway. The other two cell lines in which HSV1716 + Sunitinib 
were synergistic by combination analysis (Table 11) (U87MG and one58) were 
also analysed by caspase 3/7 assay. The results are shown in Figure 23. Again, 
caspase 3/7 activity was significantly enhanced compared to either treatment 
alone. In the 3 cell lines in which the combination analysis revealed no 
synergy between HSV1716 and Sunitinib (UVW, Huh7 and Skov3) there was no 
increases in caspase 3/7 activity (Figure 24). 
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Figure 22: HSV1716 + Sunitinib significantly enhanced caspase 3/7 activity 
compared to HSV1716 or Sunitinib alone. 
(A)Hep3b and (B) Ovcar3.Caspase 9 activity is shown in (C) Hep3b and (D) 
Ovcar3. Each bar represents the average of at least 4 separate data points. 
Error bar on graphs representing the standard deviation. Results were 
analysed by ANOVA with post test Tukey analysis which analyses the 
differences between each group with P values shown on graphs p values of 
<0.05 are considered to be statistically significant.  
 
 
 
P<0.01 
P<0.01 
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Figure 23: HSV1716 + Sunitinib significantly enhanced caspase 3/7 activity 
compared to HSV1716 or Sunitinib alone. 
(A)U87MG, (B)one58. Each bar represents the average of at least 4 separate 
data points. Error bar represent the standard deviation. Results were analysed 
by ANOVA with post test Tukey analysis which analyses the differences 
between each group with P values shown on graphs p values of <0.05 are 
considered to be statistically significant. 
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Figure 24: HSV1716 in combination with Sunitinib does not enhance 
caspase 3/7 activity compared to HSV1716 or Sunitinib alone. 
(A)UVW, (B)Huh7 , (C) Skov3. In all three cell lines there is little or no 
evidence of synergy between HSV1716 and Sunitinib (Table 11).  Each bar 
represents the average of at least three separate data points with the error 
bar representing the standard deviation within the data points. Results were 
analysed by ANOVA with post test Tukey analysis which analyses the 
differences between each group with P values shown on graphs p values of 
<0.05 are considered to be statistically significant. 
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4.3: HSV1716 + Doxorubicin– synergistic combinations of HSV1716 and 
doxorubicin correlates with enhanced caspases 3/7 activity 
Introduction 
Doxorubicin is an agent that interacts with DNA by intercalation and inhibits 
topoisomerase II. By stabilizing the DNA topoisomerase complex after it has 
broken the DNA chain the DNA double helix is prevented from resealing. The 
accumulation of such DNA damage leads to apoptosis. In preliminary 
experiments (Table 11) Doxorubicin and HSV1716 show synergy or enhanced 
cell death in Hep3b, Huh7 & Ovcar3 cells despite HSV1716 replication being 
inhibited. 
Figure 25 shows relative caspase 3/7 and caspase 9 activity for Hep3B & Huh7 
cells treated with HSV1716 + Doxorubicin. In both cell lines there were 
significantly increased levels of both caspase 3/7 and 9 compared to either 
treatment alone. As caspase 9 is activated only via the intrinsic apoptosis 
pathway this suggests that the method by which HSV1716 + Doxorubicin 
combine to enhance cell death is mediated via this pathway.  
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Figure 25: HSV1716 in combination with doxorubicin significantly 
enhances caspase 3/7 and 9 activity compared to HSV1716 or Doxorubicin 
alone.  
Hep3B (A&B), Huh7(C&D). Each bar represents the average of at least three 
separate data points with the error bar representing the standard deviation 
within the data points. Results were analysed by ANOVA with post test Tukey 
analysis. P values are shown on the graphs, p values of <0.05 are considered 
statistically significant. 
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4.4: Dovitinib and Erlotinib do not combine synergistically with HSV1716 
and fail to activate caspase 3/7. 
The EGFR TK inhibitors Dovitinib and Erlotinib are mostly antagonistic with 
HSV1716 (Table 11). In order to investigate whether the increase in caspase 
3/7 activity was a general result of giving HSV1716 in combination with 
another drug, caspase 3/7 levels were assessed in cells treated with HSV1716 
in combination. Cell lines in which all combination analysis points were 
antagonistic were chosen. In Hep3B, Hepg2 and Huh7 cells (Figure 26) 
Dovitinib does not combine synergistically with HSV1716 and the combination 
failed to enhance caspase 3/7 activity compared to drug or virus alone.  
Likewise, Erlotinib (Table 11) did not combine synergistically with HSV1716 in 
Hep3B or Ovcar3 and only at 1 point in Huh7 cells and the combination failed 
to enhance caspase 3/7 activity compared to drug or virus alone (Figure 27). 
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Figure 26: HSV1716 in combination with Dovitinib does not enhance 
caspase 3/7 activity compared to HSV1716 or Dovitinib alone. 
Each bar represents the average of at least three separate data points with 
the error bar representing the standard deviation within the data points. 
Results were analysed by ANOVA with post test Tukey analysis which analyses 
the differences between each group with P values shown on graphs p values 
<0.05 are considered to be statistically significant. 
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Figure 27: HSV1716 in combination with Erlotinib does not enhance 
caspase 3/7 activity compared to HSV1716 or Erlotinib alone. 
In all 3 cell lines there is little or no evidence of synergy between HSV1716 + 
Erlotinib. Each bar represents the average of at least three separate data 
points with the error bar representing the standard deviation within the data 
points. Results were analysed by ANOVA with post test Tukey analysis which 
analyses the differences between each group with P values shown on graphs P 
values of less than p<0.05 are considered statistically significant.  
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4.5: HSV1716 + Sorafenib– synergistic combinations of HSV1716 and 
Sorafenib does not correlate with enhanced caspases 3/7 activity 
Sorafenib is a multi-kinase tyrosine kinase inhibitor that is a standard systemic 
therapy for recurrent hepatocellular carcinoma. Like Sunitinib it targets 
VEGFR-2, but also targets Raf-1 and B-raf. Like Sunitinib, the combination of 
Sorafenib + HSV1716 synergistically enhanced cell death in a number of Virttu 
cell lines (data not discussed in Chapter III but results are in Table 11). 
Caspase assays were carried out to investigate if the synergistic effect is due 
to increased apoptosis (as described in Materials and Methods section 2.9). 
Figure 28 shows the caspase3/7 assay for Ovcar3, Hep3b and Huh7 alongside 
their combination analysis plots. Unlike Sunitinib the levels of caspase 3/7 
activity in the HSV1716 + Sorafenib combination were not enhanced. This 
suggests that the mechanism for increased cell death when Sorafenib + 
HSV1716 are given in combination is not due to increased apoptosis.  
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Figure 28: HSV1716 in combination with Sorafenib did not enhance 
caspase 3/7 activity in cell lines (Ovcar3, Hep3B & Huh7) where synergy 
was seen in the combination analysis. (B). Each bar represents the average 
of at least three separate data points with the error bar representing the 
standard deviation within the data points. Results were analysed by ANOVA 
with post test Tukey analysis which analyses the differences between each 
group with P values shown on graphs p values of <, 0.05 are considered to be 
statistically significant. 
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Conclusions- Chapter IV apoptosis 
Combination analysis described in chapter III revealed that HSV1716 was 
synergistic with AZD8055, Sunitinib and Doxorubicin, in increasing cell death in a 
number of the Virttu cell lines despite viral replication being substantially 
decreased. In order to elucidate the mechanism by which such synergy was 
occurring apoptosis was investigated.  
There is some evidence in the literature that herpes viruses can cause apoptosis 
of cancer cells, even when viral replication cannot proceed, in a process termed 
HSV dependent apoptosis (HDAP)(Nguyen and Blaho, 2009) HSV entering a host 
cell stimulates a host cell response, generally a pro apoptotic one. Usually viral 
proteins would be produced to counter this response. However, if HSV1716 
replication is blocked, as in the presence of drugs, such viral proteins would not 
be produced and the cell would become apoptotic. This premise of upregulated 
apoptosis was investigated as a mechanism that could be occurring in these cells 
in the presence of non-replicating HSV1716 and drugs such as mTOR inhibitors, 
Doxorubicin and Sunitinib.  
 The results in this chapter (IV) indicate that, at least in some instances, 
increased levels of apoptosis correlated with the synergies observed in chapter 
III. The combination of HSV1716 + AZD8055 in almost every cell line tested was 
synergistic or enhanced cell death; this correlated with significantly increased 
levels of caspase 3/7 compared to either treatment alone. There was no such 
correlation with caspase 8 levels suggesting intrinsic rather than extrinsic 
apoptosis. Caspase 8 is activated by the extrinsic apoptotic pathway – where a 
signal from outside – for example a death signal such as TNFα, CD95 or Fas ligand 
binds to the cell surface receptor, causing cleavage of pro-caspase 8 which in 
turn cleaves caspase 3.As there is no increase in caspase 8 levels the 
upregulation of apoptosis is likely to be via the intrinsic, mitochondria pathway. 
HSV1716 + Sunitinib synergy also correlated with increased levels of caspase 3/7. 
In cell lines where this combination was not synergistic, caspase 3/7 levels were 
not significantly elevated. This correlation was not restricted to targeted 
therapies as it was also observed with Doxorubicin, a chemotherapeutic that 
targets DNA. In Hep3B and Huh7 cells, both of which showed synergy with 
HSV1716 + Doxorubicin significantly increased levels of caspase 3/7 were also 
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observed. Caspase 9 activation was also examined in the Doxorubicin HSV1716 
combination and was statistically significantly higher in Huh7 and Hep3B cells 
(Students T test p<0.05). 
Non synergistic drugs such Dovitinib and Erlotinib were assessed in combination 
with HSV1716 and there was no increase in caspase 3/7 levels. 
The following model is proposed in Figure 29. When HSV1716 replication is 
efficient, the virus is able to produce viral proteins that counteract the cells 
innate antiviral responses, which include induction of apoptosis. However when 
HSV1716 replication is blocked, e.g. by an mTOR inhibitor or a tyrosine kinase 
inhibitor, viral replication and the production of viral proteins to counteract the 
host response are blocked, therefore the cell can initiate an antiviral response 
which eventually leads to apoptosis of the cell. The model proposed above 
requires the virus to have entered the cell and will only be active at high MOIs, 
especially as the presence of the drug prevents virion production. 
There are numerous instances in chapter 3 where the synergy observed was at 
low MOI in the presence of drugs that are inhibiting viral replication. This would 
therefore not fit with the above model since HSV1716 has to be present in the 
cell to initiate the apoptotic pathway. It seems likely that a secondary 
mechanism is active in these synergies and secreted signals, possibly produced in 
infected cells and ‘warning’ surrounding uninfected cells, may also be involved.  
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INNATE ANTIVIRAL RESPONSE
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Figure 29: Route of cell death – oncolysis or innate anti-viral response 
When HSV1716 replication is efficient, the virus is able to produce viral proteins 
that counteract the cells innate antiviral responses which includes induction of 
apoptosis. However when HSV1716 replication is blocked, e.g. by a mTOR 
inhibitor of a tyrosine kinase inhibitor, viral replication and the production of 
viral proteins to counteract the host response are blocked, therefore the cell 
can initiate an antiviral response which eventually leads to apoptosis of the cell.  
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Additionally, other mechanisms must be involved as Sorafenib was also 
synergistic with HSV1716 in combination analysis, yet there was not an increase 
in caspase levels. Sorafenib is a multi-kinase inhibitor that principally targets 
VEGFR2. It also inhibits PDGFR, Raf-1 and B-Raf. However, unlike Sunitinib, 
whose principal action is also thought to be through VEGFR2, its synergy with 
HSV1716 did not correlate with an increase in apoptosis. Reovirus type 3 RT3D in 
combination with B-raf inhibitors enhanced cell death in a number of cell lines 
and this was found to be mediated through ER stress induced apoptosis 
(Roulstone et al., 2015). As ER stress induced apoptosis would also result in 
increased caspase 3/7 measured, and this was not observed, it is unlikely that 
the synergy between HSV1716 and Sorafenib described in this thesis is due to 
increased ER stress-induced apoptosis. 
A constitutively active Ras pathway has been reported to prevent the activation 
of type I IFN mediated anti-viral responses in human cancer cells (Battcock et 
al., 2006), suggesting that a Ras or Raf inhibition may abrogate this blockade, 
leading to increases in the IFN-response. An increase in IFN response would block 
viral replication and it may sensitize surrounding, neighbouring cells to the 
effects of Sorafenib and account for the enhanced levels of cell death when 
HSV1716, despite not replicating (Figure 16), is given in combination with 
Sorafenib. 
  
139 
 
Chapter V:  Mechanisms of synergy of HSV1716 with 
targeted agents that reduce viral replication. 
Introduction 
Chapter III examined the combination of HSV1716 + drugs in inducing enhanced 
levels of tumour cell death. In many instances HSV1716 in combination with 
another agent acted synergistically, or enhanced cell death in tumour cell lines, 
despite the drug having a negative effect on viral replication. Further 
examination detailed in Chapter IV (apoptosis) indicates that the increased cell 
death observed when some drugs, such as the mTOR inhibitors AZD8055, 
receptor tyrosine kinase Sunitinib, or Doxorubicin, were given in combination 
with HSV1716 correlated with increased levels of intrinsic apoptosis. The 
intrinsic apoptotic pathway, as the name suggests, is stimulated from inside the 
cell, therefore in order for the virus to up regulate intrinsic apoptotic pathway it 
must be within the cell. As viral replication is inhibited by the presence of these 
drugs, increased cell death via the intrinsic apoptotic pathway would be limited 
to those cells that the initial input dose of virus entered. 
However, within the combination analysis many synergies that were observed in 
Chapter III with HSV1716 and a number of drugs were at low HSV1716 MOI. At an 
MOI 0.05 only 1 in 50 cells would be infected with the input virus and as the 
presence of all drugs tested substantially inhibited HSV1716 replication, the 
majority of the cells within the experiment are unlikely to be infected with 
HSV1716. Yet despite this, the combination of HSV1716 + drug is either 
synergistic or enhancing cell death. Therefore, it is likely that another 
mechanism is at play. In order to elucidate the mechanisms by which a non 
replicating HSV1716 at a low MOI can be combining with another agent to 
enhance cell death, experiments were designed to investigate the hypothesis 
that HSV1716 infection potentiates the anti –tumour effect of other drugs by 
secreting a virus-derived cell death signal into the microenvironment. This 
HSV1716 infection related exportable death signal (termed HIRED) could ‘warn’ 
neighbouring cells of the potential viral infection and coincidentally sensitise 
these neighbouring cells to the anti tumour effects of drugs. 
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5.1: Cells infected with HSV1716 produce an ‘HSV1716 Infection Related 
Exportable Death signal (HIRED signal)  
Production of Virus Free Conditioned Medium (VF-CM) 
Infectious HSV1716 virus will kill cells in culture by lysis. For all cell lines in the 
Virttu cell line panel (Table 8), except 3T6 cells, HSV1716 replicated well and 
caused extensive cytopathic effect (cpe) within 72 hours in cell culture. The 
yields of HSV1716 (amount of progeny virions/initial input virus) produced vary 
from cell line to cell line, but in all cases spread and propagation of virus would 
mask the more subtle effect of a secreted death signal. 
In order to separate out oncolysis from any ‘exportable death signal’ produced 
and secreted by HSV1716 infected cells, virus free conditioned medium (VF-CM) 
was produced as the basis for these experiments. Donor cells were infected with 
virus and the medium collected. This VF-CM was then added to non-infected 
cells to see if it had any effect on cell death. In order to determine if virus was 
fully removed by the filtration, plaque forming assays (Materials and Methods 
section 2.7) were performed on VF-CM. In all samples there was no detectable 
virus after filtration (confirming that the filtration step completely removed 
virus any effect seen with VF-CM was not due to oncolysis. Results are shown in 
Figure 11B. 
Production of suitable controls 
To ensure the conditioned medium transferred from donor to recipient cells did 
not simply cause increased levels of cell death due to the depletion of nutrients 
from the medium, equal volumes of fresh medium and conditioned medium were 
used for all groups in all experiments.  
In order to ensure that any exportable death signal was being produced only by 
replicating HSV1716, the amount of cell death produced by a UV irradiated 
HSV1716 virus was compared to the amount of cell death seen in HSV1716 
infected cells. Exposure to UV light for 15 minutes completely inactivates 
HSV1716 and UV irradiated HSV1716 had no effect on cell death as measured by 
DCP (data not shown).  
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5.2: Virus Free Conditioned medium (VF-CM) from infected HSV1716 Skov3 
cells exports a death signal that, in some instances, is enhanced by 
targeted agents.  
VF-CM was produced in and collected from Skov3 cells (as described in Materials 
and Methods section 2.10). Skov3 cells were chosen for the initial pilot 
experiment as they were one of the cell lines within the panel where synergy 
between HSV1716 and a wide variety of drugs and targeted agents was observed 
(see Chapter III). The effect of VF-CM alone, or in combination with compounds 
that specifically inhibited a commonly altered pathway within the cancer cell 
was measured.  
 P38 inhibitor LY2228820, the mTOR inhibitor AZD8055 and the MEK1 inhibitor 
GSK1120212 were chosen as 3 inhibitors that work in different, but key pathways 
that are often altered in cancer cells. Skov3, A431, one58, Hep3B Huh7 and 
U87MG recipient cell cultures were set up in 96 well plates and after 24 hours 
Skov3 VF-CM was added to recipient cells with either no inhibitor, p38 inhibitor 
(final concentration 1uM), mTOR inhibitor (1uM) or MEK inhibitor (1uM). DCP 
substrate was added 48 hours later and total luminosity measured as described 
in materials and methods 2.8. Figure 30 shows recipient cells treated with Skov3 
VF-CM alone, or with p38 inhibitor, mTOR inhibitor or MEK inhibitor. Results are 
expressed as change in percentage of DCP compared to UV VF-CM alone (no 
inhibitor) or as a percentage increase compared to UV VF-CM + appropriate drug. 
UV VF-CM + drug was used as a control as this will take into account any effect 
of the drug on cell death. Without exception all recipient cell lines treated with 
VF-CM had higher levels of DCP than cells treated with UV irradiated VF-CM 
(Figure 30). In all cell recipient cell lines cells treated with Skov3 VF-CM + p38 
inhibitor had enhanced cell death compared to cells treated with the UV VF-CM 
+ p38 inhibitor (Figure 30A-E). In Skov3 recipient cells (Figure 30A), 
Hep3B(Figure 30E), U87MG(Figure 30F) cell death in the presence of Skov3 VF-CM 
+ mTOR inhibitor enhanced cell death. In the other three recipient lines A431, 
one58 and Huh7 (Figure 30B, D and C respectively) mTOR inhibitor did not 
enhance cell death, but MEK inhibitor did. The results are tabulated in Table 16. 
Error! Reference source not found. 
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(A) Skov3 recipient cells treated with Skov3 VF-CM + targeted 
agents.  
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(B) A431 recipient cells treated with Skov3 VF-CM + targeted 
agents.  
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(C) Huh7 recipient cells treated with Skov3 VF-CM + targeted 
agents.  
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(D) one58 recipient cells treated with Skov3 VF-CM + targeted 
agents.  
no inhibitor 
p38 inhibitor 
mTOR inhibitor 
MEK inhibitor 
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Figure 30: Recipient cell cells treated with Skov3 VF-CM + targeted agents 
Results are shown as a percentage change in DCP levels compared the UV VF-CM 
treated cells (no inhibitor) or the percentage change from UV VF-CM + 
appropriate targeted agent. DCP levels for each treatment were averaged from 
at least three replicates. Error bars represent the standard deviation between 
the replicates expressed as a percentage of the average DCP reading (A): Skov3 
recipient cells treated with donor Skov3 VF-CM only, or VF-CM + targeted agent.  
(B): A431 recipient cells treated with donor Skov3 VF-CM only or VF-CM + 
targeted agent. (C): Huh7 recipient cells treated with donor Skov3 VF-CM only or 
VF-CM + targeted agent. (D) One58 recipient cells treated with donor Skov3 VF-
CM only or VF-CM + targeted agent. (E) Hep3B recipient cells treated with donor 
Skov3 VF-CM only or VF-CM + targeted agent. (F) U87MG recipient cells treated 
with donor Skov3 VF-CM only or VF-CM + targeted agent. 
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(E) Hep3B  recipient cells treated with Skov3 VF-CM + targeted 
agents.  
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(F) U87MG recipient cells treated with Skov3 VF-CM + targeted 
agents.  
no inhibitor 
p38 inhibitor 
mTOR inhibitor 
MEK inhibitor 
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Table 16: Enhancement of death signal exported by Skov3 (Skov3VF-CM) by 
targeted agents. 
 No inhibitor * P38 inhibitor  
** 
Mtor inhibitor 
** 
MEK inhibitor 
** 
Skov3 6 16 14 0 
A431 3 15 -4 9 
One58 11 12 -5 16 
Hep3B 8 17 11 5 
Huh7 2.5 12 1 13 
U87MG 7 11 15 3 
Enhancement of cell death is shown in light green.  No effect/inhibitory effect 
on cell death are shown in red. * is compared to the UV VF-CM **compared to the 
UV VF-CM + appropriate agent.  
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5.3: Virus Free Conditioned medium (VF-CM) from HSV1716-infected 3T6 
cells significantly enhances cell death compared to conditioned medium 
from untreated/UV inactivated HSV1716-treated 3T6 cells 
Section 5.1 described experiments carried out in a number of recipient cell lines 
looking for a death signal produced by HSV1716 infected Skov3 VF-CM that can 
be exported to uninfected cells and increase cell death in the recipient cells. 
Increases in cell death when recipient cells were treated with Skov3 VF-CM were 
seen across a number of different recipient cell lines and in a number of 
individual experiments. These increases in cell death were modest and failed to 
reach a statistically significant level. However the experiments were repeated 
with similar results suggesting the effect is real, albeit the effect is too small to 
be reliably measured using the techniques described in this thesis. 
In order to study the exportable death signal further, VF-CM was produced from 
a panel of cell lines to look for any donor line in which the enhancement of cell 
death by VF-CM was much larger and therefore changes in the effect would be 
more measurable using the DCP as a measure of cell death.  
3T6 cells are a cell line derived from Swiss mouse embryos. Unlike all the other 
cell lines described in this thesis, HSV1716 is unable to productively replicate 
within 3T6 cells. HSV1716 enters 3T6 cells, and viral protein synthesis is not 
inhibited but rather there is a block in virus release or egress (Jing et al., 2004).  
3T6 VF-CM was produced (as described in Materials and Methods section 2.10). 
The differences in DCP level between the 3T6 and UV VF-CM for 9 recipient cell 
lines shown in Figure 31 are highly significant (all are p<0.001) by Students t 
Test.  
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Figure 31: DCP values for VF-CM produced by infected 3T6 cell and added to 
recipient Skov3, A431, Ovcar3, One58, Hep3B, UVW, Huh7, U87MG and Cp70 
cells.  
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(A) 3T6 VF-CM export a potent cell death signal to recipient cells   
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5.4: Consistency of exportable death signal in 3T6 cells 
In order to check the consistency of the 3T6 cells to produce an exportable 
death signal, 3T6 VF-CM was produced from 3 different cell seed stocks from the 
Virttu cell bank. 3T6 cells were grown up on separate occasions and infected 
with either UV-inactivated HSV1716 or HSV1716 at MOI of 1 to produce VF-CM. 
The medium was harvested and filtered. CP70, U87MG & Ovcar3 cells were set 
up in 96 well plates as described and DCP measured at 48 hrs. 
The results for recipient cell lines Cp70, U87MG and Ovcar3 are shown in Figure 
33Error! Reference source not found.. There is a significant increase in DCP 
levels when all recipient cell types were treated with 3T6 VF-CM. The changes in 
DCP levels between batches (as measured in the same cell line) were not 
significant. Cells treated with UV irradiated virus had similar DCP levels to mock-
treated cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 
 
 
 
Figure 32: Consistency of exportable death signal produced by HSV1716 
infected 3T6 cells and added to Cp70, U87MG or Ovcar3 cells. 
 
3T6 medium only – medium from 3T6 cells only (no virus added), UV VF-CM: 3T6 
cells treated with UV irradiated HSV1716. 3T6 VF-CM (1, 2 and 3): 3T6 cells 
infected with HSV1716 at MOI of 1, harvested at 48 hours and VF-CM produced.  
1, 2, 3 represent the VF-CM, produced by different cell stocks and made at 
different times. DCP (y axis) is total luminosity. * P value < 0.05 by ANOVA (one 
way analysis of variance). 
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5.5: Cell death induced by 3T6 VF-CM is MOI dependent 
Donor 3T6 cells were infected with HSV1716 MOI of 1 to produce 3T6 VF-CM 
(Figure 31). This VF-CM significantly increased cell death in non HSV1716 
infected recipient cell lines. The results were consistent across 3 experiments, 
using different batches of 3T6 cells to produce the death signal, and consistently 
increased cell death on all recipient cell lines tested (Figure 32). The effects of 
infecting the donor cells with higher and lower MOI of HSV1716 were assessed. 
VF-CM was produced as described in Materials and Methods section 2.10 but 
using differing MOI (from 5 -0.1) of HSV1716 were used to make the VF-CM. The 
various VF-CM were plated out on recipient cells as described previously and DCP 
assays were preformed (Materials and Methods section 2.8). The results are 
shown in Figure 33. In all four recipient lines, cell death was maximal when the 
highest dose of HSV1716 was used to produce the VF-CM. For all 4 recipient 
lines, VF-CM produced with MOI of 0.5 or higher significantly enhanced cell 
death in non-infected recipient cell lines (P<0.05 vs. 3T6 UV).  
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Figure 33: 3T6 VF-CM induced cell death on non infected recipient cell lines 
is more potent when higher MOI of HSV1716 are used to produce the 3T6 VF-
CM.  
3T6CM is medium collected from 3T6 cells. 3T6 UV is UV VF-CM produced in 3T6 
cells. 
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5.6: VF-CM from infected HSV1716 3T6 (3T6 VF-CM) contains a death signal 
that is enhanced by p38 inhibitor and mTOR but not MEK inhibitors. 
3T6 VF-CM described in section 5.3 was also tested in combination with p38, 
mTOR and MEK inhibitors in recipient Skov3, A431, Ovcar3, one58 & Hep3b cells 
(Figure 34). The results show the percentage change in DCP levels compared to 
the DCP levels of the UV VF-CM + appropriate inhibitor. The UV VF-CM + drug 
was used as a control in order to account for any cell death causes by drug 
alone. In all 5 recipient lines, p38 inhibitor significantly increased the levels of 
cell death compared to 3T6 VF-CM alone (Students T test no inhibitor vs. P38 
inhibitor, P<0.01 in all cell lines). 
In all five recipient cell lines the addition of mTOR inhibitor increased cell death 
relative to VF-CM alone. This difference was statistically significant in A431, 
Ovcar3 and one58 cells (P<0.05: students T test no inhibitor vs. MTOR inhibitor) 
but the difference failed to meet significance in Skov3 and Hep3B.  
The presence of MEK inhibitors in combination with 3T6VF-CM in all five 
recipient lines reduced the levels of cell death relative to 3T6 VF-CM alone. The 
results are summarised in the table in Figure 34. The death signal exported by 
3T6 VF-CM is enhanced by p38 inhibitors and mTOR inhibitors in some recipient 
cell lines but not by MEK inhibitors. In the presence of MEK inhibitors the death 
signal from the 3T6 cells is reduced, suggesting that the MEK pathway is possibly 
required for the 3T6 exported death signal to have an effect.  
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B No inhibitor * P38 inhibitor 
** 
mTOR 
inhibitor** 
MEK inhibitor 
** 
Skov3     
A431     
Ovcar3     
One58     
Hep3B     
 
Figure 34 (A): Skov3, A431, one58, Ovcar3 & Hep3B recipient cells treated 
with 3T6 VF- CM in combination with p38, MTOR or MEK inhibitor.  
Results are shown as percentage increase compared to UV VF-CM or UV. Error 
bars show the standard deviation between the 3 replicate wells. (B): Comparison 
of the enhancement of cell death when recipient cells are treated with 3T6 VF-
CM + inhibitor. Dark green = significant enhancement (by Students T test) and 
light green shows were enhancement was seen but failed to meet statistical 
significance.  
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5.7: Ovcar3 VF-CM produced in the presence of mTOR inhibitor (Ovcar3 VF-
CM+AZD) exports a statistically significantly more potent death signal than 
Ovcar3 VF-CM alone in recipient Ovcar3 cells 
Experiments described in earlier sections describe VF-CM produced in donor 
Skov3, and 3T6 cells that have been added to recipient cells in the presence of a 
targeted inhibitor. However, it is possible that the presence of the targeted 
inhibitor may influence the production of the exportable death signal in the 
conditioned medium. In order to investigate this, experiments was set up where 
donor cells used to make the conditioned medium were also treated with the 
mTOR inhibitor AZD8055.  
The six different VF-CMs (Figure 35) were then plated on recipient Ovcar3 and 
Skov3 cells and DCP levels measured as described in section Materials and 
Methods 2.8. The results are shown in Figure 36. Recipient Ovcar3 cells treated 
with Ovcar3VF-CM that had been produced in the presence of mTOR inhibitor 
produced a significantly (by ANOVA P<0.05) higher level of DCP than any of the 
relevant controls. In Skov3 recipient cells, the levels of cell death when VF-CM 
was pre-treated with mTOR inhibitor was higher than VF-CM, or in CM with the 
mTOR inhibitor, although this difference was not significant by ANOVA.  
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Figure 35: Schematic diagram of production of Ovcar3 VF-CM + AZD.  
Ovcar3 cells were plated out at -24 hrs (not shown in the diagram). At time 0, 
the cells were treated with +/- 1uM AZD8055. After a subsequent 24 hrs UV 
inactivated virus or HSV1716 (MOI 1) was added to appropriate plates, giving 6 
different versions of conditioned medium as shown. Each of these was processed 
as described in Materials and Methods section 2.10 to make VF-CM.  
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(A) Ovcar3 recipient cells  
(B) Skov3 recipient cells  
Figure36: Recipient cells treated with the various Ovcar3 VF-CM processed as 
described in Figure 35.  
Absolute DCP levels (luminosity) are shown. (A) Ovcar3 Recipient cells treated 
with Ovcar3 VF-CM + AZD had significantly higher levels of DCP than recipients 
treated with any of the controls. P<0.05 vs. OV+HSV1716, p<0.01 vs. OV+UV+AZD, 
p<0.01 vs. OV+UV, P<0.01 vs. OV+AZD, p<0.001 vs. OV CM. 
(B): Skov3 recipient cells treated with various Ovcar3 VF-CM. DCP levels in the 
cells treated with OV+HSV1716+AZD were higher than controls but failed to meet 
statistical significance level by ANOVA.  
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This thesis provides preliminary evidence that VF-CM from HSV1716-infected 
cells produces a ‘death signal’ that can enhance cell death when exported to 
non infected recipient cells. This signal was detected when VF-CM was produced 
in human cancer cell lines, however the levels of enhancement of cell death in 
recipients was small (generally <10%) and although there is a trend indicating 
that the VF-CM increased cell death in recipient lines, the levels of 
enhancement failed to meet statistical significance. However, these differences 
were reproducible in different experiments, done on different occasions, using 
different cells – suggesting that this is a real, albeit small effect that warrants 
further study.  
In order to further investigate the mechanism by which this exportable death 
signal is increasing cell death in uninfected cells experiments were set up to 
measure apoptosis levels using the caspase activity levels assay described in 
Chapter 4 in cells treated with VF-CM. As the signal produced from 3T6 cells was 
much more potent than that produced in cancer cell lines, further experiments 
were carried out using 3T6VF-CM in order to maximise the chance of successfully 
being able to analyse the effect and mechanism behind this HIRED signal. 
Results – Caspase activation by HIRED signal 
Caspase assays, as described in Materials and Methods section 2.9 were set up. 
Ovcar3 recipient cells were plated out and exposed to 3T6 VF-CM. After 24hrs 
caspase 8 or 9 activity was measured (caspase 8 and 9 differentiate between the 
intrisinic and extrinsic apoptotic pathway, so caspase 3 was not used). Figure 37 
shows the results – the HIRED signal activates caspase 8 in Ovcar3 recipient cells 
but does not activate caspase 9. Caspase 8 is activated through the extrinsic 
apoptosis pathway (Figure 36) while caspase 9 is activated by an intrinsic signal. 
This further suggests that an external, secreted, exportable signal is produced 
by HSV1716 infected cells that is stimulating apoptosis in non-infected cells. 
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Figure 37: Caspase 8 (A) and Caspase 9 (B) activity in Ovcar3 recipient cells 
that have been treated with 3T6 produced VF-CM (either at HSV1716 MOI 5, 
1, with UV treated virus or no virus). 
Relative caspase 8 activity is significantly greater in cells treated with 3T6 VF-
CM HSV1716 MOI 5 or 1 compared to control VF-CM. Caspase 9 is unchanged 
(bottom graph). Each bar represents the average of three replicate wells with 
the error bar the standard deviation. * represents p<0.001 (3T6 HSV1716 MOI 5 
or 1 vs. 3T6 UV Students t Tests).  
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5. 8: Identification of the HIRED signal 
The previous experiments have identified a secreted, exportable signal produced 
by HSV1716 infected 3T6 cells that can increase the levels of cell death in 
recipient cancer cell lines. 
In order to identify the source of this signal, the 3T6VF-CMs were heated at 65oC 
for 1 hr in order to denature the proteins. Surprisingly, the results shown in 
Figure 38 indicate that heating the VF-CM made no difference to the HIRED 
signal. As most proteins would be denatured by this heat treatment it suggests 
the source of the ‘HIRED signal’ is unlikely to be a protein.  
5. 9: The HIRED signal correlates with levels of HSV DNA in conditioned 
medium.  
As the HIRED signal was not affected by heat it was postulated that the signal is 
possibly a nucleic acid. The amount of HSV DNA in the 3T6 VF-CM was estimated 
using PCR. Various VF-CM produced at different time points from infected 3T6 
cells were analysed using two HSV DNA PCRs and compared to the signals in VF-
CM from mock-infected or infected with UV-inactivated HSV1716. PCR was 
performed using the primers and conditions described in Materials and Methods 
section 2.11 for the 2 HSV genes UL42 and gH. In order to partially quantify the 
results, medium spiked with known amounts of HSV1716 was analysed for 
comparison.  
The results are shown in Figure 39. Five samples of VF-CM from HSV1716 
infected 3T6 cells all had higher levels of both UL42 and gH fragments compared 
to the low levels in the VF-CM from 3T6 cells infected with UV-irradiated 
HSV1716. There was no PCR signal in the VF-CM from mock-infected 3T6 cells. 
Electron microscopy (EM) and electron tomography (ET) studies of HSV-1 have 
revealed that virus particles have diameter ranging from 155 to 240 nms 
(Grunewald et al., 2003). Since the production of VF-CM involved filtering 
through 0.1uM filters this filtration step should remove any HSV virions. To 
confirm this, titration assays were performed of the VF-CM in the absence of 
infectious HSV virions. As there is also a weaker signal in the UV-inactivated VF-
CM this suggests that viral DNA from the input dose of virus is also being 
detected by the PCR. 
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Further analysis with primers designed to amplify larger fragments were 
unsuccessful suggesting that these signals were derived from fragmented HSV 
DNA (data not shown).  
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Figure 38: Comparing normal, untreated 3T6 VF-CM to heat inactivated 3T6 
VF-CM. 
At both MOIs there is no difference in the level of DCP after the VF-CM has been 
heat treated at 65oC in either recipient cell line.  
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Figure 39: PCR products of UL42 & gH PCR.  
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Conclusions- Chapter V - HIRED signal 
Cells infected with HSV1716 can produce an HIRED signal that can affect the non 
infected cell. All cell lines analysed in this thesis appeared to secrete some form 
of exportable signal, the most potent of which was generated by HSV1716-
infected 3T6 cells. In these cells, the HIRED signal significantly increased cell 
death in recipient cell lines treated with the 3T6VF-CM, with cell death levels 
being approximately 4-fold higher than cells treated with UV-VF-CM (relative 
controls). This HIRED signal was consistently generated by different batches of 
3T6 cells in three separate experiments.  
3T6 cells are mouse embryo fibroblast cells that support productive wild type 
HSV-1 replication but not HSV1716 replication. This growth defect of HSV1716 in 
3T6 cells occurs after viral protein synthesis – viral polypeptides are produced at 
comparable levels in 3T6 cells infected with either wild type or HSV1716; 
however HSV1716 viral particles appear to be trapped in the nucleus or 
cytoplasm and are unable to egress (Jing et al., 2004). Despite not producing 
progeny virus, 3T6 cells are killed by HSV1716, presumably due to the presence 
of viral proteins and polypeptides and not by oncolysis (Jing et al., 2004, Brown 
et al., 1994). 
Cancer cell lines also appeared to produce this HIRED signal, although the 
potency was much lower, with cell death increasing by between 5 and 15%, 
depending on the cells used to produce VF-CM and the recipient line. Recipient 
cells treated with VF-CM produced in cancer cell lines showed an increased cell 
death compared to controls, although due to the small increases seen these 
failed to meet statistical significance in many instances. Similar results showing 
small increases in cell death in recipient cells treated with VF-CM compared to 
appropriate controls were reproduced across a number of experiments 
suggesting that although the techniques used to measure this HIRED signal were 
not sensitive to yield results that could be considered statistically significant, 
there was a definite trend that suggested this signal is real and warrants further 
study.  
In Chapter III, numerous synergies and enhancement of cell death were seen 
when HSV1716 was used in combination with targeted agents such as mTOR 
inhibitors despite the ability of these agents to significantly abrogate HSV1716 
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replication. In Chapter IV, caspase assays indicate one method by which the 
combination of HSV1716 and mTOR inhibitors increased levels of intrinsic 
apoptosis. However as many of the synergies and cell death enhancements were 
seen at low MOI (bearing in mind these drugs block HSV1716 replication thus the 
amount of virus present is unlikely to increase by replication), it seems unlikely 
that intrinsic apoptosis is the only driver of increased levels of cell death in cells 
treated with HSV1716 and a targeted agent.  
Figure 40 shows the proposed hypothesis. When HSV1716 enters a cell, if viral 
replication proceeds the efficient and productive viral infection diminishes the 
antiviral response and results in weakened HIRED signals. As the lytic replication 
results in destruction of the cell and viral spread then the oncolytic virus will be 
effective in reducing tumour size. If however the virus enters a cell where 
productive infection is diminished, be that by the presence of drugs such as 
mTOR inhibitors, or because viral replication is blocked, then the inefficient or 
incomplete viral replication strengthens the antiviral response, which enhances 
the HIRED signal.  
An additional feature of this model is that the action of the HIRED signal in the 
uninfected cell could be enhanced by the targeted agent that blocks viral 
replication. In order to test this hypothesis, virus free conditioned medium (VF-
CM) from the cancer cell lines Skov3, and the more potent 3T6 VF-CM were 
tested in combination with synergistic agents. The results in chapter V suggest 
transduction of death in the uninfected cell by a HIRED signal can be enhanced 
by targeted agents, especially an mTORi, which was highly synergistic with 
HSV1716. Interestingly, targeting specific pathways seemed important to 
generate the HIRED effect since the HIRED enhancement was observed using a 
p38, mTOR but not a MEK inhibitor; for example, the death signals exported by 
3T6 cells were enhanced by p38 and mTOR inhibitor, but not by MEK inhibitor. 
Figure 40 shows the route cell death when HSV1716 is able to efficiently 
replicate and cell death when HSV1716 replication is blocked. When HSV1716 
replication is blocked, the anti viral innate immune response is not blunted, and 
the infected cell dies by apoptosis as shown in Figure 40. This apoptosis leads to 
the release of factors from the HSV1716 infected cell, a secreted death signal 
that sensitise the surrounding cells to cell death. The potency of the exportable 
death signal is inversely proportional to the amount of productive viral 
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replication: when HSV1716 replication is productive and infectious particles are 
produced then the HIRED signal is blunted. When HSV1716 replication is non 
productive (either blocked or aborted) the viral DNA itself, or as a consequence 
of the presence of the viral DNA presence, the death signal is more potent at 
warning neighbouring cells and sensitising them to cell death.  
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INNATE ANTIVIRAL RESPONSE
is blunted by HSV1716
counter-measures
mTORi
TKi
virus replication
blocked
INNATE ANTIVIRAL                   APOPTOTIC 
RESPONSE                           RESPONSE
HIRED
HIRED
HIRED
HIRED
Efficient  HSV1716 replication 
HSV1716 replication blocked
Figure 40: Route of cell death. 
When HSV1716 replication is efficient, the virus is able to produce viral proteins 
that counteract the cells innate antiviral responses which include induction of 
apoptosis. However when HSV1716 replication is blocked, e.g. by a mTOR 
inhibitor of a tyrosine kinase inhibitor, viral replication and the production of 
viral proteins to counteract the host response are blocked, therefore the cell 
can initiate an antiviral response which eventually leads to apoptosis of the cell. 
During the apoptotic process a signal is released from the dying cell that causes 
both increased apoptosis of the uninfected cells and may also sensitise these 
cells to targeted agents. 
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If the hypothesis  that cell lines in which HSV1716 replication is  inefficient or 
aborted produce a stronger HIRED signal, then using a mTOR inhibitor to  inhibit 
HSV1716 replication in the donor cell line during the production of VF-CM may 
result in a stronger HIRED signal being produced.  
Ovcar3 cells were used in this experiment as HSV1716 replicates to a high yield 
in this line (Table 8) In addition, mTOR inhibitor AZD8055 substantially reduces 
the replication efficacy of HSV1716 in Ovcar3 (Table 13) Thus it was postulated 
that if reduced HSV1716 replication = greater HIRED signal, a difference could be 
measured in Ovcar3 cells. This was indeed the case, the levels of cell death seen 
in recipient Ovcar3 treated with the VF-CM produced in the presence of AZD8055 
were significantly higher than the relative controls, indicating that using the 
mTOR inhibitor to block infection in the donor cell appeared to increase the 
potency of the exportable cell death signal.  
In order to investigate the mechanism of HIRED induced cell death, caspase 
assays, as described in detail in Chapter IV were carried out. The HIRED signal 
from 3T6 cells activated caspase 8 in recipient cancer cells, but did not activate 
caspase 9. The caspase 9 assay detects cleaved caspase 9, a caspase cleaved by 
cytochrome C release, activated by the intrinsic mitochondrial apoptotic 
cascade. The caspase 8 assay detects cleaved caspase 8. Caspase 8 is cleaved in 
response to extrinsic death signals (Figure 5). By using both assays the route of 
the apoptotic cascade can be assessed. Increased caspase 8 and no increase in 
caspase 9 suggests that the increased levels of apoptosis are mediated via the 
extrinsic apoptotic pathway, further suggesting the presence of a secreted 
extrinsic factor that can be exported from HSV1716 infected cells to uninfected 
cells(Yu and He, 2016).  
The source of this HIRED signal was at first assumed to be an IFN type response: 
the experiments detailed here describe a secreted signal, produced by virally 
infected cells that is exportable and increases apoptosis in non infected cells – 
all of which would indicate an IFN type response. However, when the VF-CM was 
heated to 65oC the potency of the signal was unaffected. Although IFNs are small 
molecules it is unlikely they would survive such heat treatment; human IFNϒ is 
destroyed by denaturation at temperatures higher than 50oC (Mulkerrin and 
Wetzel, 1989) and therefore is unlikely to be the source of the HIRED signal. 
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Small peptides, metabolites and nucleic acids would be unaffected by such 
heating – hence more likely candidates as the source of the HIRED signal.  
As well as secreting molecules such as IFNs, cells also secrete extracellular 
vesicles. Extracellular vesicles are defined as vesicles that have the ability to 
transfer ‘cargo’ from one cell to another and can influence the recipient cell.  
HSV-1 has evolved strategies that use the properties and functions of these 
vesicles to evade its host. As well as virions (as known as H (heavy) chain 
particles), other particles, L (light) particles are produced(Hogue et al., 2016). 
These are composed of virus envelope and tegument proteins and have been 
shown to facilitate HSV-1 infection (Szilagyi and Cunningham, 1991). As these 
vesicles contain viral proteins rather than genomes, it is unlikely these L 
particles are the source of the HIRED signal as these proteins would be unlikely 
to survive heating to 650C, and furthermore, the VF-CM is produced by passing 
the medium through a 0.1μM filter. These L particles are between 0.1-0.15μm in 
size(Meckes and Raab-Traub, 2011) and would be removed by such a filtration 
step.  
There are smaller vesicles, around 50 -110 nm in size that are released from 
HSV-1 infected cells (Nolte-'t Hoen et al., 2016). These would be able to pass 
through the filtration step in the production of VF-CM. The ‘cargo’ of these 
vesicles include viral and host transcripts (mRNAs, miRNAs, and long non coding 
(lnc) RNAs) as well as proteins and  components of innate defence against DNA 
viruses such as STING and markers of exosomes such as CD9, CD63 & CD81 
(Kalamvoki and Deschamps, 2016).  
Such exosomes were initially thought of as a way for cells to remove unwanted 
material from cells, but they are now recognised as important in an immune 
response to both viral and microbial infections as they are involved in antigen 
presentation. There is increasing evidence that tumour cells release excessive 
amounts of exosomes. In some instances, exosomes produced by cancer cells can 
induce proliferation and have the potential to convert non-tumourigenic cells 
into tumour forming cells (Zhang et al., 2014). The content of these exosomes 
varies between different physiological and pathological conditions and cell 
types. To date (July 2016) more than 9000 proteins and  5000 mRNA have been 
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detected and deposited in Exocarta (www.Exocarta.org) an open access 
database of contents identified in exosomes in multiple organisms.  
Although this thesis presents no direct evidence that the HIRED signal described 
in this thesis is exosomal, the experiments described show that HSV1716 
infected cells release a exportable signal that causes cell death in uninfected 
cells. The source of the signal is not infectious virions, and is under 100 nm is 
size (based on filtration step) and also survived being heated to 65oC and 
exosomes seem a likely source. 
The presence of the HIRED signal hypothesised in the thesis has also been 
observed by Prof Tim Cripe, who is working on HSV1716 in combination with the 
Aurora A kinase inhibitor (Alisertib). FACS analysis of cells treated with the 
combination revealed not only that overall cell death increased when HSV1716 
was given in combination with Alisertib, but the amount of apoptosis in 
uninfected cells was significantly higher, suggesting a paracrine death signal 
being secreted by HSV1716 infected cells. The poster presenting this early work 
was presented at American Society of Gene and Cell Therapy 2016 (ASGCT) by 
Les Sprague and is shown in Appendix 4. 
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Final Discussion – future perspective 
Oncolytic viruses, as programmable biologics that replicate in and kill cancer 
cells while leaving normal cells undamaged, have huge appeal as cancer 
treatments, and have been in development in laboratories around the world for 
over 20 years. In 2015 the field experienced a massive step forward, with the 
first oncolytic HSV, IMMLYGIC (talimogene laherparepvec, Amgen) being 
approved by the FDA and EMEA as a treatment for melanoma lesions in the skin 
and lymph nodes (Pol et al., 2016).  
The aim of my project was to consider the suitability of a combination therapy 
using HSV1716 with a number of different classes of anti-cancer agents, 
especially those agents targeted to signalling pathways upregulated in cancer. 
The first part of this project was to develop a relatively high throughput assay 
suitable for use as a ‘fishing’ exercise, to look at a large number of agents in an 
in vitro assay system. The second aim was to investigate combinations that were 
synergistic and attempt to elucidate the mechanisms behind these synergies.  
Both aims were successful – the work undertaken in this thesis shows: 
1) A large number of positive synergies suggesting broad applicability of HSV1716 
with many different current and potentially future standard of care drugs 
2) The identification of mechanisms of synergy in HSV1716 infected cells and a 
novel mode of action in uninfected cells 
Currently (as of July 2016) there are at least 2 other OVs in phase III trials, 9 in 
phase II trials and at least 8 in Phase I development and countless others in 
translational development (Pol et al., 2016).  
Most of the recently published work is focused on combining oncolytic viruses 
with cancer immunotherapy or engineering new OVs with improved 
immunostimulatory functions. For example the journal Biomedicines has just 
produced a special Issue (July 2016) on oncolytic viruses as novel form of 
immunotherapy 
(http://www.mdpi.com/journal/biomedicines/special_issues/oncolytic_viruses_
immunotherapy).  
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There are, however, at least four mechanisms which contribute to the efficacy 
of oncolytic viruses. These are (1) direct cellular lysis, (2) cytokine-induced 
apoptosis, (3) innate immune cell cytotoxicity and (4) antigen specific adaptive 
T cell killing (Figure 41). While the current trend is focusing on the 
immunotherapeutic effects of OVs, further understanding of all the mechanisms 
by which oncolytic viruses kill cells can only help design new, improved OVs and 
help to understand how  to maximise the effect of existing OVs to provide 
benefit and elicit an anti tumour immune response in cancer patients. This 
thesis describes a 5th indirect mechanism (Figure 40) that involves induction of 
apoptosis in both infected and uninfected cells when an OV is combined with 
targeted therapeutics. The targeted therapy inhibits replication, which triggers 
an apoptotic response which kills the infected cell and releases an exportable 
death signal capable of inducing apoptosis in the uninfected cells. The HIRED 
effect works as an adjuvant and sensitises uninfected cells to the targeted 
therapy. 
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Figure 41: The current model of oncolytic virotherapeutic efficacy.  
(1) Direct cellular lysis, (2) cytokine induced apoptosis (3) innate immune cell 
cytotoxicity & (4) antigen specific adaptive T cell killing. Each one of these 
distinct processes is involved in tumour regression but the extent each process 
plays is likely to vary from patient to patient, type of virus, presence of 
engineered transgenes in the virus, characteristics of the tumour cells 
themselves as well as the tumour microenvironment and the immunological 
status of the patient.  
Adapted from Cassady et al., 2016.
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From the results detailed in this thesis three main conclusions can be drawn. 
HSV1716 used in combination with some other anti-cancer agents acts 
synergistically, or can enhance the amount of tumor cell killing relative to either 
drug or HSV1716 alone, and these synergistic effects are not due to increased 
oncolysis or increasing viral spread.  
Increased levels of apoptosis, mediated through the intrinsic mitochondrial 
pathway correlates with this increase in cell death in the infected cell.  
HSV1716 infected cells secrete an exportable ‘signal’ that can cause increased 
levels of cell death in non-infected cells, and this signal can be altered by 
targeted agents.  
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HSV1716 used in combination with some other anti cancer agents acts 
synergistically, or can enhance the amount of tumour cell killing relative to 
either drug or HSV1716 alone  
It is clear from the results in chapter III that HSV1716 combines synergistically 
with many different targeted therapies for enhanced cell killing of cancer cells. 
Table 11 summarises the results of the screening.  
A total of 17 agents were assessed for synergy/enhancement with HSV1716 in 
between 9-10 cell lines. When taken as a group, mTOR inhibitors + HSV1716 had 
the most ‘synergistic hits’. AZD8055 + HSV1716 in combination generated ‘hits’ 
in every cell line. 
 In terms of least ‘hits’, Dovitinib, a FLT3/cKIT inhibitor and Erlotinib and 
Gefitinib (both EGFR inhibitors) had almost no ‘hits’, with only 1/8 combination 
points in Hep3B being synergistic with Dovitinib. 
 VEGFR inhibitors, Sunitinib and Sorafenib all had ‘hits’ in 8/10 cell lines, while 
Pazopanib, another similar VEGFR inhibitor had ‘hits’ in 9/9 lines, although Huh7 
only had 1/8 points synergistic. 
It should be noted that many kinase inhibitors are promiscuous and inhibit 
various off-target kinases and it is possible that the primary target of the 
inhibitor is not responsible for the effect. For example, the KIR database 
examines the off target effects of over 50 different kinase inhibitors 
(http://reactionbiology.com/webapps/largedata/). 
For further analysis, the KIR database could be screened using synergistic kinases 
to try and identify recurring targets and comparing the results with non-
synergistic kinases. More specific inhibitors could then be selected to confirm 
the identified targets. Furthermore, once targets are identified, RNAi could also 
be used to down regulate the specific pathways or kinases to determine the 
effects on viral replication and apoptosis. 
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Increase in cell killing by combination approach is attributable to an 
increase in apoptosis, mediated through the intrinsic mitochondrial 
pathway 
Chou Talalay analysis described in Chapter III revealed that in a number of cell 
lines HSV1716 + Sunitinib, Sorafenib, AZD8055 or Doxorubicin were synergistic in 
terms of increasing cell death. In order to investigate the mechanism by which 
these synergies were occurring, caspase assays were set up to determine if the 
increased cell killing was due to an increase in apoptosis. There are different 
assays to measure different caspases. Caspase 3/7 is an executioner caspase, 
and all routes of apoptosis converge on it, thus if activated caspase 3/7 is 
observed then the total amount of apoptosis is increased. Apoptosis can occur by 
a number of pathways. If the extrinsic pathway (shown in figure 6) is activated 
then caspase 8 is cleaved which then activates caspase 3/7. If the intrinsic 
pathway is activated, caspase 9 is cleaved, and it then cleaves caspase 3/7. Thus 
by measuring both the total caspase activation (c3/7) and either caspase 8 or 9 
the route of apoptosis can be determined.  
The results detailed in chapter IV show that caspase 3/7 but not caspase 8 is 
significantly activated when HSV1716 is given in combination with synergistic 
drugs such as AZD8055, Sunitinib or Doxorubicin. No increase in caspase 
activation was seen with HSV1716 + non-synergistic drugs such as Erlotinib and 
Dovitinib.  
Anti cancer agents, such as the mTOR inhibitor AZD8055 block tumour cell 
growth. Normally, HSV1716 would cause oncolysis in cancer cells. However, in 
the presence of drugs that block tumour growth, viral replication is also blocked- 
by shutting down growth of the cancer cell it also stops the virus that requires 
actively dividing cells for its own viral replication. However, despite this block, 
levels of tumour cell death are enhanced when the drug and virus are given in 
combination. AZD8055, Sunitinib and Doxorubicin were all highly synergistic with 
HSV1716 and all three increased levels of intrinsic apoptosis significantly.  
It is postulated that the increase in cell death due to increased apoptosis 
observed when AZD8055, Sunitinib or Doxorubicin are given in combination with 
HSV1716 is simply due to the presence of the drug inhibiting the virus from 
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transcribing the necessary anti apoptotic viral proteins necessary to prevent the 
host cell from entering apoptosis. 
Apoptosis, a critical cellular mechanism against viral infection (Blaho, 2004) is 
triggered early in infection through viral recognition by either TLR7, which binds 
ssRNA, or TLR3, which binds dsRNA. These TLRs then induce intracellular 
signalling, eventually resulting in the shutdown of protein synthesis within the 
cell and apoptosis (Kawasaki and Kawai, 2014). Membrane fusion of HSV, in the 
absence of viral replication, also induces a subset of interferon stimulating genes 
(ISGs) which may produce a pro-apoptotic signal(Noyce et al., 2011). HSV would, 
under normal circumstances be able to counteract this shutdown as it encodes 
anti-apoptotic viral proteins to subvert such apoptosis. If production of viral 
anti-apoptotic proteins are suppressed by a cytostatic drug, then these viral 
proteins will not be produced, thus the balance within the cell will be in favour 
of pro-apoptotic proteins, and apoptosis will proceed. The type of cell death, in 
cells infected with recombinant HSV lacking genes such as ICP27 and ICP4,known 
to have anti apoptotic function, was first referred to as HSV dependent 
apoptosis (HDAP) by Nguyen et al., 2007a. Cancer cells exhibit an exquisite 
sensitivity to HDAP (Nguyen et al., 2005, Aubert and Blaho, 2003, Nguyen et al., 
2007b). In contrast, cells derived from normal cells (nontransformed) were quite 
resistant to this process ((Nguyen et al., 2005, Aubert and Blaho, 2003). Within 
the mixed population of cells within the tumour microenvironment there will be 
actively dividing cells sensitive to oncolysis but there will be other cell types 
that are not actively dividing or sensitive to oncolysis and therefore other routes 
to cell death such as HDAP will be important.  
Thus the increase in apoptosis may be clinically relevant. Increasing the amount 
of apoptosis within a tumour environment will increase, for example, NF-κB 
activation, which will in turn activate innate immune cells, leading to an 
increase in adaptive immune (T –cell) activation. As a single mechanism an 
increase in apoptosis within the tumour microenvironment might not be enough 
to tip the balance in favour of an anti-tumour immune response. However, in 
scheduled combination of an immunotherapeutic, an oncolytic virus and possibly 
even targeted agent may be able to help create a ‘perfect storm’ that could 
lead to the ultimate goal of an anti-tumour response leading to a durable, 
curative treatment for cancer.  
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The next set of experiments within the combination of HSV1716 + drugs will 
require a more detailed analysis of intrinsic apoptosis by using FACs for example, 
to analyse the timing of apoptotic events. Furthermore, comparing mutant 
viruses that have defects in the anti-apoptotic genes for example, ICP27 or ICP4-
deleted HSV would allow comparisons of whether these viruses have similar 
patterns of cell death to HSV176 that is not replicating in the presence of a drug 
and perhaps even stronger synergies. Further, key pro-and anti-apoptotic factors 
could be assessed by Western Blotting or antibody arrays and these could then 
be targeted by RNAi. Importantly it will be key to show that such targeting leads 
to better synergies. 
There are other cell-type dependent routes to cell death such as necrosis, or 
necroptosis (the regulated form of necrosis) but these were not studied here. In 
follow up experiments it will be interesting to study such alternate pathway by 
measuring key markers such as RIPK1 and RIPK3.  
Crucially experiments of HSV1716 + synergistic agents in vivo will be required to 
translate these findings into a more clinically relevant setting. It may be that 
with the current interest in OVs as immunotherapeutics, for example OV’s in 
combination with immune checkpoint inhibitors, that experiments looking at the 
relatively small effects of increasing apoptosis in cancer cells are swamped by 
the potential curative potential of such immunotherapeutic combinations. That 
is not to say that such experiments are not worthwhile – increasing apoptosis 
may increase the amount of ICD. As discussed above, one of the keys to 
successful OV therapy is to induce an anti-tumour immune response.  
The field of oncolytic viruses may be entering a phase of exponential growth due 
to its potential as an immunotherapeutic, but greater understanding of how 
viruses interact at cellular levels can only lead to further advances in the field. 
Furthermore, targeted agents, such as those described in this thesis are 
increasingly being seen as an adjunct to immunotherapy drugs. Many targeted 
therapies against tumour pathways affect pathways that are also crucial for 
immune development and function, bringing forth the possibility that targeted 
agents may help optimise anti-tumour responses from immunotherapies. For 
example Sunitinib has been shown to decrease myeloid derived suppressor cells 
(MSDC), a myeloid cell subtype that silences responses of cytotoxic CD8+ T Cells 
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and helper CD4+ T cells while promoting TRegs (Jha et al., 2011).  mTOR 
inhibitors have also been shown to enhance CD8+ T cell activation and IFNγ 
production (Jiang et al., 2011). These effects could be analysed in vivo in 
combination studies with murine syngeneic models. 
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HSV1716 infected cells secrete an exportable ‘signal’ that can cause 
increased levels of cell death in non-infected cells, and this signal can be 
altered by targeted agents.  
In Chapter III a number of the synergistic combinations were found when 
HSV1716 was at MOI of 0.1. As many of the drugs in the combination analysis 
significantly reduced viral replication, an HSV1716 virion is only likely to be 
physically present in a maximum of 10% of the cells throughout the experiment.  
If the virus is not present within the cell to activate apoptosis by the intrinsic 
pathway then how is the synergy between the targeted agent and HSV1716 
occurring?  
This thesis describes a 5th indirect mechanism (Figure 40) that involves 
induction of apoptosis in both infected and uninfected cells when an OV is 
combined with targeted therapeutics. The targeted therapy inhibits replication 
which triggers an apoptotic response which kills the infected cell and releases an 
exportable death signal capable of inducing apoptosis in the uninfected cells. 
The HIRED effect works as an adjuvant and sensitises uninfected cell to the 
targeted therapy. 
Further analysis of this HIRED signal is required. The next steps in this study 
would be to look at other cell lines with other targeted agents as the pre-
treatment in order to further elucidate if drug treatment prior to infection 
alters, enhances or inhibits the HIRED signal produced. As with the combination 
of VF-CM tested when the targeted agents were added to recipient cells, 
responses varied according to the recipient cell line, further suggesting that 
there are multiple different factors at play, both in terms of the HIRED signal 
and the ability for certain targeted agents to enhance it. It will also be 
interesting to measure the HIRED signal (if any) produced by HSV mutant viruses 
that lack anti apoptotic genes such as ICP27 or ICP4. 
Furthermore, FACS analysis of the proportion of cell death in recipient cells, 
rather than the DCP assay would allow greater sensitivity. Difference in DCP 
levels of between 5-10% were measured during these experiments however these 
differences failed to meet statistical significance. With FACS analysis looking at 
live/dead cells, much smaller differentials can be measured. 
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One theory is that the HIRED signal is viral DNA fragments either free or in 
exosomes. These fragments released from the infected and apoptotic cell could 
stimulate TLR and other DNA sensors in the uninfected cell via cell surface (free) 
or intracellular (exosome) sentinels and activate apoptotic cascades via FAS or 
other death ligands. Thus activation of these pathways can be analysed in cells 
treated with VF-CM. Recent advances in exosome research mean that now 
commercially magnetic bead kits have been developed for fast, reproducible 
isolation/characterization of exosomes and analysis of their cargo which would 
allow this theory to be tested 
(https://www.thermofisher.com/uk/en/home/life-science/cell-
analysis/exosomes.html). 
In conclusion, this thesis provides preliminary evidence that oncolytic viruses can 
exert an anti-tumour effect by inducing apoptosis in both infected and 
uninfected cells when combined with targeted therapeutics. The targeted 
therapy inhibits OV replication, but triggers an apoptotic response which kills 
the infected cell and releases an exportable death signal capable of inducing 
apoptosis in the uninfected cells. 
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Appendix I –Lynne Braidwood’s HSV1716 related publications  
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8th International Conference on Oncolytic Virus Therapeutics 
Barbara-Ann Guinn, Lynne Braidwood, Alan Parker, Kah-Whye Peng, and 
Leonard Seymour 
Human Gene Therapy, 2014 25:1062–1084 (Dec-2014) 
Abstract: The 8th International Conference on Oncolytic Virus Therapeutics 
meeting was held from April 10–13, 2014, in Oxford, United Kingdom. It brought 
together experts in the field of oncolytics from Europe, Asia, Australasia, and 
the Americas and provided a unique opportunity to hear the latest research 
findings in oncolytic virotherapy. Presentations of recent work were delivered in 
an informal and intimate setting afforded by a small group of attendees and an 
exquisitely focused conference topic. Here we describe the oral presentations 
and enable the reader to share in the benefits of bringing together experts to 
share their findings. 
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Appendix 2 – Posters authored/co authored by Lynne Braidwood 2013 -
2016 involving work carried out in relation to this thesis.  
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Appendix 3: Posters authored/co authored by Lynne Braidwood 2013-2016 
related to work carried out not in relation to this thesis.  
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Appendix 4: Poster presented at ASCGT meeting – HSV1716 oncolytic herpes 
virotherapy induced a paracrine death signal causing synergistic antitumour 
efficacy with Aurora Kinase Inhibition 
 
273 
 
 
